Index	Sentence	Entity	Entity_Startindex	Entity_Stopindex	Entity_Info
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	cytochrome P450	29282	29297	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862638_OgerInput.txtOger_out.csv:53	(3) Pharmacokinetic interaction: The Pharmacokinetic interaction is related to the effects on the cytochrome P450 cytochromes and possible drug interactions when prescribed with other drugs. 	cytochrome P450	9022	9037	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862638_OgerInput.txtOger_out.csv:53	(3) Pharmacokinetic interaction: The Pharmacokinetic interaction is related to the effects on the cytochrome P450 cytochromes and possible drug interactions when prescribed with other drugs. 	cytochrome P450	9022	9037	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6974621_OgerInput.txtOger_out.csv:93	Cells are equipped with several hemoproteins and for some of them a role in cancer has been reported, including myoglobin, tryptophan 2,3-dioxygenase and indoleamine-2,3-dioxygenase 1 and 2 (IDO1/2), mitochondrial cytochromes, cytochrome P450, and cyclooxygenases (,. 	cytochrome P450	16842	16857	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6974621_OgerInput.txtOger_out.csv:93	Cells are equipped with several hemoproteins and for some of them a role in cancer has been reported, including myoglobin, tryptophan 2,3-dioxygenase and indoleamine-2,3-dioxygenase 1 and 2 (IDO1/2), mitochondrial cytochromes, cytochrome P450, and cyclooxygenases (,. 	cytochrome P450	16842	16857	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6974621_OgerInput.txtOger_out.csv:94	Studies on lung cancer demonstrated that the amount of oxygen-utilizing hemoproteins, such as cytoglobin, cytochrome c, cytochrome P450 family 1 subfamily B member 1 and prostaglandin-endoperoxide synthase 2 (COX2) are higher in tumor cells as compared to normal cells and that, at least for cytoglobin and cytochrome c, their levels depend on the rate of heme synthesis and cellular heme content. 	cytochrome P450	17003	17018	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6974621_OgerInput.txtOger_out.csv:94	Studies on lung cancer demonstrated that the amount of oxygen-utilizing hemoproteins, such as cytoglobin, cytochrome c, cytochrome P450 family 1 subfamily B member 1 and prostaglandin-endoperoxide synthase 2 (COX2) are higher in tumor cells as compared to normal cells and that, at least for cytoglobin and cytochrome c, their levels depend on the rate of heme synthesis and cellular heme content. 	cytochrome P450	17003	17018	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:7	In this article, we discuss the physiological, therapeutic and pathophysiological relevance of cytochrome P450 protein degradation. 	cytochrome P450	1729	1744	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:7	In this article, we discuss the physiological, therapeutic and pathophysiological relevance of cytochrome P450 protein degradation. 	cytochrome P450	1729	1744	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:9	In the mammalian liver, the endoplasmic reticulum (ER)-anchored P450s function together with their redox partners cytochrome P450 reductase and cytochrome b_5 in the oxidative metabolism and elimination of numerous endobiotics (arachidonic acid, retinoic acid, steroids, vitamin D) as well as xenobiotics (pharmacological and recreational drugs, carcinogens, toxins and other foreign substances of dietary or environmental origin),. 	cytochrome P450	2353	2368	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:9	In the mammalian liver, the endoplasmic reticulum (ER)-anchored P450s function together with their redox partners cytochrome P450 reductase and cytochrome b_5 in the oxidative metabolism and elimination of numerous endobiotics (arachidonic acid, retinoic acid, steroids, vitamin D) as well as xenobiotics (pharmacological and recreational drugs, carcinogens, toxins and other foreign substances of dietary or environmental origin),. 	cytochrome P450	2353	2368	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:9	CYP1A plays an important role in maintaining the health in the body.Image 1 The cytochrome P450 enzyme is one of the most abundant and diverse superfamilies, which contains hemoprotein. 	cytochrome P450	1188	1203	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:9	CYP1A plays an important role in maintaining the health in the body.Image 1 The cytochrome P450 enzyme is one of the most abundant and diverse superfamilies, which contains hemoprotein. 	cytochrome P450	1188	1203	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:4	To elucidate the celastrol biosynthetic pathway and reconstruct it in Saccharomyces cerevisiae, we mined a root-transcriptome of Tripterygium wilfordii and identified four oxidosqualene cyclases and 49 cytochrome P450s as candidates to be involved in the early steps of celastrol biosynthesis. 	cytochrome P450	574	589	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:4	To elucidate the celastrol biosynthetic pathway and reconstruct it in Saccharomyces cerevisiae, we mined a root-transcriptome of Tripterygium wilfordii and identified four oxidosqualene cyclases and 49 cytochrome P450s as candidates to be involved in the early steps of celastrol biosynthesis. 	cytochrome P450	574	589	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:35	Celastrol biosynthesis likely adheres to the common triterpenoid scheme that starts with cycloisomerization of 2,3-oxidosqualene by an oxidosqualene cyclase (OSC) and continues with oxidative decoration(s) of the 30-carbon triterpenoid core structure by cytochrome P450 enzymes [,. 	cytochrome P450	5969	5984	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:35	Celastrol biosynthesis likely adheres to the common triterpenoid scheme that starts with cycloisomerization of 2,3-oxidosqualene by an oxidosqualene cyclase (OSC) and continues with oxidative decoration(s) of the 30-carbon triterpenoid core structure by cytochrome P450 enzymes [,. 	cytochrome P450	5969	5984	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:112	For catalysis, P450s require cytochrome P450 reductases (CPRs) as a redox partner. 	cytochrome P450	19109	19124	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:112	For catalysis, P450s require cytochrome P450 reductases (CPRs) as a redox partner. 	cytochrome P450	19109	19124	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:21	Output includes metabolism to oxysterols by the cytochrome P450 enzymes Cytochromes P450 27a1 and CYP46A1, the photoreceptor phagocytosis, and efflux to lipoprotein particles, which circulate in the intraretinal space. 	cytochrome P450	3497	3512	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:21	Output includes metabolism to oxysterols by the cytochrome P450 enzymes Cytochromes P450 27a1 and CYP46A1, the photoreceptor phagocytosis, and efflux to lipoprotein particles, which circulate in the intraretinal space. 	cytochrome P450	3497	3512	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:4	Furthermore, different reconstituted fractions of extract (petasins and fatty acid fraction) were examined in three in vitro test systems using hepatocytes: Two human cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2, HepaRG) as well as a rodent cell line with high cytochrome P450 activity (H4IIE), were used. 	cytochrome P450	705	720	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:4	Furthermore, different reconstituted fractions of extract (petasins and fatty acid fraction) were examined in three in vitro test systems using hepatocytes: Two human cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2, HepaRG) as well as a rodent cell line with high cytochrome P450 activity (H4IIE), were used. 	cytochrome P450	705	720	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:4	Furthermore, different reconstituted fractions of extract (petasins and fatty acid fraction) were examined in three in vitro test systems using hepatocytes: Two human cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2, HepaRG) as well as a rodent cell line with high cytochrome P450 activity (H4IIE), were used. 	cytochrome P450	785	800	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:4	Furthermore, different reconstituted fractions of extract (petasins and fatty acid fraction) were examined in three in vitro test systems using hepatocytes: Two human cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2, HepaRG) as well as a rodent cell line with high cytochrome P450 activity (H4IIE), were used. 	cytochrome P450	785	800	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:23	The analysis focused on three different in vitro test systems of hepatocytes: two human hepatic cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2 and HepaRG, respectively, (Andersson, Kanebratt, & Kenna, ; Guillouzo et al., )) and a rat cell line (H4IIE [Fujimura, Murakami, Miwa, Aruga, & Toriumi, ; Westerink, Stevenson, & Schoonen, ]) were used. 	cytochrome P450	3853	3868	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:23	The analysis focused on three different in vitro test systems of hepatocytes: two human hepatic cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2 and HepaRG, respectively, (Andersson, Kanebratt, & Kenna, ; Guillouzo et al., )) and a rat cell line (H4IIE [Fujimura, Murakami, Miwa, Aruga, & Toriumi, ; Westerink, Stevenson, & Schoonen, ]) were used. 	cytochrome P450	3853	3868	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:34	Isolated cytochrome P450 enzymes and phosphate buffer were obtained from BD Gentest (Switzerland). 	cytochrome P450	5704	5719	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:34	Isolated cytochrome P450 enzymes and phosphate buffer were obtained from BD Gentest (Switzerland). 	cytochrome P450	5704	5719	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:68	The metabolism of petasin, isopetasin, and neopetasin was investigated using three different S9 fractions originating from three different species (isolated from rat, dog, and human liver homogenates containing cytochrome P450 isoforms) and isolated cytochromes of two different species (human and rat; rat analogues of the respective human cytochromes were used). 	cytochrome P450	10665	10680	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:68	The metabolism of petasin, isopetasin, and neopetasin was investigated using three different S9 fractions originating from three different species (isolated from rat, dog, and human liver homogenates containing cytochrome P450 isoforms) and isolated cytochromes of two different species (human and rat; rat analogues of the respective human cytochromes were used). 	cytochrome P450	10665	10680	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:141	Comparison of two human cell lines (HepG2 and HepaRG) with different activities of cytochrome P450 enzymes revealed that Ze 339 and its single constituents petasin, isopetasin, neopetasin, isopetasol, and petasol exerted higher toxicity in cells having a higher cytochrome activity. 	cytochrome P450	22394	22409	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:141	Comparison of two human cell lines (HepG2 and HepaRG) with different activities of cytochrome P450 enzymes revealed that Ze 339 and its single constituents petasin, isopetasin, neopetasin, isopetasol, and petasol exerted higher toxicity in cells having a higher cytochrome activity. 	cytochrome P450	22394	22409	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:142	Furthermore, Ze 399 and petasin, isopetasin, and neopetasin were more toxic in rat cells (H4IIE), which are known to have a high expression of cytochrome P450 (Fujimura et al., ; Westerink et al., ) than in both human cell lines. 	cytochrome P450	22737	22752	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:142	Furthermore, Ze 399 and petasin, isopetasin, and neopetasin were more toxic in rat cells (H4IIE), which are known to have a high expression of cytochrome P450 (Fujimura et al., ; Westerink et al., ) than in both human cell lines. 	cytochrome P450	22737	22752	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:84	In humans, 30-50% of Valproic Acid is metabolized by glucuronidation and by BETA oxidation in the mitochondria, and about 10-20% is metabolized by cytochrome P450 (CYP)-mediated oxidation. 	cytochrome P450	13101	13116	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:84	In humans, 30-50% of Valproic Acid is metabolized by glucuronidation and by BETA oxidation in the mitochondria, and about 10-20% is metabolized by cytochrome P450 (CYP)-mediated oxidation. 	cytochrome P450	13101	13116	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:86	Meanwhile, the examined series inhibited the cytochrome P450 isomers, ie, CYP2C19, CYP2C9, and CYP3A4-except for Compound 2g, which did not inhibit CYP2C19. 	cytochrome P450	15158	15173	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:86	Meanwhile, the examined series inhibited the cytochrome P450 isomers, ie, CYP2C19, CYP2C9, and CYP3A4-except for Compound 2g, which did not inhibit CYP2C19. 	cytochrome P450	15158	15173	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:10	Hepatocytes express a set of highly specific cytochrome P450 biotransforming enzymes that convert many drugs to inactive or hepatotoxic compounds. 	cytochrome P450	1698	1713	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:10	Hepatocytes express a set of highly specific cytochrome P450 biotransforming enzymes that convert many drugs to inactive or hepatotoxic compounds. 	cytochrome P450	1698	1713	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:4	We observed a significant increase in HIV-1 replication, which was associated with an increase in the expression of cytochrome P450 (CYPs 1A1 and 2A6) in the CCS-treated U1 cells. 	cytochrome P450	640	655	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:4	We observed a significant increase in HIV-1 replication, which was associated with an increase in the expression of cytochrome P450 (CYPs 1A1 and 2A6) in the CCS-treated U1 cells. 	cytochrome P450	640	655	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:43	We recently demonstrated that oxidative stress generated via cytochrome P450 (CYP)-mediated metabolism of tobacco constituents, especially cigarette smoke condensate and benzo(a)pyrene (BaP), triggers HIV-1 replication in monocytes and macrophages. 	cytochrome P450	6315	6330	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:43	We recently demonstrated that oxidative stress generated via cytochrome P450 (CYP)-mediated metabolism of tobacco constituents, especially cigarette smoke condensate and benzo(a)pyrene (BaP), triggers HIV-1 replication in monocytes and macrophages. 	cytochrome P450	6315	6330	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:7	The molecular docking study suggested that compound 12n fitted the active sites of cytochrome P450 17A1 (6CIZ) well. 	cytochrome P450	1361	1376	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:7	The molecular docking study suggested that compound 12n fitted the active sites of cytochrome P450 17A1 (6CIZ) well. 	cytochrome P450	1361	1376	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:91	Moreover it is important to emphasize that tocilizumab decreases the concentration of several medications as a cytochrome P450, isoenzyme CYP3A4 inducer in terms of antagonisms or synergy but this is not yet entirely clear (;. 	cytochrome P450	14720	14735	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:91	Moreover it is important to emphasize that tocilizumab decreases the concentration of several medications as a cytochrome P450, isoenzyme CYP3A4 inducer in terms of antagonisms or synergy but this is not yet entirely clear (;. 	cytochrome P450	14720	14735	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7283212_OgerInput.txtOger_out.csv:3	Here, we examined the rate of gene flow from abiotic stress-tolerant transgenic rice that over-express AtCYP78A7, a gene encoding cytochrome P450 protein, to six weedy rice accessions and compared the phenotypic performance and drought tolerance of their hybrids over generations. 	cytochrome P450	437	452	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7283212_OgerInput.txtOger_out.csv:3	Here, we examined the rate of gene flow from abiotic stress-tolerant transgenic rice that over-express AtCYP78A7, a gene encoding cytochrome P450 protein, to six weedy rice accessions and compared the phenotypic performance and drought tolerance of their hybrids over generations. 	cytochrome P450	437	452	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7283212_OgerInput.txtOger_out.csv:20	It has been reported that the overexpression of AtCYP78A7, a gene encoding cytochrome P450 protein, exhibits improved drought tolerance and increased seed size in transgenic rice^. 	cytochrome P450	4516	4531	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7283212_OgerInput.txtOger_out.csv:20	It has been reported that the overexpression of AtCYP78A7, a gene encoding cytochrome P450 protein, exhibits improved drought tolerance and increased seed size in transgenic rice^. 	cytochrome P450	4516	4531	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7283212_OgerInput.txtOger_out.csv:90	They were derived from a rice cultivar Hwayoung and contain AtCYP78A7 a gene that encodes a cytochrome P450 protein under the control of the cauliflower mosaic virus 35S promoter, nos terminator and hygromycin phosphotransferase gene for hygromycin selection^,. 	cytochrome P450	19802	19817	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7283212_OgerInput.txtOger_out.csv:90	They were derived from a rice cultivar Hwayoung and contain AtCYP78A7 a gene that encodes a cytochrome P450 protein under the control of the cauliflower mosaic virus 35S promoter, nos terminator and hygromycin phosphotransferase gene for hygromycin selection^,. 	cytochrome P450	19802	19817	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:24	Apart from this QC also reported as an inhibitor of cytochrome P450 enzyme which is the main enzyme of Mycophenolic Acid metabolism (;. 	cytochrome P450	3224	3239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:24	Apart from this QC also reported as an inhibitor of cytochrome P450 enzyme which is the main enzyme of Mycophenolic Acid metabolism (;. 	cytochrome P450	3224	3239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:203	In addition, the blood circulation time of Mycophenolic Acid also increased by QC through inhibition of Mycophenolic Acid metabolism mediated by cytochrome P450 enzyme as discussed blow in pharmacokinetic analysis. 	cytochrome P450	31511	31526	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:203	In addition, the blood circulation time of Mycophenolic Acid also increased by QC through inhibition of Mycophenolic Acid metabolism mediated by cytochrome P450 enzyme as discussed blow in pharmacokinetic analysis. 	cytochrome P450	31511	31526	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:207	Higher AUC_(_0_-__) and T_1_/_2 might be due sustained release of drugs from liposomes and long blood circulation time due Mycophenolic Acid breakdown inhibition through cytochrome P450 enzyme by QC. 	cytochrome P450	32378	32393	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:207	Higher AUC_(_0_-__) and T_1_/_2 might be due sustained release of drugs from liposomes and long blood circulation time due Mycophenolic Acid breakdown inhibition through cytochrome P450 enzyme by QC. 	cytochrome P450	32378	32393	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7315535_OgerInput.txtOger_out.csv:156	This is metabolized by ROS scavenger like cytochrome P450 to prevent cellular damages, ultimately leading to redox homeostasis. 	cytochrome P450	29429	29444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7315535_OgerInput.txtOger_out.csv:156	This is metabolized by ROS scavenger like cytochrome P450 to prevent cellular damages, ultimately leading to redox homeostasis. 	cytochrome P450	29429	29444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:186	Some parameters such as blood-brain barrier permeation, human drug-likeness, interaction with cytochrome P450 (isoenzymes that play an important role in drug elimination through metabolic transformation) and bioavailability score were predicted, . 	cytochrome P450	33370	33385	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:186	Some parameters such as blood-brain barrier permeation, human drug-likeness, interaction with cytochrome P450 (isoenzymes that play an important role in drug elimination through metabolic transformation) and bioavailability score were predicted, . 	cytochrome P450	33370	33385	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:189	The interaction of SIM-53B with cytochrome P450 isoforms plays an important role in SIM-53B elimination through metabolic biotransformation. 	cytochrome P450	34008	34023	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:189	The interaction of SIM-53B with cytochrome P450 isoforms plays an important role in SIM-53B elimination through metabolic biotransformation. 	cytochrome P450	34008	34023	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:190	SIM-53B may inhibit some of the cytochrome P450 isoforms such as CYP1A2, CYP2C9 and CYP3A4. 	cytochrome P450	34149	34164	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:190	SIM-53B may inhibit some of the cytochrome P450 isoforms such as CYP1A2, CYP2C9 and CYP3A4. 	cytochrome P450	34149	34164	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:1	 A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. 	cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:21	Output includes metabolism to oxysterols by the cytochrome P450 enzymes Cytochromes P450 27a1 and CYP46A1, the photoreceptor phagocytosis, and efflux to lipoprotein particles, which circulate in the intraretinal space. 	cytochrome P450 enzymes	3497	3520	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:4	Furthermore, different reconstituted fractions of extract (petasins and fatty acid fraction) were examined in three in vitro test systems using hepatocytes: Two human cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2, HepaRG) as well as a rodent cell line with high cytochrome P450 activity (H4IIE), were used. 	cytochrome P450 enzymes	705	728	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:23	The analysis focused on three different in vitro test systems of hepatocytes: two human hepatic cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2 and HepaRG, respectively, (Andersson, Kanebratt, & Kenna, ; Guillouzo et al., )) and a rat cell line (H4IIE [Fujimura, Murakami, Miwa, Aruga, & Toriumi, ; Westerink, Stevenson, & Schoonen, ]) were used. 	cytochrome P450 enzymes	3853	3876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:34	Isolated cytochrome P450 enzymes and phosphate buffer were obtained from BD Gentest (Switzerland). 	cytochrome P450 enzymes	5704	5727	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:176	Once absorbed in the small intestines or later in the large intestines, absorbed flavonoid aglycones will move along to the liver by portal circulation and undergo extensive first pass metabolism, as shown in A. Largely in the liver, but also in the small intestines, flavonoid aglycones undergo oxidative and reductive modifications by NADPH dependent cytochromes P450 enzymes. 	P450 enzymes	30766	30778	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:176	Once absorbed in the small intestines or later in the large intestines, absorbed flavonoid aglycones will move along to the liver by portal circulation and undergo extensive first pass metabolism, as shown in A. Largely in the liver, but also in the small intestines, flavonoid aglycones undergo oxidative and reductive modifications by NADPH dependent cytochromes P450 enzymes. 	P450 enzymes	30766	30778	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:178	For isoflavones, the gut microbiome and phase I cytochrome P450 enzymes in human liver microsome were responsible for O-demethylation at 4 carbon; hence formononetin is converted to daidzein and biochanin A to genistein Anthocyanidins, or their monoglucosides of anthocyanins, remained unchanged when incubated with rat liver microsomes in the presence of NADPH, which suggests that anthocyanidins are not affected by phase I enzymes. 	P450 enzymes	31154	31166	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:178	For isoflavones, the gut microbiome and phase I cytochrome P450 enzymes in human liver microsome were responsible for O-demethylation at 4 carbon; hence formononetin is converted to daidzein and biochanin A to genistein Anthocyanidins, or their monoglucosides of anthocyanins, remained unchanged when incubated with rat liver microsomes in the presence of NADPH, which suggests that anthocyanidins are not affected by phase I enzymes. 	P450 enzymes	31154	31166	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:31	The heme-containing Cytochrome P450 enzymes activate molecular oxygen utilizing NADPH as an electron donor. 	P450 enzymes	5158	5170	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:31	The heme-containing Cytochrome P450 enzymes activate molecular oxygen utilizing NADPH as an electron donor. 	P450 enzymes	5158	5170	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:34	Cytochrome P450 enzymes involved in steroidogenesis can be divided into two groups based on their intracellular location and mode of electron transfer. 	P450 enzymes	5527	5539	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:34	Cytochrome P450 enzymes involved in steroidogenesis can be divided into two groups based on their intracellular location and mode of electron transfer. 	P450 enzymes	5527	5539	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:186	In addition to the steroidogenic Cytochrome P450 enzymes described in Section, hepatic xenobiotic-metabolizing members of the Cytochrome P450 superfamily are able to modify steroid hormones and generate a plethora of minor steroid metabolites. 	P450 enzymes	31623	31635	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:186	In addition to the steroidogenic Cytochrome P450 enzymes described in Section, hepatic xenobiotic-metabolizing members of the Cytochrome P450 superfamily are able to modify steroid hormones and generate a plethora of minor steroid metabolites. 	P450 enzymes	31623	31635	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:126	Cytochrome P450 enzymes have potential uses in the synthesis and discovery of drugs, as well as drug development. 	P450 enzymes	23669	23681	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:126	Cytochrome P450 enzymes have potential uses in the synthesis and discovery of drugs, as well as drug development. 	P450 enzymes	23669	23681	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:127	Cytochrome P450 enzymes metabolize thousands of endogenous and exogenous chemicals. 	P450 enzymes	23783	23795	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:127	Cytochrome P450 enzymes metabolize thousands of endogenous and exogenous chemicals. 	P450 enzymes	23783	23795	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:131	Cytochrome P450 enzymes are bound to membranes within a cell and contain a heme pigment that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide. 	P450 enzymes	24539	24551	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:131	Cytochrome P450 enzymes are bound to membranes within a cell and contain a heme pigment that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide. 	P450 enzymes	24539	24551	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	P450 enzymes	24728	24740	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	P450 enzymes	24728	24740	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:133	Cytochrome P450 enzymes play a role in the synthesis of many molecules including steroid hormones, certain Fatty Acids (cholesterol and other fatty acids), and acids used to digest Fatty Acids (bile acids). 	P450 enzymes	24853	24865	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:133	Cytochrome P450 enzymes play a role in the synthesis of many molecules including steroid hormones, certain Fatty Acids (cholesterol and other fatty acids), and acids used to digest Fatty Acids (bile acids). 	P450 enzymes	24853	24865	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:164	Genetic polymorphisms of Cytochrome P450 enzymes mainly influence drug metabolism, disposition and elimination and lead to alteration of pharmacokinetic parameters resulting in changes in drug response as well as adverse drug reactions. 	P450 enzymes	31164	31176	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:164	Genetic polymorphisms of Cytochrome P450 enzymes mainly influence drug metabolism, disposition and elimination and lead to alteration of pharmacokinetic parameters resulting in changes in drug response as well as adverse drug reactions. 	P450 enzymes	31164	31176	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:187	The Cytochrome P450 enzymes activity have four recognizable metabolic categories: (a) poor metabolizers which lack functional enzymes due to deficient allele inheritance; (b) intermediate metabolizers, that are heterozygous with one deficient allele or carrying two reduced activity alleles; (c) extensive metabolizers that have normally functional enzymes due to wild type alleles inheritance, and (d) ultra-rapid metabolizers, which carry more than two copies of active alleles. 	P450 enzymes	35513	35525	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:187	The Cytochrome P450 enzymes activity have four recognizable metabolic categories: (a) poor metabolizers which lack functional enzymes due to deficient allele inheritance; (b) intermediate metabolizers, that are heterozygous with one deficient allele or carrying two reduced activity alleles; (c) extensive metabolizers that have normally functional enzymes due to wild type alleles inheritance, and (d) ultra-rapid metabolizers, which carry more than two copies of active alleles. 	P450 enzymes	35513	35525	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:217	For example, the Cytochrome P450 enzymes can play a major role in metabolic drug oxidation and accounts for approximately 75% of the total drug metabolism. 	P450 enzymes	41618	41630	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:217	For example, the Cytochrome P450 enzymes can play a major role in metabolic drug oxidation and accounts for approximately 75% of the total drug metabolism. 	P450 enzymes	41618	41630	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:218	Furthermore, Cytochrome P450 enzymes are classified based on gene similarity (cytochromes within families have more than 40% homology in their protein sequence). 	P450 enzymes	41770	41782	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:218	Furthermore, Cytochrome P450 enzymes are classified based on gene similarity (cytochromes within families have more than 40% homology in their protein sequence). 	P450 enzymes	41770	41782	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:12	For the decomposition of clinical drugs, human Cytochrome P450 enzymes belong to the Phase I drug metabolizing enzymes. 	P450 enzymes	1729	1741	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:12	For the decomposition of clinical drugs, human Cytochrome P450 enzymes belong to the Phase I drug metabolizing enzymes. 	P450 enzymes	1729	1741	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:64	Estradiol is converted into the less potent estrogens to be inactivated and hydroxylated into catechol estrogens through Cytochrome P450 enzymes. 	P450 enzymes	8810	8822	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:64	Estradiol is converted into the less potent estrogens to be inactivated and hydroxylated into catechol estrogens through Cytochrome P450 enzymes. 	P450 enzymes	8810	8822	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:79	In addition to the conjugation pathway and 17-ketosteroid pathway, hydroxylation and oxidation of hepatic Cytochrome P450 enzymes are additional pathways for testosterone metabolism. 	P450 enzymes	10628	10640	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:79	In addition to the conjugation pathway and 17-ketosteroid pathway, hydroxylation and oxidation of hepatic Cytochrome P450 enzymes are additional pathways for testosterone metabolism. 	P450 enzymes	10628	10640	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:35	Celastrol biosynthesis likely adheres to the common triterpenoid scheme that starts with cycloisomerization of 2,3-oxidosqualene by an oxidosqualene cyclase (OSC) and continues with oxidative decoration(s) of the 30-carbon triterpenoid core structure by cytochrome P450 enzymes [,. 	P450 enzymes	5980	5992	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:151	Therefore, it can be suggested that ellagic acid may affect warfarin binding to CYP2C8 and CYP3A4 by changing the conformation of these enzymes that leads to more affinity towards warfarin binding [,. 	CYP2C8	25086	25092	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:151	Therefore, it can be suggested that ellagic acid may affect warfarin binding to CYP2C8 and CYP3A4 by changing the conformation of these enzymes that leads to more affinity towards warfarin binding [,. 	CYP2C8	25086	25092	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:152	These results contradict those of a previous study by Kaneko, 2013 where ellagic acid had a clear inhibitory effect on CYP2C8 and CYP3A4 activities. 	CYP2C8	25326	25332	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:152	These results contradict those of a previous study by Kaneko, 2013 where ellagic acid had a clear inhibitory effect on CYP2C8 and CYP3A4 activities. 	CYP2C8	25326	25332	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:156	Although guava leaves extract showed an insignificant effect on CYP2C8 when used alone, it significantly reduced its activity when combined with warfarin (p < 0.01). 	CYP2C8	25950	25956	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:156	Although guava leaves extract showed an insignificant effect on CYP2C8 when used alone, it significantly reduced its activity when combined with warfarin (p < 0.01). 	CYP2C8	25950	25956	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:157	In a previous study conducted by Kaneko in 2013, it was reported that guava leaves extract had an inhibitory effect on CYP2C8. 	CYP2C8	26171	26177	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:157	In a previous study conducted by Kaneko in 2013, it was reported that guava leaves extract had an inhibitory effect on CYP2C8. 	CYP2C8	26171	26177	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:158	Therefore, it might be suggested that CYP2C8 enzyme can be influenced by the presence of warfarin, which can modify the uncompetitive binding of the active extract components on the enzyme. 	CYP2C8	26217	26223	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:158	Therefore, it might be suggested that CYP2C8 enzyme can be influenced by the presence of warfarin, which can modify the uncompetitive binding of the active extract components on the enzyme. 	CYP2C8	26217	26223	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:159	It seems possible that some competition could have happened between quercetin and warfarin on the binding site of CYP2C8 since previous studies showed that quercetin can competitively inhibit the effect of CYP2C8 [,. 	CYP2C8	26483	26489	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:159	It seems possible that some competition could have happened between quercetin and warfarin on the binding site of CYP2C8 since previous studies showed that quercetin can competitively inhibit the effect of CYP2C8 [,. 	CYP2C8	26483	26489	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:159	It seems possible that some competition could have happened between quercetin and warfarin on the binding site of CYP2C8 since previous studies showed that quercetin can competitively inhibit the effect of CYP2C8 [,. 	CYP2C8	26575	26581	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:159	It seems possible that some competition could have happened between quercetin and warfarin on the binding site of CYP2C8 since previous studies showed that quercetin can competitively inhibit the effect of CYP2C8 [,. 	CYP2C8	26575	26581	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:160	Thus, explains the influence of quercetin in reducing CYP2C8 activity in tested rat hepatocytes. 	CYP2C8	26640	26646	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:160	Thus, explains the influence of quercetin in reducing CYP2C8 activity in tested rat hepatocytes. 	CYP2C8	26640	26646	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:237	Mostly all the compounds were found to be a substrate of CYP1A2, except F25, whereas, for CYP2C8, only compound F2 was found to be the substrate. 	CYP2C8	38346	38352	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:237	Mostly all the compounds were found to be a substrate of CYP1A2, except F25, whereas, for CYP2C8, only compound F2 was found to be the substrate. 	CYP2C8	38346	38352	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:100	Moreover, even if sorafenib is not a substrate for the cytochrome isoforms CYP2B6, CYP2C8, and CYP2C9 and the UDP glucuronosyltransferase UGT1A1, the biological agent in vivo inhibits activity of these enzymes with potential pharmacological consequences and drug-interaction events. 	CYP2C8	18739	18745	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:100	Moreover, even if sorafenib is not a substrate for the cytochrome isoforms CYP2B6, CYP2C8, and CYP2C9 and the UDP glucuronosyltransferase UGT1A1, the biological agent in vivo inhibits activity of these enzymes with potential pharmacological consequences and drug-interaction events. 	CYP2C8	18739	18745	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2C8	39787	39793	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2C8	39787	39793	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:139	Visual inspection of the data points of the correlation between CYP2C9 activity and flucloxacillin hydroxylation shows a trend that the line does not cross the Xaxis at the origin but at 280 pmolmin^1mg^1 protein. 	CYP2C9	23177	23183	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:146	At 10 M flucloxacillin, CYP2C9 showed a 8 to 10fold lower activity. 	CYP2C9	24407	24413	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:149	did not detect 5HMFLX in incubations with recombinant CYP1A2, CYP2C9 and CYP3A5 might be attributed to the less sensitive analytical method used (HPLC-UV detection versus LC-MS) and/or the use of yeastexpressed CYPs with lower specific activity than the Supersomes used in the present study. 	CYP2C9	24657	24663	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:169	Remarkably, sulfaphenazole, which is considered to be a highly selective inhibitor of CYP2C9 (Khojasteh et al., ), showed clear inhibition of flucloxacillin hydroxylation by pooled HLM, CYP3A4 and CYP3A7, whereas the 6BETAhydroxylation of testosterone was not affected. 	CYP2C9	27990	27996	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:171	A similar situation has been described recently in a study where sulfaphenazole significantly inhibited bioactivation of hydroxylapatinib by HLM, although recombinant CYP2C9 showed only very low activity (Towles et al.,. 	CYP2C9	28559	28565	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:177	In conclusion, the results of this present study confirm the involvement of CYP3A4 in the hydroxylation of flucloxacillin, whereas CYP3A7 and CYP2C9 may also contribute significantly in individuals expressing high hepatic levels. 	CYP2C9	29350	29356	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:178	The large variability of both hepatic CYP3A and CYP2C9 levels may contribute to the variability of plasma levels of 5HMFLX, which is suspected to play a role in flucloxacillin induced DILI by causing cytotoxicity to biliary epithelial cells. 	CYP2C9	29486	29492	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:179	The strong inhibition of CYP3Acatalysed hydroxylation of flucloxacillin by the commonly used CYP2C9 inhibitor sulfaphenazole suggest that unanticipated drug-drug interactions can occur with coadministered drugs. 	CYP2C9	29773	29779	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:21	For example, St Johns wort induces microsomal cytochrome P450 enzyme-mediated metabolism of warfarin, particularly CYP2C9 and increases warfarin clearance. 	CYP2C9	3679	3685	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:54	P450-Glo CYP2C9 with Luciferin-H, P450-Glo 2C8 with Luciferin-ME and P450-Glo 3A4 with Luciferin-IPA Assay kits were purchased from Promega (Madison, USA). 	CYP2C9	8293	8299	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:118	All utilized control inhibitors namely; sulfamethoxazole, trimethoprim and ketoconazole significantly reduced corresponding CYPs, CYP2C9, 2C8 and 3A4 activities, respectively (p < 0.01). 	CYP2C9	18616	18622	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:119	Combination of ellagic acid with warfarin significantly inhibited activities of CYP2C8, 2C9 and 3A4 (p < 0.05), however treatment of cells with ellagic acid alone presented significant inhibition on CYP2C9 activity despite other CYPs (p < 0.05). 	CYP2C9	18872	18878	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:120	Although guava leaves extract showed an insignificant effect on CYP2C8 when used alone, it significantly reduced its activity when combined with warfarin (p < 0.01) and however, inhibited the activities of CYP2C9 and 3A4 when used alone and concomitantly with warfarin (p-values are marked in Figs. 	CYP2C9	19125	19131	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	CYP2C9	21765	21771	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:137	In regard to results presented for ellagic acid, and since it is known to exert inhibition on CYP2C9, its effect may be due to a decrease in hepatic first-pass metabolism of warfarin due to its ability to inhibit such Cytochrome P450 Enzymes isoform. 	CYP2C9	22217	22223	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:143	Furthermore, the ability of guava leaves extract and quercetin to inhibit some of hepatic Cytochrome P450 Enzymes isoforms associated with warfarin metabolism such as CYP2C9, 2C8 and 3A4 may be responsible for increasing warfarin plasma concentration [,. 	CYP2C9	23574	23580	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:145	In vitro warfarin-herb interactions and their effects on hepatic Cytochrome P450 Enzymes isoforms showed that CYP2C9, 2C8 and 3A4 activities in primary isolated and cultured rat hepatocytes were not affected by warfarin. 	CYP2C9	23929	23935	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:148	Significant reduction exerted by the use of ellagic acid whether used alone or concomitantly with warfarin is in line with those reported in previous studies which showed that ellagic acid had inhibitory effect on many CYPs isoforms including CYP2C9. 	CYP2C9	24625	24631	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:153	In reviewing the literature, no data was found on warfarin combinations with pomegranate peel extract and ellagic acid effect on CYP2C9, 2C8 and 3A4 activities. 	CYP2C9	25485	25491	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:154	The observed reduction in CYP2C9 activity upon treatment with by guava leaves extract, quercetin and their combinations with warfarin could be attributed to the competitive inhibitory effect of quercetin on CYP2C9. 	CYP2C9	25543	25549	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:154	The observed reduction in CYP2C9 activity upon treatment with by guava leaves extract, quercetin and their combinations with warfarin could be attributed to the competitive inhibitory effect of quercetin on CYP2C9. 	CYP2C9	25724	25730	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:155	These results were consistent with previous studies that demonstrated the inhibitory effects of guava leaves extract and quercetin on CYP2C9 activity [,. 	CYP2C9	25866	25872	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:166	The possible mechanism for that is their inhibitory effect on CYP2C9, 2C8 and 3A4 isoforms which are responsible for warfarin metabolism. 	CYP2C9	27609	27615	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:172	The previously mentioned interactions might be attributed to the inhibitory effects of guava leaves, quercetin and ellagic acid on CYP2C9, 2C8 and 3A4 that are responsible for the metabolism of warfarin. 	CYP2C9	28378	28384	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:238	Additionally, the compounds F2, F3, F11, F20, and F21 were found to be the substrate of CYP2C9. 	CYP2C9	38490	38496	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:242	Likewise for predicting the site of enzyme CYP2C9, the K_m value was 3.43, 5.38, 3.81, 3.59 and 37.40 M, whereas the V_max constant was 0.38, 0.35, 0.24, 0.49 and 4.95 nM/min/nM and the C_Lint was 8.14, 4.8, 4.61, 9.97 and 9.67 L/min/mg for compounds F2, F3, F11, F20 and F21, respectively. 	CYP2C9	39289	39295	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2C9	40387	40393	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:100	Moreover, even if sorafenib is not a substrate for the cytochrome isoforms CYP2B6, CYP2C8, and CYP2C9 and the UDP glucuronosyltransferase UGT1A1, the biological agent in vivo inhibits activity of these enzymes with potential pharmacological consequences and drug-interaction events. 	CYP2C9	18751	18757	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2C9	39795	39801	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:245	This drug undergoes hepatic metabolism by Cytochrome P450 3a4 and, to a minor extent, by CYP2C9. 	CYP2C9	50271	50277	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP2C9	24758	24764	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:140	The CYP2C19 gene is part of the CYP2C cluster comprising four genes (CYP2C8, CYP2C9, CYP2C18 and CYP2C19). 	CYP2C9	26256	26262	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:179	In additions, others have also reported strong association between CYP2C9 allelic variants and phenytoin dose requirement. 	CYP2C9	34050	34056	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:188	Several studies have been focused on drug-drug interactions and genetic polymorphisms including CYP2D6, CYP2C9 and CYP2C19 activities. 	CYP2C9	36083	36089	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:222	In contrast, variants of CYP2C9 are more prevalent among whites (35%) compared with African-American and Asian populations (<10%). 	CYP2C9	42254	42260	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:19	CYP1A-catalyzed reactions include hydroxylation and oxidation of aromatic compounds, in which CYP1A1 is mainly involved in the metabolism of aromatic hydrocarbon, while CYP1A2 prefers aromatic amines and heterocyclic compounds. 	CYP1A1	2770	2776	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:19	CYP1A-catalyzed reactions include hydroxylation and oxidation of aromatic compounds, in which CYP1A1 is mainly involved in the metabolism of aromatic hydrocarbon, while CYP1A2 prefers aromatic amines and heterocyclic compounds. 	CYP1A1	2770	2776	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:33	Compared with CYP1A2, CYP1A1 is the main isoform mediating the biotransformation of pregnenolone. 	CYP1A1	4950	4956	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:33	Compared with CYP1A2, CYP1A1 is the main isoform mediating the biotransformation of pregnenolone. 	CYP1A1	4950	4956	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:34	Previous studies have shown that CYP1A1 is the dominating enzyme and catalyzes the BETA-hydroxylation of pregnenolone at the C-7 site, with the K_m of 3.2-4.1 mol/L and CL_int of 117-135 pmol/min/nmol. 	CYP1A1	5059	5065	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:34	Previous studies have shown that CYP1A1 is the dominating enzyme and catalyzes the BETA-hydroxylation of pregnenolone at the C-7 site, with the K_m of 3.2-4.1 mol/L and CL_int of 117-135 pmol/min/nmol. 	CYP1A1	5059	5065	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:35	Moreover, the CYP1A1, which involves 7-hydroxylated steroids, may contribute to the activation of immune defense. 	CYP1A1	5242	5248	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:35	Moreover, the CYP1A1, which involves 7-hydroxylated steroids, may contribute to the activation of immune defense. 	CYP1A1	5242	5248	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:36	Furthermore, CYP1A1 also hydroxylates pregnenolone to form 16ALPHA- and 17ALPHA-hydroxylated pregnenolone. 	CYP1A1	5355	5361	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:36	Furthermore, CYP1A1 also hydroxylates pregnenolone to form 16ALPHA- and 17ALPHA-hydroxylated pregnenolone. 	CYP1A1	5355	5361	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:48	For example, CYP1A1 shows high hydroxylase activity of progesterone, which results in the formation of 6BETA-hydroxyl and 16ALPHA-hydroxyl progesterone, with the V_max at 16.4 and 7.7 pmol/min/pmol P450, respectively. 	CYP1A1	7078	7084	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:48	For example, CYP1A1 shows high hydroxylase activity of progesterone, which results in the formation of 6BETA-hydroxyl and 16ALPHA-hydroxyl progesterone, with the V_max at 16.4 and 7.7 pmol/min/pmol P450, respectively. 	CYP1A1	7078	7084	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:58	Both CYP1A1 and CYP1A2 are involved in the biotransformation of estrone, but they mediate different reaction types. 	CYP1A1	8166	8172	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:58	Both CYP1A1 and CYP1A2 are involved in the biotransformation of estrone, but they mediate different reaction types. 	CYP1A1	8166	8172	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:60	In contrast, CYP1A1 oxidizes estrone to quinol at the C-10 position. 	CYP1A1	8397	8403	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:60	In contrast, CYP1A1 oxidizes estrone to quinol at the C-10 position. 	CYP1A1	8397	8403	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:66	CYP1A1 is the main isoform mediating the hydroxylation of estradiol at different sites (A). 	CYP1A1	8871	8877	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:66	CYP1A1 is the main isoform mediating the hydroxylation of estradiol at different sites (A). 	CYP1A1	8871	8877	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:68	CYP1A1 mediates the hydroxylation of estradiol at a relatively low K_m of 2.9 and 2.7 mol/L, respectively. 	CYP1A1	9040	9046	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:68	CYP1A1 mediates the hydroxylation of estradiol at a relatively low K_m of 2.9 and 2.7 mol/L, respectively. 	CYP1A1	9040	9046	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:69	The V_max of CYP1A1 at C-2 and C-4 are 14.7 and 0.4 nmol/min/nmol P450, respectively, which indicates the main production of 2-hydroxylation estradiol compared with 4-hydroxylation estradiol^,. 	CYP1A1	9160	9166	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:69	The V_max of CYP1A1 at C-2 and C-4 are 14.7 and 0.4 nmol/min/nmol P450, respectively, which indicates the main production of 2-hydroxylation estradiol compared with 4-hydroxylation estradiol^,. 	CYP1A1	9160	9166	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:70	Moreover, CYP1A1 also hydroxylates estradiol at C-6 and C-15, and forms ALPHA-hydroxylated estradiol at corresponding sites. 	CYP1A1	9351	9357	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:70	Moreover, CYP1A1 also hydroxylates estradiol at C-6 and C-15, and forms ALPHA-hydroxylated estradiol at corresponding sites. 	CYP1A1	9351	9357	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:71	In addition to participating in the hydroxylation of estradiol, CYP1A1 is also involved in the quinol formation, with the product of 10BETA,17BETA-dihydroxy-1,4-estradiene-3-one. 	CYP1A1	9530	9536	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:71	In addition to participating in the hydroxylation of estradiol, CYP1A1 is also involved in the quinol formation, with the product of 10BETA,17BETA-dihydroxy-1,4-estradiene-3-one. 	CYP1A1	9530	9536	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:72	Compared with CYP1A1, CYP1A2 contributes to the hydroxylation of estradiol at C-2 and C-4 with a lower V_max^,^, (A). 	CYP1A1	9659	9665	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:72	Compared with CYP1A1, CYP1A2 contributes to the hydroxylation of estradiol at C-2 and C-4 with a lower V_max^,^, (A). 	CYP1A1	9659	9665	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:75	CYP1A1 and CYP1A2 metabolize estradiol 3-methyl ether to estradiol through 3-demethylation reaction with the V_max of 0.07 and 0.02 pmol/min/pmol P450, respectively (B). 	CYP1A1	9992	9998	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:75	CYP1A1 and CYP1A2 metabolize estradiol 3-methyl ether to estradiol through 3-demethylation reaction with the V_max of 0.07 and 0.02 pmol/min/pmol P450, respectively (B). 	CYP1A1	9992	9998	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:80	CYP1A1 hydroxylates testosterone to produce 6BETA-hydroxyl testosterone, with the K_m and V_max at 10.1 mol/L and 14.8 pmol/min/pmol P450, respectively. 	CYP1A1	10694	10700	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:80	CYP1A1 hydroxylates testosterone to produce 6BETA-hydroxyl testosterone, with the K_m and V_max at 10.1 mol/L and 14.8 pmol/min/pmol P450, respectively. 	CYP1A1	10694	10700	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:84	CYP1A1 and CYP1A2 both catalyze melatonin to form 6-hydroxymelatonin, and CYP1A2 is the primary isoform, which promotes this biotransformation^, (A). 	CYP1A1	11104	11110	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:84	CYP1A1 and CYP1A2 both catalyze melatonin to form 6-hydroxymelatonin, and CYP1A2 is the primary isoform, which promotes this biotransformation^, (A). 	CYP1A1	11104	11110	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A1	12011	12017	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A1	12011	12017	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A1	12107	12113	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A1	12107	12113	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A1	12192	12198	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A1	12192	12198	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:92	At the same time, CYP1A1 and CYP1A2 also showed high activity of retinal dehydrogenase, forming the functional metabolite t-RA (B). 	CYP1A1	12272	12278	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:92	At the same time, CYP1A1 and CYP1A2 also showed high activity of retinal dehydrogenase, forming the functional metabolite t-RA (B). 	CYP1A1	12272	12278	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:93	These studies indicate that CYP1A1 and CYP1A2 are two major enzymes for human t-ROH to form t-RA, compared with other Cytochrome P450 isoforms. 	CYP1A1	12414	12420	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:93	These studies indicate that CYP1A1 and CYP1A2 are two major enzymes for human t-ROH to form t-RA, compared with other Cytochrome P450 isoforms. 	CYP1A1	12414	12420	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:109	In particular, CYP1A1 or CYP1A2 mutations are reported to be associated with many human diseases, suggesting that CYP1A may affect these diseases by regulating the formation or metabolism of some endogenous mediators. 	CYP1A1	14501	14507	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:109	In particular, CYP1A1 or CYP1A2 mutations are reported to be associated with many human diseases, suggesting that CYP1A may affect these diseases by regulating the formation or metabolism of some endogenous mediators. 	CYP1A1	14501	14507	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:116	At the Pharmacogene Variation Consortium (https://www.pharmvar.org/), there are 27 and 48 Single Nucleotide Polymorphisms for human CYP1A1 and CYP1A2, respectively, of which 14 and 40 variants have been identified. 	CYP1A1	15643	15649	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:116	At the Pharmacogene Variation Consortium (https://www.pharmvar.org/), there are 27 and 48 Single Nucleotide Polymorphisms for human CYP1A1 and CYP1A2, respectively, of which 14 and 40 variants have been identified. 	CYP1A1	15643	15649	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:120	In this section, we will focus on the relationship between single nucleotide changes in CYP1A1/2 and human diseases. 	CYP1A1	16181	16187	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:120	In this section, we will focus on the relationship between single nucleotide changes in CYP1A1/2 and human diseases. 	CYP1A1	16181	16187	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:123	Eleven Single Nucleotide Polymorphisms of CYP1A1 in human diseases such as chronic obstructive pulmonary disease, male infertility, and various cancers were collected. 	CYP1A1	16550	16556	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:123	Eleven Single Nucleotide Polymorphisms of CYP1A1 in human diseases such as chronic obstructive pulmonary disease, male infertility, and various cancers were collected. 	CYP1A1	16550	16556	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:125	CYP1A1*2A (SNP ID: rs4646903), also known as Mspl, has T-C mutation at 3801. 	CYP1A1	16779	16785	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:125	CYP1A1*2A (SNP ID: rs4646903), also known as Mspl, has T-C mutation at 3801. 	CYP1A1	16779	16785	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:126	CYP1A1*2A is reported to be positively correlated with the risk or incidence of a series of cancers, including esophageal, oral, laryngeal, prostate, cervical, bladder, and lung cancers. 	CYP1A1	16856	16862	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:126	CYP1A1*2A is reported to be positively correlated with the risk or incidence of a series of cancers, including esophageal, oral, laryngeal, prostate, cervical, bladder, and lung cancers. 	CYP1A1	16856	16862	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:49	In contrast, CYP1A2 is more likely to mediate hydroxylation at the C-6 site, resulting in the formation of 6BETA-hydroxyl progesterone. 	CYP1A2	7296	7302	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:49	In contrast, CYP1A2 is more likely to mediate hydroxylation at the C-6 site, resulting in the formation of 6BETA-hydroxyl progesterone. 	CYP1A2	7296	7302	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:58	Both CYP1A1 and CYP1A2 are involved in the biotransformation of estrone, but they mediate different reaction types. 	CYP1A2	8177	8183	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:58	Both CYP1A1 and CYP1A2 are involved in the biotransformation of estrone, but they mediate different reaction types. 	CYP1A2	8177	8183	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:59	CYP1A2 is thought to be involved in estrone metabolism by direct hydrolysis of C-2, C-4, and C-16 sites^,. 	CYP1A2	8277	8283	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:59	CYP1A2 is thought to be involved in estrone metabolism by direct hydrolysis of C-2, C-4, and C-16 sites^,. 	CYP1A2	8277	8283	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:72	Compared with CYP1A1, CYP1A2 contributes to the hydroxylation of estradiol at C-2 and C-4 with a lower V_max^,^, (A). 	CYP1A2	9667	9673	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:72	Compared with CYP1A1, CYP1A2 contributes to the hydroxylation of estradiol at C-2 and C-4 with a lower V_max^,^, (A). 	CYP1A2	9667	9673	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:73	CYP1A2 also participates in the hydroxylation of estradiol at C-16, while the C-2 hydroxylation estradiol is a dominant hydroxylated metabolite catalyzed by CYP1A2^, (A). 	CYP1A2	9763	9769	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:73	CYP1A2 also participates in the hydroxylation of estradiol at C-16, while the C-2 hydroxylation estradiol is a dominant hydroxylated metabolite catalyzed by CYP1A2^, (A). 	CYP1A2	9763	9769	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:73	CYP1A2 also participates in the hydroxylation of estradiol at C-16, while the C-2 hydroxylation estradiol is a dominant hydroxylated metabolite catalyzed by CYP1A2^, (A). 	CYP1A2	9920	9926	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:73	CYP1A2 also participates in the hydroxylation of estradiol at C-16, while the C-2 hydroxylation estradiol is a dominant hydroxylated metabolite catalyzed by CYP1A2^, (A). 	CYP1A2	9920	9926	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:75	CYP1A1 and CYP1A2 metabolize estradiol 3-methyl ether to estradiol through 3-demethylation reaction with the V_max of 0.07 and 0.02 pmol/min/pmol P450, respectively (B). 	CYP1A2	10003	10009	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:75	CYP1A1 and CYP1A2 metabolize estradiol 3-methyl ether to estradiol through 3-demethylation reaction with the V_max of 0.07 and 0.02 pmol/min/pmol P450, respectively (B). 	CYP1A2	10003	10009	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:76	CYP1A2 also hydroxylates estradiol 3-methyl ether at C-2 to increase its hydrophilicity, which may contribute to its excretion from the body. 	CYP1A2	10162	10168	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:76	CYP1A2 also hydroxylates estradiol 3-methyl ether at C-2 to increase its hydrophilicity, which may contribute to its excretion from the body. 	CYP1A2	10162	10168	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:84	CYP1A1 and CYP1A2 both catalyze melatonin to form 6-hydroxymelatonin, and CYP1A2 is the primary isoform, which promotes this biotransformation^, (A). 	CYP1A2	11115	11121	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:84	CYP1A1 and CYP1A2 both catalyze melatonin to form 6-hydroxymelatonin, and CYP1A2 is the primary isoform, which promotes this biotransformation^, (A). 	CYP1A2	11115	11121	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:84	CYP1A1 and CYP1A2 both catalyze melatonin to form 6-hydroxymelatonin, and CYP1A2 is the primary isoform, which promotes this biotransformation^, (A). 	CYP1A2	11178	11184	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:84	CYP1A1 and CYP1A2 both catalyze melatonin to form 6-hydroxymelatonin, and CYP1A2 is the primary isoform, which promotes this biotransformation^, (A). 	CYP1A2	11178	11184	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:85	In addition, CYP1A2 catalyzes the O-demethylation of melatonin to produce N-acetylserotonin (A). 	CYP1A2	11267	11273	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:85	In addition, CYP1A2 catalyzes the O-demethylation of melatonin to produce N-acetylserotonin (A). 	CYP1A2	11267	11273	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:86	In recent ten years, a new metabolite of melatonin has been reported, named melatonin metabolite VII, which is also a metabolite mediated by CYP1A2. 	CYP1A2	11492	11498	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:86	In recent ten years, a new metabolite of melatonin has been reported, named melatonin metabolite VII, which is also a metabolite mediated by CYP1A2. 	CYP1A2	11492	11498	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A2	12022	12028	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A2	12022	12028	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A2	12130	12136	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A2	12130	12136	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A2	12241	12247	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	CYP1A2	12241	12247	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:92	At the same time, CYP1A1 and CYP1A2 also showed high activity of retinal dehydrogenase, forming the functional metabolite t-RA (B). 	CYP1A2	12283	12289	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:92	At the same time, CYP1A1 and CYP1A2 also showed high activity of retinal dehydrogenase, forming the functional metabolite t-RA (B). 	CYP1A2	12283	12289	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:93	These studies indicate that CYP1A1 and CYP1A2 are two major enzymes for human t-ROH to form t-RA, compared with other Cytochrome P450 isoforms. 	CYP1A2	12425	12431	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:93	These studies indicate that CYP1A1 and CYP1A2 are two major enzymes for human t-ROH to form t-RA, compared with other Cytochrome P450 isoforms. 	CYP1A2	12425	12431	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:97	In particular, CYP1A2 converts linoleic acid into hydroxyoctadecdienoic acids and cis-epoxyoctadecenoics (C) with comparable catalytic activity. 	CYP1A2	12994	13000	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:97	In particular, CYP1A2 converts linoleic acid into hydroxyoctadecdienoic acids and cis-epoxyoctadecenoics (C) with comparable catalytic activity. 	CYP1A2	12994	13000	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:99	CYP1A2 possesses an unusual catalytic activity similar to phospholipase D-type hydrolysis enzymes. 	CYP1A2	13222	13228	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:99	CYP1A2 possesses an unusual catalytic activity similar to phospholipase D-type hydrolysis enzymes. 	CYP1A2	13222	13228	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:100	Based on the metabolic activity, CYP1A2 converts phosphatidylcholine to choline and phosphatidic acid^,^, (A). 	CYP1A2	13354	13360	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:100	Based on the metabolic activity, CYP1A2 converts phosphatidylcholine to choline and phosphatidic acid^,^, (A). 	CYP1A2	13354	13360	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:101	This may imply the important physiological role of CYP1A2, because as a signal transduction messenger, phosphatidic acid plays a key role in regulating cell activity. 	CYP1A2	13483	13489	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:101	This may imply the important physiological role of CYP1A2, because as a signal transduction messenger, phosphatidic acid plays a key role in regulating cell activity. 	CYP1A2	13483	13489	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:103	Previous studies have also found that human CYP1A2 catalyzes the oxidation of uroporphyrinogen^, (B). 	CYP1A2	13760	13766	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:103	Previous studies have also found that human CYP1A2 catalyzes the oxidation of uroporphyrinogen^, (B). 	CYP1A2	13760	13766	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:109	In particular, CYP1A1 or CYP1A2 mutations are reported to be associated with many human diseases, suggesting that CYP1A may affect these diseases by regulating the formation or metabolism of some endogenous mediators. 	CYP1A2	14511	14517	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:109	In particular, CYP1A1 or CYP1A2 mutations are reported to be associated with many human diseases, suggesting that CYP1A may affect these diseases by regulating the formation or metabolism of some endogenous mediators. 	CYP1A2	14511	14517	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:116	At the Pharmacogene Variation Consortium (https://www.pharmvar.org/), there are 27 and 48 Single Nucleotide Polymorphisms for human CYP1A1 and CYP1A2, respectively, of which 14 and 40 variants have been identified. 	CYP1A2	15654	15660	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:116	At the Pharmacogene Variation Consortium (https://www.pharmvar.org/), there are 27 and 48 Single Nucleotide Polymorphisms for human CYP1A1 and CYP1A2, respectively, of which 14 and 40 variants have been identified. 	CYP1A2	15654	15660	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:131	For CYP1A2, nine Single Nucleotide Polymorphisms are found to be associated with human diseases, including hypertension, age-related macular degeneration, and some cancers. 	CYP1A2	17607	17613	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:131	For CYP1A2, nine Single Nucleotide Polymorphisms are found to be associated with human diseases, including hypertension, age-related macular degeneration, and some cancers. 	CYP1A2	17607	17613	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:133	CYP1A2*1F (SNP ID: rs762551) has a C to A mutation at -163, which may be related to breast cancer, ovarian cancer, mammographic density, and risk of infant birth size, because it is involved in the biological transformation of sex hormones^,^,^,. 	CYP1A2	17833	17839	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:133	CYP1A2*1F (SNP ID: rs762551) has a C to A mutation at -163, which may be related to breast cancer, ovarian cancer, mammographic density, and risk of infant birth size, because it is involved in the biological transformation of sex hormones^,^,^,. 	CYP1A2	17833	17839	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:143	As mentioned earlier, CYP1A1 and CYP1A2 are involved in the biotransformation of multiple estrogens, and thus are important for maintaining the balance of estrogens. 	CYP1A2	19448	19454	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:143	As mentioned earlier, CYP1A1 and CYP1A2 are involved in the biotransformation of multiple estrogens, and thus are important for maintaining the balance of estrogens. 	CYP1A2	19448	19454	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:190	However, the metabolic activity of CYP1A2 SNP (rs2069514) was lower than that of wild type. 	CYP1A2	25271	25277	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:190	However, the metabolic activity of CYP1A2 SNP (rs2069514) was lower than that of wild type. 	CYP1A2	25271	25277	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:191	There was no significant correlation between CYP1A2 SNP and mental disorders. 	CYP1A2	25373	25379	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:191	There was no significant correlation between CYP1A2 SNP and mental disorders. 	CYP1A2	25373	25379	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:192	Similarly, another CYP1A2 SNP (rs762551) showed no significant dependence on mental disorders with the increase of inducibility. 	CYP1A2	25425	25431	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:192	Similarly, another CYP1A2 SNP (rs762551) showed no significant dependence on mental disorders with the increase of inducibility. 	CYP1A2	25425	25431	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:193	However, for super-refractory schizophrenia, the frequency of CYP1A2 SNP (rs762551) in super-refractory group (87%) was significantly higher than that in refractory group (53.7%). 	CYP1A2	25597	25603	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:193	However, for super-refractory schizophrenia, the frequency of CYP1A2 SNP (rs762551) in super-refractory group (87%) was significantly higher than that in refractory group (53.7%). 	CYP1A2	25597	25603	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:194	Therefore, the role of CYP1A2 SNP in mental disorders should be studied in more detail. 	CYP1A2	25738	25744	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:194	Therefore, the role of CYP1A2 SNP in mental disorders should be studied in more detail. 	CYP1A2	25738	25744	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:196	Although neonatal survival is associated with CYP1A2 in Cyp1a2 knockout mice, the relationship between retinol and reproductive diseases remains unclear. 	CYP1A2	26008	26014	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:196	Although neonatal survival is associated with CYP1A2 in Cyp1a2 knockout mice, the relationship between retinol and reproductive diseases remains unclear. 	CYP1A2	26008	26014	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:201	However, CYP1A1 SNP (rs1048943) and CYP1A2 Single Nucleotide Polymorphisms (rs762551, rs1133323, and rs1378942) are positively correlated with hypertension susceptibility^,. 	CYP1A2	26639	26645	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:201	However, CYP1A1 SNP (rs1048943) and CYP1A2 Single Nucleotide Polymorphisms (rs762551, rs1133323, and rs1378942) are positively correlated with hypertension susceptibility^,. 	CYP1A2	26639	26645	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:205	CYP1A2 is mainly responsible for the transformation of uroporphyrinogen to uroporphyrin. 	CYP1A2	27279	27285	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:205	CYP1A2 is mainly responsible for the transformation of uroporphyrinogen to uroporphyrin. 	CYP1A2	27279	27285	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:207	Nonetheless, the association between CYP1A2 Single Nucleotide Polymorphisms and porphyria cutanea tarda remains uncertain. 	CYP1A2	27525	27531	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:207	Nonetheless, the association between CYP1A2 Single Nucleotide Polymorphisms and porphyria cutanea tarda remains uncertain. 	CYP1A2	27525	27531	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:226	In this part, the Single Nucleotide Polymorphisms of CYP1A (11 for CYP1A1 and 9 for CYP1A2) studied most in recent 10 years are reviewed for the first time, and the relationship between CYP1A Single Nucleotide Polymorphisms and human diseases is summarized. 	CYP1A2	30218	30224	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:226	In this part, the Single Nucleotide Polymorphisms of CYP1A (11 for CYP1A1 and 9 for CYP1A2) studied most in recent 10 years are reviewed for the first time, and the relationship between CYP1A Single Nucleotide Polymorphisms and human diseases is summarized. 	CYP1A2	30218	30224	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP1A2	11176	11182	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:169	We identified the position of each amino acid for each Single Nucleotide Polymorphisms and the upstream Single Nucleotide Polymorphisms and downstream Single Nucleotide Polymorphisms including Single Nucleotide Polymorphisms (rs28399504 (CYP2C19*4) located on amino acid number 1 (valine), rs17878459 (CYP2C19*17), located on amino acid 92, (aspartic, D), rs4986893 CYP2C19*3 located on amino acid number 212 (NA), rs4244285 (CYP2C19*2) located on amino acid 227 (proline), and rs56337013 (CYP2C19*5) located on amino acid number 433 (tryptophan, W).  	CYP2C19	32345	32352	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:169	We identified the position of each amino acid for each Single Nucleotide Polymorphisms and the upstream Single Nucleotide Polymorphisms and downstream Single Nucleotide Polymorphisms including Single Nucleotide Polymorphisms (rs28399504 (CYP2C19*4) located on amino acid number 1 (valine), rs17878459 (CYP2C19*17), located on amino acid 92, (aspartic, D), rs4986893 CYP2C19*3 located on amino acid number 212 (NA), rs4244285 (CYP2C19*2) located on amino acid 227 (proline), and rs56337013 (CYP2C19*5) located on amino acid number 433 (tryptophan, W).  	CYP2C19	32409	32416	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:171	In general terms, people carrying two loss-of-function CYP2C19 alleles (eg, CYP2C19*2, CYP2C19*3 or CYP2C19*4) are considered to be poor metabolizers with deficient enzyme activity. 	CYP2C19	32617	32624	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:171	In general terms, people carrying two loss-of-function CYP2C19 alleles (eg, CYP2C19*2, CYP2C19*3 or CYP2C19*4) are considered to be poor metabolizers with deficient enzyme activity. 	CYP2C19	32638	32645	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:171	In general terms, people carrying two loss-of-function CYP2C19 alleles (eg, CYP2C19*2, CYP2C19*3 or CYP2C19*4) are considered to be poor metabolizers with deficient enzyme activity. 	CYP2C19	32649	32656	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:171	In general terms, people carrying two loss-of-function CYP2C19 alleles (eg, CYP2C19*2, CYP2C19*3 or CYP2C19*4) are considered to be poor metabolizers with deficient enzyme activity. 	CYP2C19	32662	32669	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:172	Individuals with single loss-of-function allele and a wild-type allele (CYP2C19*1) are intermediate metabolizers, whereas two wild-type are extensive metabolizers. 	CYP2C19	32816	32823	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:173	People that are homozygous or heterozygous for CYP2C19*17 alleles are typically considered to be ultrarapid metabolizers, supposing loss-of-function alleles are not present. 	CYP2C19	32955	32962	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:174	It has been suggested that inherited genetic variation in CYP2C19 and its variable hepatic expression can contribute to inter-individual phenotypic variability in CYP2C19-substrate metabolism. 	CYP2C19	33140	33147	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:174	It has been suggested that inherited genetic variation in CYP2C19 and its variable hepatic expression can contribute to inter-individual phenotypic variability in CYP2C19-substrate metabolism. 	CYP2C19	33245	33252	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:175	CYP2C19 proteins can catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids, and this protein localizes to the endoplasmic reticulum and is known to metabolize many drugs. 	CYP2C19	33275	33282	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:177	The genotype has been suggested CYP2C19 to affect the metabolism of several. 	CYP2C19	33720	33727	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:178	It has been reported that CYP2C19*2 and *3 mutant alleles caused decreased hydroxylation of phenytoin in vivo, whereas the mutant alleles of CYP2C19 played only a minor role in the metabolism of phenytoin in subjects. 	CYP2C19	33791	33798	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:178	It has been reported that CYP2C19*2 and *3 mutant alleles caused decreased hydroxylation of phenytoin in vivo, whereas the mutant alleles of CYP2C19 played only a minor role in the metabolism of phenytoin in subjects. 	CYP2C19	33906	33913	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:181	The genetic polymorphisms of CYP2C19 have been associated with variable responses of drugs with clinical relevance, by affecting drug metabolic clearance that subsequently contribute to variabilities in pharmacodynamics that include both efficacy and safety. 	CYP2C19	34284	34291	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:188	Several studies have been focused on drug-drug interactions and genetic polymorphisms including CYP2D6, CYP2C9 and CYP2C19 activities. 	CYP2C19	36094	36101	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:189	In particular, CYP2C19 enzyme is involved in the hepatic metabolism of drugs such as chemotherapeutic agents (cyclophosphamide), anti-epileptics (S-mephenytoin, diazepam, phenobarbitone), antiplatelets (clopidogrel), proton pump inhibitors (omeprazole, pantoprazole, lansoprazole, rabeprazole), antivirals (nelfinavir), and antidepressants (amitriptyline, clomipramine). 	CYP2C19	36129	36136	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:197	To better understand the genetics and drug metabolizing enzymes of CYP2C19 it is important to study the variability in drug response and adverse drug reactions. 	CYP2C19	37912	37919	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:199	Subjects with epilepsy can be classified based on the ability to metabolize CYP2C19 substrates. 	CYP2C19	38321	38328	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:200	For example, Extensive Metabolizers individuals are homozygous for the CYP2C19*1 allele, which is associated with functional CYP2C19-mediated metabolism. 	CYP2C19	38412	38419	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:200	For example, Extensive Metabolizers individuals are homozygous for the CYP2C19*1 allele, which is associated with functional CYP2C19-mediated metabolism. 	CYP2C19	38466	38473	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:201	The IM genotype consists of one wild-type allele and one variant allele that encodes reduced or absent enzyme function (eg, *1/*2, *1/*3), resulting in decreased CYP2C19 activity, while, PM individuals have two loss-of-function alleles (eg, *2/*2, *2/*3, *3/*3), resulting in markedly reduced or absent CYP2C19 activity. 	CYP2C19	38657	38664	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:201	The IM genotype consists of one wild-type allele and one variant allele that encodes reduced or absent enzyme function (eg, *1/*2, *1/*3), resulting in decreased CYP2C19 activity, while, PM individuals have two loss-of-function alleles (eg, *2/*2, *2/*3, *3/*3), resulting in markedly reduced or absent CYP2C19 activity. 	CYP2C19	38798	38805	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:202	For CYP2C19 (rs12248560), SNP is located on the CYP2C19*17 allele and is a C > T transition in the promoter that creates a consensus binding site for the GATA transcription factor family, resulting in increased CYP2C19 expression and activity. 	CYP2C19	38820	38827	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:202	For CYP2C19 (rs12248560), SNP is located on the CYP2C19*17 allele and is a C > T transition in the promoter that creates a consensus binding site for the GATA transcription factor family, resulting in increased CYP2C19 expression and activity. 	CYP2C19	38864	38871	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:202	For CYP2C19 (rs12248560), SNP is located on the CYP2C19*17 allele and is a C > T transition in the promoter that creates a consensus binding site for the GATA transcription factor family, resulting in increased CYP2C19 expression and activity. 	CYP2C19	39027	39034	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:203	It has been indicated that the CYP2C19*17 allele frequencies are approximately 21% in Caucasians, 16% in African-Americans, and 3% in Asians. 	CYP2C19	39091	39098	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:206	There was conflict about whether CYP2C19*1/*17 is considered an Ultrarapid Metabolizers or Extensive Metabolizers in literature. 	CYP2C19	39589	39596	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:207	Two studies reported about this CYP2C19*1/*17 metabolism, while, another considered those with the CYP2C19*1/*17 heterozygotes as Ultrarapid Metabolizers, while, other considered them as EMs within the same group as the wild-type CYP2C19*1 homozygotes. 	CYP2C19	39717	39724	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:207	Two studies reported about this CYP2C19*1/*17 metabolism, while, another considered those with the CYP2C19*1/*17 heterozygotes as Ultrarapid Metabolizers, while, other considered them as EMs within the same group as the wild-type CYP2C19*1 homozygotes. 	CYP2C19	39784	39791	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:207	Two studies reported about this CYP2C19*1/*17 metabolism, while, another considered those with the CYP2C19*1/*17 heterozygotes as Ultrarapid Metabolizers, while, other considered them as EMs within the same group as the wild-type CYP2C19*1 homozygotes. 	CYP2C19	39915	39922	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:130	Finally, a CYP2D6*17 polymorphism with reduced activity was not investigated in our study as it was not included in the array used for the PI. 	CYP2D6	21357	21363	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:130	Finally, a CYP2D6*17 polymorphism with reduced activity was not investigated in our study as it was not included in the array used for the PI. 	CYP2D6	21357	21363	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:130	Finally, a CYP2D6*17 polymorphism with reduced activity was not investigated in our study as it was not included in the array used for the PI. 	CYP2D6	21357	21363	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:130	Finally, a CYP2D6*17 polymorphism with reduced activity was not investigated in our study as it was not included in the array used for the PI. 	CYP2D6	21357	21363	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:114	Carriers of CYP2C19*2 (rs4244285; Pro227Pro) or CYP2D6*10 (rs1065852, Pro34Ser) had sorafenib plasma levels and associated liver/renal toxicity that were intermediate between those of rats carrying CYP3A5*3 or CYP3A4*1 genetic variants. 	CYP2D6	22247	22253	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:114	Carriers of CYP2C19*2 (rs4244285; Pro227Pro) or CYP2D6*10 (rs1065852, Pro34Ser) had sorafenib plasma levels and associated liver/renal toxicity that were intermediate between those of rats carrying CYP3A5*3 or CYP3A4*1 genetic variants. 	CYP2D6	22247	22253	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:114	Carriers of CYP2C19*2 (rs4244285; Pro227Pro) or CYP2D6*10 (rs1065852, Pro34Ser) had sorafenib plasma levels and associated liver/renal toxicity that were intermediate between those of rats carrying CYP3A5*3 or CYP3A4*1 genetic variants. 	CYP2D6	22247	22253	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:114	Carriers of CYP2C19*2 (rs4244285; Pro227Pro) or CYP2D6*10 (rs1065852, Pro34Ser) had sorafenib plasma levels and associated liver/renal toxicity that were intermediate between those of rats carrying CYP3A5*3 or CYP3A4*1 genetic variants. 	CYP2D6	22247	22253	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2D6	39832	39838	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2D6	39832	39838	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2D6	39832	39838	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2D6	39832	39838	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP2D6	24775	24781	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP2D6	24775	24781	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP2D6	24775	24781	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP2D6	24775	24781	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:188	Several studies have been focused on drug-drug interactions and genetic polymorphisms including CYP2D6, CYP2C9 and CYP2C19 activities. 	CYP2D6	36075	36081	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:188	Several studies have been focused on drug-drug interactions and genetic polymorphisms including CYP2D6, CYP2C9 and CYP2C19 activities. 	CYP2D6	36075	36081	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:188	Several studies have been focused on drug-drug interactions and genetic polymorphisms including CYP2D6, CYP2C9 and CYP2C19 activities. 	CYP2D6	36075	36081	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:188	Several studies have been focused on drug-drug interactions and genetic polymorphisms including CYP2D6, CYP2C9 and CYP2C19 activities. 	CYP2D6	36075	36081	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:103	Specific UPD/ALD probes reveal that CYP2D6 and CYP2A5 also similarly turn over via both pathways,. 	CYP2D6	23819	23825	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:103	Specific UPD/ALD probes reveal that CYP2D6 and CYP2A5 also similarly turn over via both pathways,. 	CYP2D6	23819	23825	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:103	Specific UPD/ALD probes reveal that CYP2D6 and CYP2A5 also similarly turn over via both pathways,. 	CYP2D6	23819	23825	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:103	Specific UPD/ALD probes reveal that CYP2D6 and CYP2A5 also similarly turn over via both pathways,. 	CYP2D6	23819	23825	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP2D6	32332	32338	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP2D6	32332	32338	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP2D6	32332	32338	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:141	Anti-P450 autoantibodies (anti-liver kidney microsomal Type I) targeting CYP2D6 are also detected in chronic autoimmune hepatitis and hepatitis C viral infections, anti-CYP11A1 in type II autoimmune hepatic polyendocrine syndrome, and anti-CYP17 and anti-CYP21 in Addison's disease,. 	CYP2D6	32332	32338	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2D6	11266	11272	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2D6	11266	11272	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2D6	11266	11272	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2D6	11266	11272	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2D6	13884	13890	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2D6	13884	13890	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2D6	13884	13890	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2D6	13884	13890	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP2D6	19457	19463	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP2D6	19457	19463	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP2D6	19457	19463	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP2D6	19457	19463	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:126	However, for isopetasin and neopetasin, the cytochromes mainly involved in their metabolism were CYP3A4 (87% and 86%), CYP2D6 (61% and 83%), and CYP2C8 (44% and 71%). 	CYP2D6	19738	19744	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:126	However, for isopetasin and neopetasin, the cytochromes mainly involved in their metabolism were CYP3A4 (87% and 86%), CYP2D6 (61% and 83%), and CYP2C8 (44% and 71%). 	CYP2D6	19738	19744	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:126	However, for isopetasin and neopetasin, the cytochromes mainly involved in their metabolism were CYP3A4 (87% and 86%), CYP2D6 (61% and 83%), and CYP2C8 (44% and 71%). 	CYP2D6	19738	19744	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:126	However, for isopetasin and neopetasin, the cytochromes mainly involved in their metabolism were CYP3A4 (87% and 86%), CYP2D6 (61% and 83%), and CYP2C8 (44% and 71%). 	CYP2D6	19738	19744	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:132	Most pronounced was the difference for the CYP2D family: Extend of petasin/neopetasin/isopetasin metabolism was 82%/61%/83% for CYP2D6 (human) versus 37%/36%/7% for CYP2D2 (rats). 	CYP2D6	20712	20718	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:132	Most pronounced was the difference for the CYP2D family: Extend of petasin/neopetasin/isopetasin metabolism was 82%/61%/83% for CYP2D6 (human) versus 37%/36%/7% for CYP2D2 (rats). 	CYP2D6	20712	20718	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:132	Most pronounced was the difference for the CYP2D family: Extend of petasin/neopetasin/isopetasin metabolism was 82%/61%/83% for CYP2D6 (human) versus 37%/36%/7% for CYP2D2 (rats). 	CYP2D6	20712	20718	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:132	Most pronounced was the difference for the CYP2D family: Extend of petasin/neopetasin/isopetasin metabolism was 82%/61%/83% for CYP2D6 (human) versus 37%/36%/7% for CYP2D2 (rats). 	CYP2D6	20712	20718	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:134	In HepaRG cells, the effect of cytochrome inhibition on the toxic effects of Ze 339 was investigated; addition of quinidine (CYP2D6 inhibitor) and montelukast (CYP2C8 inhibitor) attenuated (p < .001 and p = .041, respectively); most of the cytotoxic effect of Ze 339 demonstrated for the highest concentration studied (100 g/ml). 	CYP2D6	21270	21276	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:134	In HepaRG cells, the effect of cytochrome inhibition on the toxic effects of Ze 339 was investigated; addition of quinidine (CYP2D6 inhibitor) and montelukast (CYP2C8 inhibitor) attenuated (p < .001 and p = .041, respectively); most of the cytotoxic effect of Ze 339 demonstrated for the highest concentration studied (100 g/ml). 	CYP2D6	21270	21276	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:134	In HepaRG cells, the effect of cytochrome inhibition on the toxic effects of Ze 339 was investigated; addition of quinidine (CYP2D6 inhibitor) and montelukast (CYP2C8 inhibitor) attenuated (p < .001 and p = .041, respectively); most of the cytotoxic effect of Ze 339 demonstrated for the highest concentration studied (100 g/ml). 	CYP2D6	21270	21276	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:134	In HepaRG cells, the effect of cytochrome inhibition on the toxic effects of Ze 339 was investigated; addition of quinidine (CYP2D6 inhibitor) and montelukast (CYP2C8 inhibitor) attenuated (p < .001 and p = .041, respectively); most of the cytotoxic effect of Ze 339 demonstrated for the highest concentration studied (100 g/ml). 	CYP2D6	21270	21276	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:137	The biggest contribution was shown for CYP2D6. 	CYP2D6	21798	21804	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:137	The biggest contribution was shown for CYP2D6. 	CYP2D6	21798	21804	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:137	The biggest contribution was shown for CYP2D6. 	CYP2D6	21798	21804	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:137	The biggest contribution was shown for CYP2D6. 	CYP2D6	21798	21804	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:152	Inhibition of different cytochromes in HepaRG showed an attenuation of the toxic effects, which was pronounced for CYP2D6 and to a minor extend CYP2C8. 	CYP2D6	24913	24919	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:152	Inhibition of different cytochromes in HepaRG showed an attenuation of the toxic effects, which was pronounced for CYP2D6 and to a minor extend CYP2C8. 	CYP2D6	24913	24919	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:152	Inhibition of different cytochromes in HepaRG showed an attenuation of the toxic effects, which was pronounced for CYP2D6 and to a minor extend CYP2C8. 	CYP2D6	24913	24919	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:152	Inhibition of different cytochromes in HepaRG showed an attenuation of the toxic effects, which was pronounced for CYP2D6 and to a minor extend CYP2C8. 	CYP2D6	24913	24919	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:156	However, HepaRG cells are generated from a donor carrying a polymorphism for CYP2D6 (Guillouzo et al., ), which leads to a lower expression of this enzyme in HepaRG cells compared with, for example, primary hepatocytes (Kanebratt & Andersson, ; Zanelli, Caradonna, Hallifax, Turlizzi, & Houston, ), and therefore, CYP2D6 activity might be underestimated. 	CYP2D6	25527	25533	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:156	However, HepaRG cells are generated from a donor carrying a polymorphism for CYP2D6 (Guillouzo et al., ), which leads to a lower expression of this enzyme in HepaRG cells compared with, for example, primary hepatocytes (Kanebratt & Andersson, ; Zanelli, Caradonna, Hallifax, Turlizzi, & Houston, ), and therefore, CYP2D6 activity might be underestimated. 	CYP2D6	25527	25533	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:156	However, HepaRG cells are generated from a donor carrying a polymorphism for CYP2D6 (Guillouzo et al., ), which leads to a lower expression of this enzyme in HepaRG cells compared with, for example, primary hepatocytes (Kanebratt & Andersson, ; Zanelli, Caradonna, Hallifax, Turlizzi, & Houston, ), and therefore, CYP2D6 activity might be underestimated. 	CYP2D6	25527	25533	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:156	However, HepaRG cells are generated from a donor carrying a polymorphism for CYP2D6 (Guillouzo et al., ), which leads to a lower expression of this enzyme in HepaRG cells compared with, for example, primary hepatocytes (Kanebratt & Andersson, ; Zanelli, Caradonna, Hallifax, Turlizzi, & Houston, ), and therefore, CYP2D6 activity might be underestimated. 	CYP2D6	25527	25533	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:156	However, HepaRG cells are generated from a donor carrying a polymorphism for CYP2D6 (Guillouzo et al., ), which leads to a lower expression of this enzyme in HepaRG cells compared with, for example, primary hepatocytes (Kanebratt & Andersson, ; Zanelli, Caradonna, Hallifax, Turlizzi, & Houston, ), and therefore, CYP2D6 activity might be underestimated. 	CYP2D6	25764	25770	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:156	However, HepaRG cells are generated from a donor carrying a polymorphism for CYP2D6 (Guillouzo et al., ), which leads to a lower expression of this enzyme in HepaRG cells compared with, for example, primary hepatocytes (Kanebratt & Andersson, ; Zanelli, Caradonna, Hallifax, Turlizzi, & Houston, ), and therefore, CYP2D6 activity might be underestimated. 	CYP2D6	25764	25770	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:156	However, HepaRG cells are generated from a donor carrying a polymorphism for CYP2D6 (Guillouzo et al., ), which leads to a lower expression of this enzyme in HepaRG cells compared with, for example, primary hepatocytes (Kanebratt & Andersson, ; Zanelli, Caradonna, Hallifax, Turlizzi, & Houston, ), and therefore, CYP2D6 activity might be underestimated. 	CYP2D6	25764	25770	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:156	However, HepaRG cells are generated from a donor carrying a polymorphism for CYP2D6 (Guillouzo et al., ), which leads to a lower expression of this enzyme in HepaRG cells compared with, for example, primary hepatocytes (Kanebratt & Andersson, ; Zanelli, Caradonna, Hallifax, Turlizzi, & Houston, ), and therefore, CYP2D6 activity might be underestimated. 	CYP2D6	25764	25770	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:157	On the other hand, because CYP2D6 inhibition by quinidine resulted in attenuated toxicity of Ze 339 in HepaRG cells, this still emphasizes the involvement of this cytochrome enzyme in the development of the hepatotoxicity. 	CYP2D6	25832	25838	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:157	On the other hand, because CYP2D6 inhibition by quinidine resulted in attenuated toxicity of Ze 339 in HepaRG cells, this still emphasizes the involvement of this cytochrome enzyme in the development of the hepatotoxicity. 	CYP2D6	25832	25838	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:157	On the other hand, because CYP2D6 inhibition by quinidine resulted in attenuated toxicity of Ze 339 in HepaRG cells, this still emphasizes the involvement of this cytochrome enzyme in the development of the hepatotoxicity. 	CYP2D6	25832	25838	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:157	On the other hand, because CYP2D6 inhibition by quinidine resulted in attenuated toxicity of Ze 339 in HepaRG cells, this still emphasizes the involvement of this cytochrome enzyme in the development of the hepatotoxicity. 	CYP2D6	25832	25838	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP2D6	13415	13421	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP2D6	13415	13421	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP2D6	13415	13421	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP2D6	13415	13421	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:87	On the other hand, all the screened molecules emerged as non-inhibitors of the cytochromes CYP1A2 and CYP2D6. 	CYP2D6	15372	15378	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:87	On the other hand, all the screened molecules emerged as non-inhibitors of the cytochromes CYP1A2 and CYP2D6. 	CYP2D6	15372	15378	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:87	On the other hand, all the screened molecules emerged as non-inhibitors of the cytochromes CYP1A2 and CYP2D6. 	CYP2D6	15372	15378	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:87	On the other hand, all the screened molecules emerged as non-inhibitors of the cytochromes CYP1A2 and CYP2D6. 	CYP2D6	15372	15378	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:9	Genotype for the CYP2D6 enzyme, the primary metabolic pathway for metoprolol, was evaluated for each subject. 	CYP2D6	925	931	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:9	Genotype for the CYP2D6 enzyme, the primary metabolic pathway for metoprolol, was evaluated for each subject. 	CYP2D6	925	931	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:9	Genotype for the CYP2D6 enzyme, the primary metabolic pathway for metoprolol, was evaluated for each subject. 	CYP2D6	925	931	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:9	Genotype for the CYP2D6 enzyme, the primary metabolic pathway for metoprolol, was evaluated for each subject. 	CYP2D6	925	931	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:11	Urinary metoprolol metabolite ratios are indicative of patient CYP2D6 genotypes. 	CYP2D6	1178	1184	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:11	Urinary metoprolol metabolite ratios are indicative of patient CYP2D6 genotypes. 	CYP2D6	1178	1184	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:11	Urinary metoprolol metabolite ratios are indicative of patient CYP2D6 genotypes. 	CYP2D6	1178	1184	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:11	Urinary metoprolol metabolite ratios are indicative of patient CYP2D6 genotypes. 	CYP2D6	1178	1184	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:15	In summary, urinary metabolites predict CYP2D6 genotype in hypertensive patients taking metoprolol. 	CYP2D6	1665	1671	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:15	In summary, urinary metabolites predict CYP2D6 genotype in hypertensive patients taking metoprolol. 	CYP2D6	1665	1671	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:15	In summary, urinary metabolites predict CYP2D6 genotype in hypertensive patients taking metoprolol. 	CYP2D6	1665	1671	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:15	In summary, urinary metabolites predict CYP2D6 genotype in hypertensive patients taking metoprolol. 	CYP2D6	1665	1671	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:29	However, metoprolol is primarily metabolized through a saturable metabolic pathway, hepatic cytochrome 2D6 (CYP2D6), that is responsible for the metabolism of approximately 25% of all xenobiotics in addition to many endogenous hormones. 	CYP2D6	3722	3728	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:29	However, metoprolol is primarily metabolized through a saturable metabolic pathway, hepatic cytochrome 2D6 (CYP2D6), that is responsible for the metabolism of approximately 25% of all xenobiotics in addition to many endogenous hormones. 	CYP2D6	3722	3728	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:29	However, metoprolol is primarily metabolized through a saturable metabolic pathway, hepatic cytochrome 2D6 (CYP2D6), that is responsible for the metabolism of approximately 25% of all xenobiotics in addition to many endogenous hormones. 	CYP2D6	3722	3728	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:29	However, metoprolol is primarily metabolized through a saturable metabolic pathway, hepatic cytochrome 2D6 (CYP2D6), that is responsible for the metabolism of approximately 25% of all xenobiotics in addition to many endogenous hormones. 	CYP2D6	3722	3728	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:30	Metoprolol is primarily metabolized to ALPHA-hydroxymetoprolol and O-demethylmetoprolol by CYP2D6 (Fig. 	CYP2D6	3942	3948	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:30	Metoprolol is primarily metabolized to ALPHA-hydroxymetoprolol and O-demethylmetoprolol by CYP2D6 (Fig. 	CYP2D6	3942	3948	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:30	Metoprolol is primarily metabolized to ALPHA-hydroxymetoprolol and O-demethylmetoprolol by CYP2D6 (Fig. 	CYP2D6	3942	3948	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:30	Metoprolol is primarily metabolized to ALPHA-hydroxymetoprolol and O-demethylmetoprolol by CYP2D6 (Fig. 	CYP2D6	3942	3948	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:55	Additionally, co-administration of other CYP2D6 metabolized drugs did not impact the abundance of metoprolol metabolites. 	CYP2D6	7539	7545	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:55	Additionally, co-administration of other CYP2D6 metabolized drugs did not impact the abundance of metoprolol metabolites. 	CYP2D6	7539	7545	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:55	Additionally, co-administration of other CYP2D6 metabolized drugs did not impact the abundance of metoprolol metabolites. 	CYP2D6	7539	7545	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:55	Additionally, co-administration of other CYP2D6 metabolized drugs did not impact the abundance of metoprolol metabolites. 	CYP2D6	7539	7545	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:66	Metoprolol metabolite abundance was compared in all patient samples and analyzed by CYP2D6 metabolizer phenotype, namely Intermediate Metabolizer, Normal Metabolizer, and Ultra-Rapid Metabolizer and CYP2D6 activity scores. 	CYP2D6	8950	8956	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:66	Metoprolol metabolite abundance was compared in all patient samples and analyzed by CYP2D6 metabolizer phenotype, namely Intermediate Metabolizer, Normal Metabolizer, and Ultra-Rapid Metabolizer and CYP2D6 activity scores. 	CYP2D6	8950	8956	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:66	Metoprolol metabolite abundance was compared in all patient samples and analyzed by CYP2D6 metabolizer phenotype, namely Intermediate Metabolizer, Normal Metabolizer, and Ultra-Rapid Metabolizer and CYP2D6 activity scores. 	CYP2D6	8950	8956	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:66	Metoprolol metabolite abundance was compared in all patient samples and analyzed by CYP2D6 metabolizer phenotype, namely Intermediate Metabolizer, Normal Metabolizer, and Ultra-Rapid Metabolizer and CYP2D6 activity scores. 	CYP2D6	8950	8956	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:66	Metoprolol metabolite abundance was compared in all patient samples and analyzed by CYP2D6 metabolizer phenotype, namely Intermediate Metabolizer, Normal Metabolizer, and Ultra-Rapid Metabolizer and CYP2D6 activity scores. 	CYP2D6	9065	9071	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:66	Metoprolol metabolite abundance was compared in all patient samples and analyzed by CYP2D6 metabolizer phenotype, namely Intermediate Metabolizer, Normal Metabolizer, and Ultra-Rapid Metabolizer and CYP2D6 activity scores. 	CYP2D6	9065	9071	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:66	Metoprolol metabolite abundance was compared in all patient samples and analyzed by CYP2D6 metabolizer phenotype, namely Intermediate Metabolizer, Normal Metabolizer, and Ultra-Rapid Metabolizer and CYP2D6 activity scores. 	CYP2D6	9065	9071	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:66	Metoprolol metabolite abundance was compared in all patient samples and analyzed by CYP2D6 metabolizer phenotype, namely Intermediate Metabolizer, Normal Metabolizer, and Ultra-Rapid Metabolizer and CYP2D6 activity scores. 	CYP2D6	9065	9071	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:67	Unmetabolized metoprolol and metoprolol glucuronide concentrations decreased with increasing CYP2D6 activity. 	CYP2D6	9182	9188	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:67	Unmetabolized metoprolol and metoprolol glucuronide concentrations decreased with increasing CYP2D6 activity. 	CYP2D6	9182	9188	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:67	Unmetabolized metoprolol and metoprolol glucuronide concentrations decreased with increasing CYP2D6 activity. 	CYP2D6	9182	9188	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:67	Unmetabolized metoprolol and metoprolol glucuronide concentrations decreased with increasing CYP2D6 activity. 	CYP2D6	9182	9188	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:68	Conversely, urinary hydroxymetoprolol abundance increased with increasing CYP2D6 metabolic capacity. 	CYP2D6	9273	9279	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:68	Conversely, urinary hydroxymetoprolol abundance increased with increasing CYP2D6 metabolic capacity. 	CYP2D6	9273	9279	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:68	Conversely, urinary hydroxymetoprolol abundance increased with increasing CYP2D6 metabolic capacity. 	CYP2D6	9273	9279	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:68	Conversely, urinary hydroxymetoprolol abundance increased with increasing CYP2D6 metabolic capacity. 	CYP2D6	9273	9279	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:69	Comparing classification by CYP2D6 phenotype and activity score found that urinary metoprolol metabolite profiles of patients with an activity score of 2.0 more closely correlate to Ultra-Rapid Metabolizer patients than other Normal Metabolizer activity score groups, namely 1.0 and 1.5. 	CYP2D6	9328	9334	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:69	Comparing classification by CYP2D6 phenotype and activity score found that urinary metoprolol metabolite profiles of patients with an activity score of 2.0 more closely correlate to Ultra-Rapid Metabolizer patients than other Normal Metabolizer activity score groups, namely 1.0 and 1.5. 	CYP2D6	9328	9334	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:69	Comparing classification by CYP2D6 phenotype and activity score found that urinary metoprolol metabolite profiles of patients with an activity score of 2.0 more closely correlate to Ultra-Rapid Metabolizer patients than other Normal Metabolizer activity score groups, namely 1.0 and 1.5. 	CYP2D6	9328	9334	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:69	Comparing classification by CYP2D6 phenotype and activity score found that urinary metoprolol metabolite profiles of patients with an activity score of 2.0 more closely correlate to Ultra-Rapid Metabolizer patients than other Normal Metabolizer activity score groups, namely 1.0 and 1.5. 	CYP2D6	9328	9334	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:74	Metoprolol to demethylmetoprolol ratios (M to DM) and metoprolol to hydroxymetoprolol ratios (M to HM) closely correlated to increasing CYP2D6 activity. 	CYP2D6	10417	10423	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:74	Metoprolol to demethylmetoprolol ratios (M to DM) and metoprolol to hydroxymetoprolol ratios (M to HM) closely correlated to increasing CYP2D6 activity. 	CYP2D6	10417	10423	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:74	Metoprolol to demethylmetoprolol ratios (M to DM) and metoprolol to hydroxymetoprolol ratios (M to HM) closely correlated to increasing CYP2D6 activity. 	CYP2D6	10417	10423	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:74	Metoprolol to demethylmetoprolol ratios (M to DM) and metoprolol to hydroxymetoprolol ratios (M to HM) closely correlated to increasing CYP2D6 activity. 	CYP2D6	10417	10423	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:75	An inverse relationship was observed when samples were normalized to metoprolol acid and ratios decreased with reduced CYP2D6 capacity as reflected by patient phenotype and activity scores. 	CYP2D6	10553	10559	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:75	An inverse relationship was observed when samples were normalized to metoprolol acid and ratios decreased with reduced CYP2D6 capacity as reflected by patient phenotype and activity scores. 	CYP2D6	10553	10559	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:75	An inverse relationship was observed when samples were normalized to metoprolol acid and ratios decreased with reduced CYP2D6 capacity as reflected by patient phenotype and activity scores. 	CYP2D6	10553	10559	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:75	An inverse relationship was observed when samples were normalized to metoprolol acid and ratios decreased with reduced CYP2D6 capacity as reflected by patient phenotype and activity scores. 	CYP2D6	10553	10559	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:76	The fact that metoprolol metabolites can quickly be used to provide insight into CYP2D6 genotype independent of dose or time after the dosage is interesting. 	CYP2D6	10705	10711	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:76	The fact that metoprolol metabolites can quickly be used to provide insight into CYP2D6 genotype independent of dose or time after the dosage is interesting. 	CYP2D6	10705	10711	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:76	The fact that metoprolol metabolites can quickly be used to provide insight into CYP2D6 genotype independent of dose or time after the dosage is interesting. 	CYP2D6	10705	10711	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:76	The fact that metoprolol metabolites can quickly be used to provide insight into CYP2D6 genotype independent of dose or time after the dosage is interesting. 	CYP2D6	10705	10711	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:82	The numbers of the more uncommon CYP2D6 genotypes, Poor Metabolizer and Ultra-Rapid Metabolizer, are low in this cohort, which limits our ability to identify endogenous metabolites associated with CYP2D6 genotype. 	CYP2D6	11635	11641	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:82	The numbers of the more uncommon CYP2D6 genotypes, Poor Metabolizer and Ultra-Rapid Metabolizer, are low in this cohort, which limits our ability to identify endogenous metabolites associated with CYP2D6 genotype. 	CYP2D6	11635	11641	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:82	The numbers of the more uncommon CYP2D6 genotypes, Poor Metabolizer and Ultra-Rapid Metabolizer, are low in this cohort, which limits our ability to identify endogenous metabolites associated with CYP2D6 genotype. 	CYP2D6	11635	11641	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:82	The numbers of the more uncommon CYP2D6 genotypes, Poor Metabolizer and Ultra-Rapid Metabolizer, are low in this cohort, which limits our ability to identify endogenous metabolites associated with CYP2D6 genotype. 	CYP2D6	11635	11641	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:82	The numbers of the more uncommon CYP2D6 genotypes, Poor Metabolizer and Ultra-Rapid Metabolizer, are low in this cohort, which limits our ability to identify endogenous metabolites associated with CYP2D6 genotype. 	CYP2D6	11799	11805	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:82	The numbers of the more uncommon CYP2D6 genotypes, Poor Metabolizer and Ultra-Rapid Metabolizer, are low in this cohort, which limits our ability to identify endogenous metabolites associated with CYP2D6 genotype. 	CYP2D6	11799	11805	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:82	The numbers of the more uncommon CYP2D6 genotypes, Poor Metabolizer and Ultra-Rapid Metabolizer, are low in this cohort, which limits our ability to identify endogenous metabolites associated with CYP2D6 genotype. 	CYP2D6	11799	11805	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:82	The numbers of the more uncommon CYP2D6 genotypes, Poor Metabolizer and Ultra-Rapid Metabolizer, are low in this cohort, which limits our ability to identify endogenous metabolites associated with CYP2D6 genotype. 	CYP2D6	11799	11805	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:85	However, we were powered to detect metabolites with more than 95% power when advised by drug ingestion and CYP2D6 genotype. 	CYP2D6	12173	12179	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:85	However, we were powered to detect metabolites with more than 95% power when advised by drug ingestion and CYP2D6 genotype. 	CYP2D6	12173	12179	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:85	However, we were powered to detect metabolites with more than 95% power when advised by drug ingestion and CYP2D6 genotype. 	CYP2D6	12173	12179	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:85	However, we were powered to detect metabolites with more than 95% power when advised by drug ingestion and CYP2D6 genotype. 	CYP2D6	12173	12179	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:97	Metoprolol metabolites segregated very well with CYP2D6 phenotype, suggesting that drug metabolism can be predicted based upon knowledge of CYP2D6 genotype and the presence of drug-drug interactions. 	CYP2D6	14211	14217	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:97	Metoprolol metabolites segregated very well with CYP2D6 phenotype, suggesting that drug metabolism can be predicted based upon knowledge of CYP2D6 genotype and the presence of drug-drug interactions. 	CYP2D6	14211	14217	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:97	Metoprolol metabolites segregated very well with CYP2D6 phenotype, suggesting that drug metabolism can be predicted based upon knowledge of CYP2D6 genotype and the presence of drug-drug interactions. 	CYP2D6	14211	14217	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:97	Metoprolol metabolites segregated very well with CYP2D6 phenotype, suggesting that drug metabolism can be predicted based upon knowledge of CYP2D6 genotype and the presence of drug-drug interactions. 	CYP2D6	14211	14217	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:50	The individual roles of CHIP and gp78 in CYP3A and CYP2E1 ubiquitination and Endoplasmic Reticulum-Associated Degradation were verified upon lentiviral shRNA interference analyses targeted individually against each of these E3s in cultured rat hepatocytes,. 	CYP2E1	11378	11384	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:98	CYP2E1 degradation, on the other hand, is biphasic, exhibiting a rapid phase (t_1/2, 7 h) and a slow phase (t_1/2, 37 h) presumed to reflect its Endoplasmic Reticulum-Associated Degradation via Ubiquitin-Dependent Proteasomal Degradation and Autophagic-Lysosomal Degradation, respectively,. 	CYP2E1	22823	22829	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:98	CYP2E1 degradation, on the other hand, is biphasic, exhibiting a rapid phase (t_1/2, 7 h) and a slow phase (t_1/2, 37 h) presumed to reflect its Endoplasmic Reticulum-Associated Degradation via Ubiquitin-Dependent Proteasomal Degradation and Autophagic-Lysosomal Degradation, respectively,. 	CYP2E1	22823	22829	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:100	Functional inactivation of its catalytic partner Cytochrome P450 Reductase abolishes all redox-flux, thus minimizing oxidative damage and stabilizing CYP2E1 by prolonging its t_1/2,. 	CYP2E1	23372	23378	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:100	Functional inactivation of its catalytic partner Cytochrome P450 Reductase abolishes all redox-flux, thus minimizing oxidative damage and stabilizing CYP2E1 by prolonging its t_1/2,. 	CYP2E1	23372	23378	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:101	Notably, this dual CYP2E1 proteolytic mode is conserved upon its heterologous expression in yeast, even though P450 redox flux and consequent ROS-generating potential are greatly minimized by the poor yeast Cytochrome P450 Reductase content. 	CYP2E1	23424	23430	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:101	Notably, this dual CYP2E1 proteolytic mode is conserved upon its heterologous expression in yeast, even though P450 redox flux and consequent ROS-generating potential are greatly minimized by the poor yeast Cytochrome P450 Reductase content. 	CYP2E1	23424	23430	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:125	Hepatic CYP2E1 stabilization upon liver-specific genetic ablation of gp78 E3-ligase in mice enhances acetaminophen-metabolism to its reactive N-acetyl-p-quinoneimine, thereby predisposing the hepatocytes to drug-induced hepatotoxicity at relatively innocuous concentrations. 	CYP2E1	28545	28551	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:125	Hepatic CYP2E1 stabilization upon liver-specific genetic ablation of gp78 E3-ligase in mice enhances acetaminophen-metabolism to its reactive N-acetyl-p-quinoneimine, thereby predisposing the hepatocytes to drug-induced hepatotoxicity at relatively innocuous concentrations. 	CYP2E1	28545	28551	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:126	On the other hand, hepatic CYP2E1 stabilization through disruption of its Endoplasmic Reticulum-Associated Degradation via genetic CHIP-ablation contributes to pathogenic NASH (non-alcoholic steatohepatitis) syndrome (see below). 	CYP2E1	28839	28845	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:126	On the other hand, hepatic CYP2E1 stabilization through disruption of its Endoplasmic Reticulum-Associated Degradation via genetic CHIP-ablation contributes to pathogenic NASH (non-alcoholic steatohepatitis) syndrome (see below). 	CYP2E1	28839	28845	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:138	In patients with severe INH-induced liver injury, not only serum autoantibodies to CYP2E1, CYP3A4 and CYP2C9 (the three major P450s that metabolize and/or interact with INH), but also serum antibodies to INH-adducted CYP2E1 and other INH-adducted non-P450 proteins are detected. 	CYP2E1	31437	31443	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:138	In patients with severe INH-induced liver injury, not only serum autoantibodies to CYP2E1, CYP3A4 and CYP2C9 (the three major P450s that metabolize and/or interact with INH), but also serum antibodies to INH-adducted CYP2E1 and other INH-adducted non-P450 proteins are detected. 	CYP2E1	31437	31443	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:138	In patients with severe INH-induced liver injury, not only serum autoantibodies to CYP2E1, CYP3A4 and CYP2C9 (the three major P450s that metabolize and/or interact with INH), but also serum antibodies to INH-adducted CYP2E1 and other INH-adducted non-P450 proteins are detected. 	CYP2E1	31571	31577	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:138	In patients with severe INH-induced liver injury, not only serum autoantibodies to CYP2E1, CYP3A4 and CYP2C9 (the three major P450s that metabolize and/or interact with INH), but also serum antibodies to INH-adducted CYP2E1 and other INH-adducted non-P450 proteins are detected. 	CYP2E1	31571	31577	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP2E1	32052	32058	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP2E1	32052	32058	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP2E1	32220	32226	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP2E1	32220	32226	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP2E1	32249	32255	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP2E1	32249	32255	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:148	In parallel, starting at 2-months of age, Chip-KO hepatocytes exhibited oxidative stress-induced activation of the pathogenic ASK1-MKK4-JNK1-c-Jun-ATF2 and ASK1-MKK4-JNK1-c-Jun-AP-1 signaling pathways, which were not only found to be CYP2E1-dependent, but also to remain persistently activated throughout the observation period, ie, first 12 months of age. 	CYP2E1	34482	34488	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:148	In parallel, starting at 2-months of age, Chip-KO hepatocytes exhibited oxidative stress-induced activation of the pathogenic ASK1-MKK4-JNK1-c-Jun-ATF2 and ASK1-MKK4-JNK1-c-Jun-AP-1 signaling pathways, which were not only found to be CYP2E1-dependent, but also to remain persistently activated throughout the observation period, ie, first 12 months of age. 	CYP2E1	34482	34488	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:157	It revealed a two-fold activation of the energy sensor, AMP-protein kinase (AMPKALPHA1) in these 2-month-old Chip-KO livers relative to corresponding age-matched controls that was also CYP2E1-dependent. 	CYP2E1	36518	36524	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:157	It revealed a two-fold activation of the energy sensor, AMP-protein kinase (AMPKALPHA1) in these 2-month-old Chip-KO livers relative to corresponding age-matched controls that was also CYP2E1-dependent. 	CYP2E1	36518	36524	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:170	The magnitude of CYP2E1 and CYP3A functional stabilization is comparable in Gp78-KO and Chip-KO mouse livers,. 	CYP2E1	39465	39471	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:170	The magnitude of CYP2E1 and CYP3A functional stabilization is comparable in Gp78-KO and Chip-KO mouse livers,. 	CYP2E1	39465	39471	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:171	However, in marked contrast to cultured Chip-KO hepatocytes, Gp78-KO hepatocytes upon culture retained much higher basal CYP2E1 levels (comparable to the INH-induced levels in cultured Chip-KO hepatocytes), which were further increased upon INH-induction (C). 	CYP2E1	39680	39686	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:171	However, in marked contrast to cultured Chip-KO hepatocytes, Gp78-KO hepatocytes upon culture retained much higher basal CYP2E1 levels (comparable to the INH-induced levels in cultured Chip-KO hepatocytes), which were further increased upon INH-induction (C). 	CYP2E1	39680	39686	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:173	Additionally, in the course of defining the liver specific Gp78-KO mouse phenotype, preliminary SILAC-like proteomic analyses of unlabeled Gp78-KO and stable isotope-labeled Wild-Type age/strain-matched livers revealed that in addition to the stabilization of several hepatic P450s (including CYP2E1 and CYPs 3A), several cytoplasmic enzymes in the fructose metabolic pathway were increased in Gp78-KO-liver [ie, ketohexokinase (500%); 3-phosphoglycerokinase (200%-300%); phosphoglyceromutase (177%-250%);. 	CYP2E1	40427	40433	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:173	Additionally, in the course of defining the liver specific Gp78-KO mouse phenotype, preliminary SILAC-like proteomic analyses of unlabeled Gp78-KO and stable isotope-labeled Wild-Type age/strain-matched livers revealed that in addition to the stabilization of several hepatic P450s (including CYP2E1 and CYPs 3A), several cytoplasmic enzymes in the fructose metabolic pathway were increased in Gp78-KO-liver [ie, ketohexokinase (500%); 3-phosphoglycerokinase (200%-300%); phosphoglyceromutase (177%-250%);. 	CYP2E1	40427	40433	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:176	These relative differences in FA- and TG-accumulation were maintained even upon further INH-mediated induction of CYP2E1 content (B). 	CYP2E1	41190	41196	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:176	These relative differences in FA- and TG-accumulation were maintained even upon further INH-mediated induction of CYP2E1 content (B). 	CYP2E1	41190	41196	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:177	Furthermore, only minor relative increases in Malondialdehyde levels were observed, indicative of a mild oxidative stress response, despite the relatively elevated basal CYP2E1 content in Gp78-KO hepatocytes, and its further elevation upon INH-induction (B). 	CYP2E1	41380	41386	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:177	Furthermore, only minor relative increases in Malondialdehyde levels were observed, indicative of a mild oxidative stress response, despite the relatively elevated basal CYP2E1 content in Gp78-KO hepatocytes, and its further elevation upon INH-induction (B). 	CYP2E1	41380	41386	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:178	Several converging factors, we believe, synergistically contribute to the observed striking differences in CYP2E1-elicited lipogenic potential in Chip-KO versus Gp78-KO hepatocytes: (i) The differential effects of each E3-KO on hepatic Insig and SREBP-1c protein levels: upon INH-induction of CYP2E1, hepatic Insig 1 and Insig 2 proteins decline in Chip-KO hepatocytes due to the progressive hepatic insulin resistance, whereas these proteins being bona fide gp78-substrates are markedly stabilized in Gp78-KO hepatocytes. 	CYP2E1	41576	41582	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:178	Several converging factors, we believe, synergistically contribute to the observed striking differences in CYP2E1-elicited lipogenic potential in Chip-KO versus Gp78-KO hepatocytes: (i) The differential effects of each E3-KO on hepatic Insig and SREBP-1c protein levels: upon INH-induction of CYP2E1, hepatic Insig 1 and Insig 2 proteins decline in Chip-KO hepatocytes due to the progressive hepatic insulin resistance, whereas these proteins being bona fide gp78-substrates are markedly stabilized in Gp78-KO hepatocytes. 	CYP2E1	41576	41582	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:178	Several converging factors, we believe, synergistically contribute to the observed striking differences in CYP2E1-elicited lipogenic potential in Chip-KO versus Gp78-KO hepatocytes: (i) The differential effects of each E3-KO on hepatic Insig and SREBP-1c protein levels: upon INH-induction of CYP2E1, hepatic Insig 1 and Insig 2 proteins decline in Chip-KO hepatocytes due to the progressive hepatic insulin resistance, whereas these proteins being bona fide gp78-substrates are markedly stabilized in Gp78-KO hepatocytes. 	CYP2E1	41762	41768	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:178	Several converging factors, we believe, synergistically contribute to the observed striking differences in CYP2E1-elicited lipogenic potential in Chip-KO versus Gp78-KO hepatocytes: (i) The differential effects of each E3-KO on hepatic Insig and SREBP-1c protein levels: upon INH-induction of CYP2E1, hepatic Insig 1 and Insig 2 proteins decline in Chip-KO hepatocytes due to the progressive hepatic insulin resistance, whereas these proteins being bona fide gp78-substrates are markedly stabilized in Gp78-KO hepatocytes. 	CYP2E1	41762	41768	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:183	Thus, in contrast to Chip-KO mice, despite CYP2E1 functional stabilization, the Gp78-KO mice exhibit enhanced energy expenditure relative to Wild-Type controls, remain leaner and do not develop NASH, even upon aging and/or a high fat-high sucrose obesity-inducing diet. 	CYP2E1	42948	42954	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:183	Thus, in contrast to Chip-KO mice, despite CYP2E1 functional stabilization, the Gp78-KO mice exhibit enhanced energy expenditure relative to Wild-Type controls, remain leaner and do not develop NASH, even upon aging and/or a high fat-high sucrose obesity-inducing diet. 	CYP2E1	42948	42954	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:187	Intriguingly, in spite of the comparable CYP2E1 content upon INH induction, hepatic MDA-levels were only minimally increased in Gp78-KO hepatocytes (B), in contrast to the marked Malondialdehyde elevation observed in Chip-KO hepatocytes. 	CYP2E1	43739	43745	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:187	Intriguingly, in spite of the comparable CYP2E1 content upon INH induction, hepatic MDA-levels were only minimally increased in Gp78-KO hepatocytes (B), in contrast to the marked Malondialdehyde elevation observed in Chip-KO hepatocytes. 	CYP2E1	43739	43745	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:189	This finding strongly suggests that hepatic CYP2E1-dependent ROS-elicited lipid peroxidation with consequent JNK1 activation and insulin resistance occur only when hepatic lipid is markedly elevated and available for peroxidation. 	CYP2E1	44155	44161	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:154	demonstrated that in the 713 human livers analysed, CYP3A4 levels varied markedly, ranging from 0 to 601 pmolmg^1 protein (Achour et al.,. 	CYP3A	25402	25407	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:156	As mentioned, next to CYP3A4, another CYP, CYP3A7, showed high activity in flucloxacillin hydroxylation. 	CYP3A	25642	25647	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:156	As mentioned, next to CYP3A4, another CYP, CYP3A7, showed high activity in flucloxacillin hydroxylation. 	CYP3A	25663	25668	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:157	CYP3A7 was originally considered to be a CYP only expressed in fetal tissues (Schuetz et al.,. 	CYP3A	25725	25730	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:158	However, more recent studies have indicated that in approximately 10% of adult livers, CYP3A7 is expressed to a significant extent, up to 90 pmolmg^1 protein, which equals the mean level of CYP3A4 (Sim et al., ; Ohtsuki et al.,. 	CYP3A	25907	25912	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:158	However, more recent studies have indicated that in approximately 10% of adult livers, CYP3A7 is expressed to a significant extent, up to 90 pmolmg^1 protein, which equals the mean level of CYP3A4 (Sim et al., ; Ohtsuki et al.,. 	CYP3A	26010	26015	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:159	This markedly increased CYP3A7 expression appears to be strongly associated with the CYP3A7*1C allele which has arisen through the conversion of 60 bp of the promotor of CYP3A4 into the corresponding region of CYP3A7 (Burk et al.,. 	CYP3A	26073	26078	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:159	This markedly increased CYP3A7 expression appears to be strongly associated with the CYP3A7*1C allele which has arisen through the conversion of 60 bp of the promotor of CYP3A4 into the corresponding region of CYP3A7 (Burk et al.,. 	CYP3A	26134	26139	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:159	This markedly increased CYP3A7 expression appears to be strongly associated with the CYP3A7*1C allele which has arisen through the conversion of 60 bp of the promotor of CYP3A4 into the corresponding region of CYP3A7 (Burk et al.,. 	CYP3A	26219	26224	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:159	This markedly increased CYP3A7 expression appears to be strongly associated with the CYP3A7*1C allele which has arisen through the conversion of 60 bp of the promotor of CYP3A4 into the corresponding region of CYP3A7 (Burk et al.,. 	CYP3A	26259	26264	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:160	To what extent the variability in CYP3A7 expression contributes to the variability of flucloxacillin hydroxylation remains to be established and is complicated by the present lack of specific inhibitors for the CYP3A isoforms. 	CYP3A	26315	26320	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:160	To what extent the variability in CYP3A7 expression contributes to the variability of flucloxacillin hydroxylation remains to be established and is complicated by the present lack of specific inhibitors for the CYP3A isoforms. 	CYP3A	26492	26497	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:162	Involvement of CYP3A isoforms in drug metabolism is well known to result in very diverse types of enzyme kinetics and poorly predictable drug-drug interactions. 	CYP3A	26700	26705	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:163	Dependent on the substrate used, for all CYP3A isoforms, enzyme kinetics can appear as normal Michaelis-Menten kinetics or atypical kinetics such as autoactivation and substrate inhibition (Williams et al., ; Atkins,. 	CYP3A	26887	26892	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:165	Because of the multiple binding sites in CYP3A enzymes, also the type of drug-drug interactions appears complex and strongly substrate dependent (Stresser et al., ; Ekins et al.,. 	CYP3A	27357	27362	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:166	Therefore, to predict the ability to cause CYP3A4 inhibition, the use of multiple CYP3A4 substrates has been recommended (Stresser et al.,. 	CYP3A	27539	27544	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:166	Therefore, to predict the ability to cause CYP3A4 inhibition, the use of multiple CYP3A4 substrates has been recommended (Stresser et al.,. 	CYP3A	27578	27583	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:167	The inhibition experiments in the present study seem to confirm the complicated inhibition pattern of CYP3A reactions. 	CYP3A	27738	27743	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:168	The established CYP3A4 inhibitors ketoconazole, troleandomycin and miconazole showed relatively low degree of inhibition at the concentrations used. 	CYP3A	27771	27776	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:169	Remarkably, sulfaphenazole, which is considered to be a highly selective inhibitor of CYP2C9 (Khojasteh et al., ), showed clear inhibition of flucloxacillin hydroxylation by pooled HLM, CYP3A4 and CYP3A7, whereas the 6BETAhydroxylation of testosterone was not affected. 	CYP3A	28090	28095	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:169	Remarkably, sulfaphenazole, which is considered to be a highly selective inhibitor of CYP2C9 (Khojasteh et al., ), showed clear inhibition of flucloxacillin hydroxylation by pooled HLM, CYP3A4 and CYP3A7, whereas the 6BETAhydroxylation of testosterone was not affected. 	CYP3A	28101	28106	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:170	These results suggest that flucloxacillin has a unique binding mode to the active site to CYP3A4, explaining the relatively weak inhibition by 1 M ketaconazole and the unexpectedly strong inhibition by sulfaphenazole. 	CYP3A	28264	28269	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:172	Therefore, the CYP3A family in rare occurrences can be inhibited by sulfaphenazole in a substratedependent manner. 	CYP3A	28628	28633	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:177	In conclusion, the results of this present study confirm the involvement of CYP3A4 in the hydroxylation of flucloxacillin, whereas CYP3A7 and CYP2C9 may also contribute significantly in individuals expressing high hepatic levels. 	CYP3A	29284	29289	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:177	In conclusion, the results of this present study confirm the involvement of CYP3A4 in the hydroxylation of flucloxacillin, whereas CYP3A7 and CYP2C9 may also contribute significantly in individuals expressing high hepatic levels. 	CYP3A	29339	29344	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:178	The large variability of both hepatic CYP3A and CYP2C9 levels may contribute to the variability of plasma levels of 5HMFLX, which is suspected to play a role in flucloxacillin induced DILI by causing cytotoxicity to biliary epithelial cells. 	CYP3A	29476	29481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:138	Recently, it has been confirmed that ellagic acid can significantly inhibit CYP3A and P-glycoprotein (P-gp)-mediated efflux in the intestine, thus, increase warfarin plasma concentration and its pharmacological effect. 	CYP3A	22450	22455	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:151	Therefore, it can be suggested that ellagic acid may affect warfarin binding to CYP2C8 and CYP3A4 by changing the conformation of these enzymes that leads to more affinity towards warfarin binding [,. 	CYP3A	25097	25102	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:152	These results contradict those of a previous study by Kaneko, 2013 where ellagic acid had a clear inhibitory effect on CYP2C8 and CYP3A4 activities. 	CYP3A	25337	25342	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:161	It has been suggested that guava leaves extract constituents, such as gallic acid and ursolic acid, have the ability to diminish the activity of CYP3A4 in human liver microsomes [,. 	CYP3A	26828	26833	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:162	That comes in line with the results obtained from testing guava leaves extract both alone and in combination with warfarin in significantly affecting CYP3A4 activity in primary isolated rat hepatocytes. 	CYP3A	27015	27020	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:163	Further reduction in CYP3A4 activity was observed upon administerating quercetin concomitantly with warfarin, suggesting that CYP3A4 may undergo an allosteric change during its binding with warfarin that possibly enhances quercetin binding which leads to increase its inhibitory effect. 	CYP3A	27089	27094	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:163	Further reduction in CYP3A4 activity was observed upon administerating quercetin concomitantly with warfarin, suggesting that CYP3A4 may undergo an allosteric change during its binding with warfarin that possibly enhances quercetin binding which leads to increase its inhibitory effect. 	CYP3A	27194	27199	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:5	Hepatocyte spheroids formed in this device were subjected to different flow rates, of which a flow rate of 50 L/min provided the optimal microenvironment for spheroid formation, maintained significantly higher rates of albumin and urea synthesis, yielded higher CYP3A1 (cytochrome P450 3A1) and CYP2C11 (cytochrome P450 2C11) enzyme activities for metabolism, and demonstrated higher expression levels of liver-specific genes. 	CYP3A	662	667	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:93	BFC and 7-Methoxy-4-Trifluoromethylcoumarin were used as fluorescent substrates to measure the activities of CYP3A1 and CYP2C11 enzymes under different culture systems. 	CYP3A	12489	12494	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:100	Changes in gene expression of CYP3A1 and CYP2C11 enzymes were investigated by quantitative reverse-transcription polymerase chain reaction (RT-PCR) as described previously. 	CYP3A	13608	13613	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:101	The sequences of primers for CYP3A1, CYP2C11, and BETA-actin are shown in. 	CYP3A	13780	13785	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:111	To investigate the specific action of different drugs on hepatic-metabolism enzymes, testosterone and tolbutamide were chosen to study the hepatic clearance rates by CYP3A1 and CYP2C11, respectively. 	CYP3A	15110	15115	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:180	In the rat liver, CYP3A1 is the main CYP3A, and CYP2C11 is its predominant isoform, with both comprising up to 50% of the total CYP content. 	CYP3A	26215	26220	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:180	In the rat liver, CYP3A1 is the main CYP3A, and CYP2C11 is its predominant isoform, with both comprising up to 50% of the total CYP content. 	CYP3A	26234	26239	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:182	The maintenance of the activity of the drug-metabolizing enzymes CYP3A1 and CYP2C11 were examined in hepatocytes at flow rates of 0 and 50 L/min and in PELA mats. 	CYP3A	26459	26464	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:183	At 0 L/min, hepatocytes showed higher expression levels of CYP3A1 (5.3-fold higher) and CYP2C11 (4.7-fold higher) than those of hepatocytes cultured in PELA. 	CYP3A	26616	26621	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:184	However, there were significant reductions, by around 10.2% and 8.4%, respectively, in the mRNA levels of CYP3A1 and CYP2C11 enzymes at 0 L/min for 15 days, compared with those after 7 days. 	CYP3A	26821	26826	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:186	Given that 7-Benzyloxy-4-Trifluoromethylcoumarin and 7-Methoxy-4-Trifluoromethylcoumarin are the specific substrates for CYP3A1 and CYP2C11, we investigated the effect of drug-metabolizing enzymes throughout the culture period. 	CYP3A	27250	27255	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:188	CYP3A1 and CYP2C11 enzymatic activities in PELA fibrous mats were much lower and fluctuating than hepatocytes on the chip at a flow rate of 0 L/min (p < 0.05). 	CYP3A	27531	27536	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:190	lac-PLA enhanced hepatocyte function, and there was a continuous increase in the activities of CYP3A1 and CYP2C11 enzymes in hepatocytes at 0 L/min during the 15-day incubation. 	CYP3A	27983	27988	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:191	Hepatocytes at a flow rate of 50 L/min were therefore comparatively more stable and maintained the highest enzyme activities among the groups, reaching 6.7 and 3.8 pmol/min/10^6 cells for CYP3A1 and CYP2C11, respectively. 	CYP3A	28254	28259	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:193	The level of activity of CYP3A1 and CYP2C11 enzymes showed a similar trend until 15 days. 	CYP3A	28476	28481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:194	After culture for 15 days, the CYP3A1 and CYP2C11 activities of the hepatocytes at a flow of 50 L/min were more than 3.9- and 3.4-fold higher, respectively, than those of hepatocytes cultured on PELA. 	CYP3A	28572	28577	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:198	Tolbutamide and testosterone were used as the substrates of hepatocyte CYP3A1 and CYP2C11 enzymes, respectively, for the drug metabolism study. 	CYP3A	29476	29481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:200	The results of testosterone metabolism by CYP2C11 indicated a profile similar to that of CYP3A1 (b). 	CYP3A	29856	29861	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:239	Moreover, only compound F13 was found to be the substrate of CYP2C19 and compound F25 was found to be the substrate of CYP3A4. 	CYP3A	38617	38622	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:244	On the other hand for predicting the site of enzyme CYP3A4 mediated metabolism the K_m value was 46.37 M and the Human Liver Microsomes Km value was 1055.87 M, whereas the V_max constant was 6.36 nM/min/nM and Human Liver Microsomes V_max constant was 1.25 nM/min/nM, and the C_Lint was 15.23 L/min/mg, and the Human Liver Microsomes C_Lint was 1.19 for compound F25. 	CYP3A	39776	39781	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:248	Moreover, the compounds when studies for CYP3A4, it was observed that compound F2, F8 and F13 may inhibit the CYP3A4. 	CYP3A	40557	40562	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:248	Moreover, the compounds when studies for CYP3A4, it was observed that compound F2, F8 and F13 may inhibit the CYP3A4. 	CYP3A	40626	40631	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:249	Results showed that all compounds might inhibit the CYP3A4 mediated midazolam and testosterone metabolism. 	CYP3A	40686	40691	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:56	While cytochromes P450 (CYP) 2D6 and CYP3A4 have been implicated in the metabolism of Paliperidone in in vitro studies, these isoenzymes play a limited role in the metabolism of Paliperidone in vivo. 	CYP3A	8624	8629	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP3A	3431	3436	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP3A	8097	8102	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP3A	9835	9840	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:111	In preclinical aflatoxin-induced Hepatocellular Carcinoma rat models, CYP3A4*1B (rs2740574; located in the 5 untranslated region [5UTR]) and CYP3A5*3 (rs776746; located in the intron 3) variants were associated with the lowest and highest sorafenib plasma concentrations, respectively. 	CYP3A	21410	21415	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:111	In preclinical aflatoxin-induced Hepatocellular Carcinoma rat models, CYP3A4*1B (rs2740574; located in the 5 untranslated region [5UTR]) and CYP3A5*3 (rs776746; located in the intron 3) variants were associated with the lowest and highest sorafenib plasma concentrations, respectively. 	CYP3A	21481	21486	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:112	This difference in drug disposition was consistent with a different toxicity risk; CYP3A5*3-carrier rats had the most severe liver (measured as a change in alanine aminotransferase [ALT] and Aspartate Aminotransferase blood concentration [IU/L] over time) and renal (measured as a change in blood urea nitrogen [nmol/L] and creatinin [umol/L] blood concentration [IU/L] over time) injury, whereas CYP3A4*1-carrier rats had the mildest toxicity outcome. 	CYP3A	21709	21714	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:112	This difference in drug disposition was consistent with a different toxicity risk; CYP3A5*3-carrier rats had the most severe liver (measured as a change in alanine aminotransferase [ALT] and Aspartate Aminotransferase blood concentration [IU/L] over time) and renal (measured as a change in blood urea nitrogen [nmol/L] and creatinin [umol/L] blood concentration [IU/L] over time) injury, whereas CYP3A4*1-carrier rats had the mildest toxicity outcome. 	CYP3A	22023	22028	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:114	Carriers of CYP2C19*2 (rs4244285; Pro227Pro) or CYP2D6*10 (rs1065852, Pro34Ser) had sorafenib plasma levels and associated liver/renal toxicity that were intermediate between those of rats carrying CYP3A5*3 or CYP3A4*1 genetic variants. 	CYP3A	22397	22402	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:114	Carriers of CYP2C19*2 (rs4244285; Pro227Pro) or CYP2D6*10 (rs1065852, Pro34Ser) had sorafenib plasma levels and associated liver/renal toxicity that were intermediate between those of rats carrying CYP3A5*3 or CYP3A4*1 genetic variants. 	CYP3A	22409	22414	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:116	In these patients, the CYP3A5*3 polymorphism was associated with rapid worsening of hepatic damage, but CYP3A4*1 carriers showed only a small effect. 	CYP3A	22651	22656	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:116	In these patients, the CYP3A5*3 polymorphism was associated with rapid worsening of hepatic damage, but CYP3A4*1 carriers showed only a small effect. 	CYP3A	22732	22737	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:117	The findings therefore suggested that the CYP3A5*3 variant that determines decreased CYP3A5 enzymatic activity could influence hepatic and renal exposure to sorafenib, with severe associated damage. 	CYP3A	22820	22825	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:117	The findings therefore suggested that the CYP3A5*3 variant that determines decreased CYP3A5 enzymatic activity could influence hepatic and renal exposure to sorafenib, with severe associated damage. 	CYP3A	22863	22868	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP3A	39941	39946	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:264	However, a very recent study by Ozeki et al on Japanese patients with thyroid cancer, demonstrated for the first time an impact of CYP3A4/5 and Atp-Binding Cassette transporter genetic variants on lenvatinib pharmacokinetics. 	CYP3A	53760	53765	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:265	Particularly, the CYP3A4*1G (rs2242480, intronic variation) and ABCC2 rs717620 polymorphisms were suggested to have an effect on the steady-state mean plasma [ie, mean dose-adjusted C_0, (ng/mL/mg)] trough concentrations of lenvatinib. 	CYP3A	53873	53878	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:266	The mean dose-adjusted C_0 values of lenvatinib in patients with the CYP3A4*1/*1 genotype and ABCC2 rs717620-T allele were significantly higher than those in patients with the CYP3A4*1G allele and ABCC2 rs717620-CC genotype, respectively (effect size: 0.863, P = 0.018 and effect size: 0.605, P=0.036, respectively). 	CYP3A	54160	54165	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:266	The mean dose-adjusted C_0 values of lenvatinib in patients with the CYP3A4*1/*1 genotype and ABCC2 rs717620-T allele were significantly higher than those in patients with the CYP3A4*1G allele and ABCC2 rs717620-CC genotype, respectively (effect size: 0.863, P = 0.018 and effect size: 0.605, P=0.036, respectively). 	CYP3A	54267	54272	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:267	Moreover, the dose-adjusted C_0 of lenvatinib in patients with both the CYP3A4*1/*1 genotype and ABCC2 rs717620-T allele (median 6.70 ng/mL/mg) was about 1.5-fold higher than that in patients with both the CYP3A4*1G/*1G and ABCC2 rs717620-CC genotypes (median 4.42 ng/mL/mg; P = 0.007). 	CYP3A	54480	54485	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:267	Moreover, the dose-adjusted C_0 of lenvatinib in patients with both the CYP3A4*1/*1 genotype and ABCC2 rs717620-T allele (median 6.70 ng/mL/mg) was about 1.5-fold higher than that in patients with both the CYP3A4*1G/*1G and ABCC2 rs717620-CC genotypes (median 4.42 ng/mL/mg; P = 0.007). 	CYP3A	54614	54619	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:321	Following oral administration, palbociclib and ribociclib undergo extensive hepatic metabolism mainly by CYP3A; palbociclib also is metabolized through the sulfotransferase enzyme SULT2A1. 	CYP3A	65512	65517	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:335	In term of pharmacokinetics, tivantinib is metabolized by CYP2C19, CYP3A4/5, Udp Glucuronosyltransferase 1a9, and alcohol dehydrogenase isoform 4. 	CYP3A	68240	68245	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:336	CYP2C19 shows catalytic activity for the formation of the hydroxylated metabolite (M5), whereas CYP3A4/5 catalyzes formation of M5 and its stereoisomer (M4). 	CYP3A	68416	68421	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:337	Moreover, CYP3A4/5 represents the major cytochrome isoform involved in the elimination of M4, M5, and the keto-metabolite (M8), and together with Udp Glucuronosyltransferase 1a9, involved in the glucuronidation of M4 and M5. 	CYP3A	68488	68493	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6737677_OgerInput.txtOger_out.csv:22	About 20% of apixaban undergoes P450 Cytochromes metabolism (mainly via the same CYP3A4), while 30% of the drug is eliminated via urinary excretion. 	CYP3A	3204	3209	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6836233_OgerInput.txtOger_out.csv:112	stated that the continued ingestion of (88) isolated from K. parviflora decreases liver CYP3A expression, which in turn increased levels of compounds metabolized by CYP3As such as midazolam. 	CYP3A	20293	20298	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:191	In addition, differential expression profiles of functionally different isoforms of the CYP3A subfamily during prenatal and early postnatal life complicate the assessment of hepatic steroid metabolism. 	CYP3A	32764	32769	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:192	CYP3A4 is the most abundant Cytochrome P450 expressed in the adult liver and makes the major contribution to steroid metabolism. 	CYP3A	32878	32883	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:193	CYP3A5 catalyzes a comparable range of reactions as CYP3A4 but its role in drug and steroid metabolism is limited due to its generally low activity and expression in a relatively small percentage of individuals [,. 	CYP3A	33007	33012	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:193	CYP3A5 catalyzes a comparable range of reactions as CYP3A4 but its role in drug and steroid metabolism is limited due to its generally low activity and expression in a relatively small percentage of individuals [,. 	CYP3A	33059	33064	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:194	CYP3A7 is the major CYP3A isoform in prenatal and early postnatal life and differs from CYP3A4 in terms of expression and function. 	CYP3A	33222	33227	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:194	CYP3A7 is the major CYP3A isoform in prenatal and early postnatal life and differs from CYP3A4 in terms of expression and function. 	CYP3A	33242	33247	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:194	CYP3A7 is the major CYP3A isoform in prenatal and early postnatal life and differs from CYP3A4 in terms of expression and function. 	CYP3A	33310	33315	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:198	CYP3A4-catalyzed 6BETA-hydroxylation is the most common hydroxylation for ^4 steroids, eg cortisol ((e)), while 6ALPHA-hydroxylated pregnanolones are quantitatively important urine steroid metabolites during pregnancy. 	CYP3A	33690	33695	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:201	The differential substrate specificity, regioselectivity and catalytic activity of CYP3A4 and CYP3A7 and the dynamic expression pattern of the two isoforms throughout fetal development and the first year of life lead to substantial changes in the hepatic steroid metabolome during this period of life. 	CYP3A	34231	34236	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:201	The differential substrate specificity, regioselectivity and catalytic activity of CYP3A4 and CYP3A7 and the dynamic expression pattern of the two isoforms throughout fetal development and the first year of life lead to substantial changes in the hepatic steroid metabolome during this period of life. 	CYP3A	34242	34247	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:202	CYP3A7 is highly expressed in fetal liver and up to 6 months postnatal but expression levels gradually decrease over this time. 	CYP3A	34450	34455	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:203	CYP3A4 levels are low in the fetus and newborn compared to the adult. 	CYP3A	34578	34583	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:204	Thus, there is a switch from CYP3A7 to CYP3A4 during the first months after birth. 	CYP3A	34677	34682	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:204	Thus, there is a switch from CYP3A7 to CYP3A4 during the first months after birth. 	CYP3A	34687	34692	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:205	Additionally, the total liver CYP3A content is significantly higher prenatally followed by a reduction after birth reaching plateau at 6 months. 	CYP3A	34761	34766	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:208	In fact, CYP2C19 and CYP3A4 can 21-hydroxylate progesterone and pregnenolone, possibly partially compensating mineralocorticoid deficiency in CAH due to 21-hydroxylase deficiency; however, the two enzymes are not capable of catalyzing the 21-hydroxylation of 17OHP to 11-deoxycortisol. 	CYP3A	35306	35311	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:337	Cortisol can also be 6BETA-hydroxylated by CYP3A4 expressed in the liver, resulting in 6BETA-hydroxycortisol (6BETA-OHF). 	CYP3A	56091	56096	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:405	Circulating Dehydroepiandrosterone is readily 16ALPHA-hydroxylated by CYP3A4/7 within the liver. 	CYP3A	67378	67383	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:425	CYP3A4 is the major enzyme responsible for the 16ALPHA-hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and CYP3A5 can also catalyze the reaction. 	CYP3A	70253	70258	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:425	CYP3A4 is the major enzyme responsible for the 16ALPHA-hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and CYP3A5 can also catalyze the reaction. 	CYP3A	70371	70376	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP3A	70515	70520	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP3A	70821	70826	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP3A	70867	70872	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP3A	24783	24788	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP3A	24795	24800	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:24	Accordingly, the dominant human liver/intestinal CYP3A4 and human liver CYP2E1 are found to be prototypic ERAD-C substrates. 	CYP3A	5114	5119	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:25	CYP3A4, accounting for 30% of the hepatic P450 content, is engaged in the metabolism of >50% of clinically relevant drugs and other xenobiotics, whereas CYP2E1 biotransforms clinically relevant drugs (acetaminophen, halothane), EtOH, and other xenobiotics, carcinogens (nitrosamines), endogenous acetone and fatty acids (arachidonic acid) to toxic/reactive intermediates,. 	CYP3A	5190	5195	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:26	Substrates such as troleandomycin, ketoconazole, and clotrimazole that bind tightly to CYP3A prosthetic heme and/or active site stabilize the P450 protein, reduce its oxidative turnover and extend its t_1/2,. 	CYP3A	5650	5655	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:27	Furthermore, reduced futile oxidative cycling upon conditional deletion of the liver Cytochrome P450 Reductase gene elevates the constitutive hepatic CYP3A content in mice, plausibly via protein stabilization. 	CYP3A	5922	5927	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:30	Systematic dissection of the hepatic CYP3A and CYP2E1 ERAD-C process employing various in vivo and in vitro reconstituted eukaryotic systems has revealed that it involves initial post-translational phosphorylation by cytosolic protein kinases A and C of P450 Ser/Thr residues,. 	CYP3A	6272	6277	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP3A	9246	9251	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:39	We turned our attention to other carbon nanostructures, such as diamond nanoparticles (DN), graphene oxide (GO) and graphite nanoparticles (GN), which were previously shown to be nontoxic or low toxic; however, no data are available on their potential interactions with CYP isoenzymes.,, We hypothesized that a physicochemical interaction occurs between employed carbon nanostructures and CYP1A2, CYP2D6 and CYP3A4 enzymes. 	CYP3A4	6220	6226	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:69	Additionally, the control Baculosomes without CYP450 expression were mixed in the same manner as the Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expression. 	CYP3A4	10344	10350	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:80	Known inhibitors of CYP450 enzymes were used as positive controls: miconazole for CYP1A2, quinidine for CYP2D6 and ketoconazole for CYP3A4. 	CYP3A4	11820	11826	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:82	In the first step, Vivid Substrates (EOMCC for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were reconstituted in anhydrous acetonitrile, and then 40 L of tested compounds (DN, GO, GN or inhibitors) or working buffer (control) was added to each well on 96-well black-bottom plate (Corning, New York, NY, USA). 	CYP3A4	12142	12148	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP3A4	12460	12466	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP3A4	18377	18383	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP3A4	20657	20663	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP3A4	20797	20803	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP3A4	20982	20988	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP3A4	21072	21078	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP3A4	22077	22083	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP3A4	22274	22280	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP3A4	22461	22467	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:147	The inhibition rate of CYP3A4 was comparable for DN, GO and GN at all concentrations (50%-60% inhibition); however, at the highest concentration, we observed an effect similar to the one in CYP1A2. 	CYP3A4	23218	23224	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:159	The level of CYP3A4 was decreased in all nanostructure groups in both cell lines (<40% of the control, reaching only 1% in the GO group in HepaRG cells), except the GN group in HepaRG cells, where no changes occurred. 	CYP3A4	25136	25142	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP3A4	25847	25853	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP3A4	28403	28409	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP3A4	28591	28597	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:176	Interestingly, inhibition of CYP1A2 and CYP3A4 was lower in the presence of the highest concentration of DN and GN (100 mg/L), which could be related to the formation of nanoparticle agglomerates in higher concentrations and then reduction of their surface area available to interact. 	CYP3A4	28700	28706	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP3A4	31174	31180	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:202	It was previously reported that SWCNT inhibited the most important of the isoenzymes, CYP3A4, mostly due to the occurrence of - stacking interactions between the nanotube walls and aromatic residues of the enzyme. 	CYP3A4	33903	33909	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:4	Recombinant CYPs showing the highest specific activity were CYP3A4, CYP3A7 and to lower extent CYP2C9 and CTP2C8. 	CYP3A4	703	709	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:5	Michaelis-Menten enzyme kinetics were determined for pooled human liver microsomes, recombinant CYP3A4, CYP3A7 and CYP2C9. 	CYP3A4	853	859	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:6	Surprisingly, sulfaphenazole appeared to be a potent inhibitor of 5hydroxylation of flucloxacillin by both recombinant CYP3A4 and CYP3A7. 	CYP3A4	999	1005	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:7	The combined results show that the 5hydroxylation of flucloxacillin is primarily catalysed by CYP3A4, CYP3A7 and CYP2C9. 	CYP3A4	1112	1118	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:10	There are large interindividual differences in plasma concentrations of flucloxacillin and 5hydroxymethyl flucloxacillin.5Hydroxymethyl flucloxacillin is much more toxic to biliary epithelial cells than flucloxacillin.A previous study on four human CYPs showed that CYP3A4 exerted the highest activity of flucloxacillin hydroxylation. 	CYP3A4	1812	1818	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:12	Quantification of specific activities and enzyme kinetics of flucloxacillin hydroxylation by HLM and 14 recombinant human CYPs.Next to CYP3A4, CYP3A7 and CYP2C9 may contribute significantly to flucloxacillin hydroxylation.Sulfaphenazole, considered as a selective CYP2C9 inhibitor, strongly inhibits CYP3Amediated flucloxacillin hydroxylation. 	CYP3A4	2154	2160	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:13	Interindividual variability and drugdrug interactions at the level of CYP3A4, CYP3A7 and CYP2C9 may be important factors determining the risk of flucloxacillininduced liver injury. 	CYP3A4	2433	2439	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:29	Nonrenal clearance of flucloxacillin occurs predominantly by cytochrome P450mediated hydroxylation of flucloxacillin to 5HMFLX and partly by hydrolysis to the corresponding penicilloic acid, showed that CYP3A4 was able to catalyse the 5hydroxylation of flucloxacillin. 	CYP3A4	6146	6152	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:31	Another study showed that flucloxacillin induces CYP3A4 in cell lines exposed to 200-400 M flucloxacillin (Huwyler et al.,. 	CYP3A4	6398	6404	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:36	Furthermore, a major involvement of CYP3A4 in drug metabolism complicates prediction of pharmacokinetics based on enzyme kinetics because of the occurrence of atypical enzyme kinetics, such as substrate activation (Houston and Kenworthy, ; Ekins et al., ; Atkins, ; Houston and Galetin,. 	CYP3A4	7245	7251	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:37	Furthermore, inhibition of CYP3A4 by drugs appears to be substratedependent, further complicating prediction of drug-drug interactions (Stresser et al.,. 	CYP3A4	7524	7530	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:52	456264), CYP3A4 (Lot No. 	CYP3A4	8497	8503	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:78	Because these incubations were only performed to identify the most active enzymes, duplicate experiments were deemed sufficient since reproducibility of incubations with recombinant enzymes from the same source was always within 5%, For the most active Gentest Supersomes and pooled HLM, the enzyme kinetics of the formation of 5HMFLX were determined by incubating with 11 concentrations of flucloxacillin, ranging from 0 to 500 M. Each flucloxacillin concentration was incubated in duplicate for 10 min with 0.5 mgmL^1 pooled HLM, 100 nM CYP3A4, CYP3A7 and CYP2C9 Supersomes in 100 mM potassium phosphate buffer, pH 7.4 supplemented with 5 mM MgCl_2 and 2 mM EDTA. 	CYP3A4	12223	12229	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A4	13056	13062	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A4	13081	13087	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A4	13107	13113	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:85	Because the CYP2C9specific inhibitor sulfaphenazole appeared to almost completely block formation of 5HMFLX by pooled HLM, it was also added at different concentrations to incubations of CYP3A4 and CYP3A7 Supersomes with flucloxacillin (10 M) and testosterone (50 M). 	CYP3A4	13733	13739	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP3A4	14334	14340	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:118	At a flucloxacillin concentration of 10 M, recombinant CYP3A4, CYP3A7 and to a lesser extent CYP2C9 showed the highest activity, in terms of the formation of 5HMFLX. 	CYP3A4	19651	19657	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:119	At 100 M flucloxacillin, CYP3A7 was the most active CYP followed by CYP3A4. 	CYP3A4	19830	19836	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:121	As CYP3A4, CYP3A7 and CYP2C9 Supersomes showed highest activity at both concentrations, the enzyme kinetics of 5HMFLX formation was also determined for these recombinant CYPs. 	CYP3A4	19999	20005	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:123	Using the Michaelis-Menten model, the following enzyme kinetic parameters were determined: CYP3A4, K _M 124  15 M, V_max 197  9 pmolmin^1nmol^1 P450; CYP3A7: K _M 65  8 M, V_max 193  7 pmolmin^1nmol^1 P450; and CYP2C9: K _M of 508  82 M, V_max 67  7 pmolmin^1nmol^1 P450. 	CYP3A4	20348	20354	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:127	The other CYP3A4 inhibitors showed only 20 to 40% inhibition at 10 M flucloxacillin concentration. 	CYP3A4	20987	20993	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:128	Although recombinant CYP2C9 showed much lower activity when compared to CYP3A4, an almost 90% inhibition of 5HMFLX formation was observed in the presence of sulfaphenazole, which is considered to be a selective CYP2C9 inhibitor. 	CYP3A4	21148	21154	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:130	To study whether sulfaphenazole has the ability to inhibit CYP3Amediated hydroxylation of flucloxacillin, the inhibitor was added at different concentrations to incubations of CYP3A4 and CYP3A7, with flucloxacillin and testosterone as substrates. 	CYP3A4	21593	21599	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:131	As shown in Figure A, B, sulfaphenazole appeared to be a potent inhibitor of flucloxacillin hydroxylation by recombinant CYP3A4 and CYP3A7 with an IC_50 of 4.1  0.4 M and 6.1  0.5 M respectively. 	CYP3A4	21785	21791	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:132	At these sulfaphenazole concentrations, no inhibition of CYP3A4catalysed 6BETAhydroxylation of testosterone was observed. 	CYP3A4	21917	21923	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:145	By using recombinant CYPs, at both substrate concentrations used, CYP3A4 and CYP3A7 appeared to be the most active enzymes. 	CYP3A4	24325	24331	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:152	that CYP3A4 is likely to play a major role in the formation of 5HMFLX, as it is, on average, the most abundant CYP in human liver (mean 93 pmolmg^1 protein) (Achour et al.,. 	CYP3A4	25138	25144	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:154	demonstrated that in the 713 human livers analysed, CYP3A4 levels varied markedly, ranging from 0 to 601 pmolmg^1 protein (Achour et al.,. 	CYP3A4	25402	25408	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:156	As mentioned, next to CYP3A4, another CYP, CYP3A7, showed high activity in flucloxacillin hydroxylation. 	CYP3A4	25642	25648	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:158	However, more recent studies have indicated that in approximately 10% of adult livers, CYP3A7 is expressed to a significant extent, up to 90 pmolmg^1 protein, which equals the mean level of CYP3A4 (Sim et al., ; Ohtsuki et al.,. 	CYP3A4	26010	26016	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:159	This markedly increased CYP3A7 expression appears to be strongly associated with the CYP3A7*1C allele which has arisen through the conversion of 60 bp of the promotor of CYP3A4 into the corresponding region of CYP3A7 (Burk et al.,. 	CYP3A4	26219	26225	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:166	Therefore, to predict the ability to cause CYP3A4 inhibition, the use of multiple CYP3A4 substrates has been recommended (Stresser et al.,. 	CYP3A4	27539	27545	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:166	Therefore, to predict the ability to cause CYP3A4 inhibition, the use of multiple CYP3A4 substrates has been recommended (Stresser et al.,. 	CYP3A4	27578	27584	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:168	The established CYP3A4 inhibitors ketoconazole, troleandomycin and miconazole showed relatively low degree of inhibition at the concentrations used. 	CYP3A4	27771	27777	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:169	Remarkably, sulfaphenazole, which is considered to be a highly selective inhibitor of CYP2C9 (Khojasteh et al., ), showed clear inhibition of flucloxacillin hydroxylation by pooled HLM, CYP3A4 and CYP3A7, whereas the 6BETAhydroxylation of testosterone was not affected. 	CYP3A4	28090	28096	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:170	These results suggest that flucloxacillin has a unique binding mode to the active site to CYP3A4, explaining the relatively weak inhibition by 1 M ketaconazole and the unexpectedly strong inhibition by sulfaphenazole. 	CYP3A4	28264	28270	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:177	In conclusion, the results of this present study confirm the involvement of CYP3A4 in the hydroxylation of flucloxacillin, whereas CYP3A7 and CYP2C9 may also contribute significantly in individuals expressing high hepatic levels. 	CYP3A4	29284	29290	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:151	Therefore, it can be suggested that ellagic acid may affect warfarin binding to CYP2C8 and CYP3A4 by changing the conformation of these enzymes that leads to more affinity towards warfarin binding [,. 	CYP3A4	25097	25103	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:152	These results contradict those of a previous study by Kaneko, 2013 where ellagic acid had a clear inhibitory effect on CYP2C8 and CYP3A4 activities. 	CYP3A4	25337	25343	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:161	It has been suggested that guava leaves extract constituents, such as gallic acid and ursolic acid, have the ability to diminish the activity of CYP3A4 in human liver microsomes [,. 	CYP3A4	26828	26834	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:162	That comes in line with the results obtained from testing guava leaves extract both alone and in combination with warfarin in significantly affecting CYP3A4 activity in primary isolated rat hepatocytes. 	CYP3A4	27015	27021	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:163	Further reduction in CYP3A4 activity was observed upon administerating quercetin concomitantly with warfarin, suggesting that CYP3A4 may undergo an allosteric change during its binding with warfarin that possibly enhances quercetin binding which leads to increase its inhibitory effect. 	CYP3A4	27089	27095	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:163	Further reduction in CYP3A4 activity was observed upon administerating quercetin concomitantly with warfarin, suggesting that CYP3A4 may undergo an allosteric change during its binding with warfarin that possibly enhances quercetin binding which leads to increase its inhibitory effect. 	CYP3A4	27194	27200	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:239	Moreover, only compound F13 was found to be the substrate of CYP2C19 and compound F25 was found to be the substrate of CYP3A4. 	CYP3A4	38617	38623	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:244	On the other hand for predicting the site of enzyme CYP3A4 mediated metabolism the K_m value was 46.37 M and the Human Liver Microsomes Km value was 1055.87 M, whereas the V_max constant was 6.36 nM/min/nM and Human Liver Microsomes V_max constant was 1.25 nM/min/nM, and the C_Lint was 15.23 L/min/mg, and the Human Liver Microsomes C_Lint was 1.19 for compound F25. 	CYP3A4	39776	39782	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:248	Moreover, the compounds when studies for CYP3A4, it was observed that compound F2, F8 and F13 may inhibit the CYP3A4. 	CYP3A4	40557	40563	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:248	Moreover, the compounds when studies for CYP3A4, it was observed that compound F2, F8 and F13 may inhibit the CYP3A4. 	CYP3A4	40626	40632	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:249	Results showed that all compounds might inhibit the CYP3A4 mediated midazolam and testosterone metabolism. 	CYP3A4	40686	40692	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:56	While cytochromes P450 (CYP) 2D6 and CYP3A4 have been implicated in the metabolism of Paliperidone in in vitro studies, these isoenzymes play a limited role in the metabolism of Paliperidone in vivo. 	CYP3A4	8624	8630	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:111	In preclinical aflatoxin-induced Hepatocellular Carcinoma rat models, CYP3A4*1B (rs2740574; located in the 5 untranslated region [5UTR]) and CYP3A5*3 (rs776746; located in the intron 3) variants were associated with the lowest and highest sorafenib plasma concentrations, respectively. 	CYP3A4	21410	21416	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:112	This difference in drug disposition was consistent with a different toxicity risk; CYP3A5*3-carrier rats had the most severe liver (measured as a change in alanine aminotransferase [ALT] and Aspartate Aminotransferase blood concentration [IU/L] over time) and renal (measured as a change in blood urea nitrogen [nmol/L] and creatinin [umol/L] blood concentration [IU/L] over time) injury, whereas CYP3A4*1-carrier rats had the mildest toxicity outcome. 	CYP3A4	22023	22029	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:114	Carriers of CYP2C19*2 (rs4244285; Pro227Pro) or CYP2D6*10 (rs1065852, Pro34Ser) had sorafenib plasma levels and associated liver/renal toxicity that were intermediate between those of rats carrying CYP3A5*3 or CYP3A4*1 genetic variants. 	CYP3A4	22409	22415	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:116	In these patients, the CYP3A5*3 polymorphism was associated with rapid worsening of hepatic damage, but CYP3A4*1 carriers showed only a small effect. 	CYP3A4	22732	22738	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP3A4	39941	39947	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:264	However, a very recent study by Ozeki et al on Japanese patients with thyroid cancer, demonstrated for the first time an impact of CYP3A4/5 and Atp-Binding Cassette transporter genetic variants on lenvatinib pharmacokinetics. 	CYP3A4	53760	53766	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:265	Particularly, the CYP3A4*1G (rs2242480, intronic variation) and ABCC2 rs717620 polymorphisms were suggested to have an effect on the steady-state mean plasma [ie, mean dose-adjusted C_0, (ng/mL/mg)] trough concentrations of lenvatinib. 	CYP3A4	53873	53879	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:266	The mean dose-adjusted C_0 values of lenvatinib in patients with the CYP3A4*1/*1 genotype and ABCC2 rs717620-T allele were significantly higher than those in patients with the CYP3A4*1G allele and ABCC2 rs717620-CC genotype, respectively (effect size: 0.863, P = 0.018 and effect size: 0.605, P=0.036, respectively). 	CYP3A4	54160	54166	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:266	The mean dose-adjusted C_0 values of lenvatinib in patients with the CYP3A4*1/*1 genotype and ABCC2 rs717620-T allele were significantly higher than those in patients with the CYP3A4*1G allele and ABCC2 rs717620-CC genotype, respectively (effect size: 0.863, P = 0.018 and effect size: 0.605, P=0.036, respectively). 	CYP3A4	54267	54273	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:267	Moreover, the dose-adjusted C_0 of lenvatinib in patients with both the CYP3A4*1/*1 genotype and ABCC2 rs717620-T allele (median 6.70 ng/mL/mg) was about 1.5-fold higher than that in patients with both the CYP3A4*1G/*1G and ABCC2 rs717620-CC genotypes (median 4.42 ng/mL/mg; P = 0.007). 	CYP3A4	54480	54486	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:267	Moreover, the dose-adjusted C_0 of lenvatinib in patients with both the CYP3A4*1/*1 genotype and ABCC2 rs717620-T allele (median 6.70 ng/mL/mg) was about 1.5-fold higher than that in patients with both the CYP3A4*1G/*1G and ABCC2 rs717620-CC genotypes (median 4.42 ng/mL/mg; P = 0.007). 	CYP3A4	54614	54620	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:335	In term of pharmacokinetics, tivantinib is metabolized by CYP2C19, CYP3A4/5, Udp Glucuronosyltransferase 1a9, and alcohol dehydrogenase isoform 4. 	CYP3A4	68240	68246	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:336	CYP2C19 shows catalytic activity for the formation of the hydroxylated metabolite (M5), whereas CYP3A4/5 catalyzes formation of M5 and its stereoisomer (M4). 	CYP3A4	68416	68422	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:337	Moreover, CYP3A4/5 represents the major cytochrome isoform involved in the elimination of M4, M5, and the keto-metabolite (M8), and together with Udp Glucuronosyltransferase 1a9, involved in the glucuronidation of M4 and M5. 	CYP3A4	68488	68494	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6737677_OgerInput.txtOger_out.csv:22	About 20% of apixaban undergoes P450 Cytochromes metabolism (mainly via the same CYP3A4), while 30% of the drug is eliminated via urinary excretion. 	CYP3A4	3204	3210	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:192	CYP3A4 is the most abundant Cytochrome P450 expressed in the adult liver and makes the major contribution to steroid metabolism. 	CYP3A4	32878	32884	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP3A5	8097	8103	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP3A5	9835	9841	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:111	In preclinical aflatoxin-induced Hepatocellular Carcinoma rat models, CYP3A4*1B (rs2740574; located in the 5 untranslated region [5UTR]) and CYP3A5*3 (rs776746; located in the intron 3) variants were associated with the lowest and highest sorafenib plasma concentrations, respectively. 	CYP3A5	21481	21487	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:112	This difference in drug disposition was consistent with a different toxicity risk; CYP3A5*3-carrier rats had the most severe liver (measured as a change in alanine aminotransferase [ALT] and Aspartate Aminotransferase blood concentration [IU/L] over time) and renal (measured as a change in blood urea nitrogen [nmol/L] and creatinin [umol/L] blood concentration [IU/L] over time) injury, whereas CYP3A4*1-carrier rats had the mildest toxicity outcome. 	CYP3A5	21709	21715	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:114	Carriers of CYP2C19*2 (rs4244285; Pro227Pro) or CYP2D6*10 (rs1065852, Pro34Ser) had sorafenib plasma levels and associated liver/renal toxicity that were intermediate between those of rats carrying CYP3A5*3 or CYP3A4*1 genetic variants. 	CYP3A5	22397	22403	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:116	In these patients, the CYP3A5*3 polymorphism was associated with rapid worsening of hepatic damage, but CYP3A4*1 carriers showed only a small effect. 	CYP3A5	22651	22657	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:117	The findings therefore suggested that the CYP3A5*3 variant that determines decreased CYP3A5 enzymatic activity could influence hepatic and renal exposure to sorafenib, with severe associated damage. 	CYP3A5	22820	22826	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:117	The findings therefore suggested that the CYP3A5*3 variant that determines decreased CYP3A5 enzymatic activity could influence hepatic and renal exposure to sorafenib, with severe associated damage. 	CYP3A5	22863	22869	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:75	No lauric acid hydroxylation (CYP4A1-selective) was observed. 	CYP4A	11720	11725	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:111	According to the GTEx portal (https://www.gtexportal.org) (Access on: 10 February 2021), the expression quantitative trait loci analysis showed that rs17102977 was significantly associated with CYP4A22 gene expression in the brain, but not in the breast tissue. 	CYP4A	16054	16059	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:39	P450 Oxidoreductase contains a flavin adenine dinucleotide and a flavin mononucleotide allowing the enzyme to oxidize NADPH and reduce the Cytochrome P450 enzyme in a stepwise manner. 	Cytochrome P450	6525	6540	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:39	P450 Oxidoreductase contains a flavin adenine dinucleotide and a flavin mononucleotide allowing the enzyme to oxidize NADPH and reduce the Cytochrome P450 enzyme in a stepwise manner. 	Cytochrome P450	6525	6540	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:40	The availability of NADPH is a vital aspect of CYP-catalyzed reactions, with redox partner ratios differentially influencing Cytochrome P450 activities [,. 	Cytochrome P450	6695	6710	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:40	The availability of NADPH is a vital aspect of CYP-catalyzed reactions, with redox partner ratios differentially influencing Cytochrome P450 activities [,. 	Cytochrome P450	6695	6710	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:186	In addition to the steroidogenic Cytochrome P450 enzymes described in Section, hepatic xenobiotic-metabolizing members of the Cytochrome P450 superfamily are able to modify steroid hormones and generate a plethora of minor steroid metabolites. 	Cytochrome P450	31612	31627	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:186	In addition to the steroidogenic Cytochrome P450 enzymes described in Section, hepatic xenobiotic-metabolizing members of the Cytochrome P450 superfamily are able to modify steroid hormones and generate a plethora of minor steroid metabolites. 	Cytochrome P450	31612	31627	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:186	In addition to the steroidogenic Cytochrome P450 enzymes described in Section, hepatic xenobiotic-metabolizing members of the Cytochrome P450 superfamily are able to modify steroid hormones and generate a plethora of minor steroid metabolites. 	Cytochrome P450	31705	31720	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:186	In addition to the steroidogenic Cytochrome P450 enzymes described in Section, hepatic xenobiotic-metabolizing members of the Cytochrome P450 superfamily are able to modify steroid hormones and generate a plethora of minor steroid metabolites. 	Cytochrome P450	31705	31720	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:190	A high inter- and intra-individual variability of hepatic Cytochrome P450 activity results from the strong potential for induction by pharmacological and natural compounds, the high frequency and number of polymorphisms, and promoter and copy number variants. 	Cytochrome P450	32474	32489	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:190	A high inter- and intra-individual variability of hepatic Cytochrome P450 activity results from the strong potential for induction by pharmacological and natural compounds, the high frequency and number of polymorphisms, and promoter and copy number variants. 	Cytochrome P450	32474	32489	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:192	CYP3A4 is the most abundant Cytochrome P450 expressed in the adult liver and makes the major contribution to steroid metabolism. 	Cytochrome P450	32906	32921	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:192	CYP3A4 is the most abundant Cytochrome P450 expressed in the adult liver and makes the major contribution to steroid metabolism. 	Cytochrome P450	32906	32921	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:125	Human Cytochrome P450 are primarily membrane-associated proteins located either in the inner membrane of mitochondria or in the endoplasmic reticulum of cells. 	Cytochrome P450	23504	23519	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:125	Human Cytochrome P450 are primarily membrane-associated proteins located either in the inner membrane of mitochondria or in the endoplasmic reticulum of cells. 	Cytochrome P450	23504	23519	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:126	Cytochrome P450 enzymes have potential uses in the synthesis and discovery of drugs, as well as drug development. 	Cytochrome P450	23658	23673	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:126	Cytochrome P450 enzymes have potential uses in the synthesis and discovery of drugs, as well as drug development. 	Cytochrome P450	23658	23673	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:127	Cytochrome P450 enzymes metabolize thousands of endogenous and exogenous chemicals. 	Cytochrome P450	23772	23787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:127	Cytochrome P450 enzymes metabolize thousands of endogenous and exogenous chemicals. 	Cytochrome P450	23772	23787	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:128	Cytochrome P450 constitutes the major enzyme family capable of catalyzing the oxidative biotransformation of most drugs and other lipophilic xenobiotics and are therefore of particular relevance for clinical pharmacology, primarily found in liver cells but they are also located in cells throughout the body. 	Cytochrome P450	23856	23871	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:128	Cytochrome P450 constitutes the major enzyme family capable of catalyzing the oxidative biotransformation of most drugs and other lipophilic xenobiotics and are therefore of particular relevance for clinical pharmacology, primarily found in liver cells but they are also located in cells throughout the body. 	Cytochrome P450	23856	23871	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:131	Cytochrome P450 enzymes are bound to membranes within a cell and contain a heme pigment that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide. 	Cytochrome P450	24528	24543	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:131	Cytochrome P450 enzymes are bound to membranes within a cell and contain a heme pigment that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide. 	Cytochrome P450	24528	24543	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	Cytochrome P450	24717	24732	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	Cytochrome P450	24717	24732	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:133	Cytochrome P450 enzymes play a role in the synthesis of many molecules including steroid hormones, certain Fatty Acids (cholesterol and other fatty acids), and acids used to digest Fatty Acids (bile acids). 	Cytochrome P450	24842	24857	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:133	Cytochrome P450 enzymes play a role in the synthesis of many molecules including steroid hormones, certain Fatty Acids (cholesterol and other fatty acids), and acids used to digest Fatty Acids (bile acids). 	Cytochrome P450	24842	24857	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:134	Up-to-date, there are approximately 60 Cytochrome P450 genes in humans (https://ghr.nlm.nih.gov/primer/genefamily/cytochromep450). 	Cytochrome P450	25088	25103	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:134	Up-to-date, there are approximately 60 Cytochrome P450 genes in humans (https://ghr.nlm.nih.gov/primer/genefamily/cytochromep450). 	Cytochrome P450	25088	25103	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:135	Hepatic Cytochrome P450 mutations can alter systemic drug metabolism and distribution, however, the possibility that mutated or polymorphic variants of Cytochrome P450 exist in the brain is not well studied. 	Cytochrome P450	25188	25203	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:135	Hepatic Cytochrome P450 mutations can alter systemic drug metabolism and distribution, however, the possibility that mutated or polymorphic variants of Cytochrome P450 exist in the brain is not well studied. 	Cytochrome P450	25188	25203	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:135	Hepatic Cytochrome P450 mutations can alter systemic drug metabolism and distribution, however, the possibility that mutated or polymorphic variants of Cytochrome P450 exist in the brain is not well studied. 	Cytochrome P450	25332	25347	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:135	Hepatic Cytochrome P450 mutations can alter systemic drug metabolism and distribution, however, the possibility that mutated or polymorphic variants of Cytochrome P450 exist in the brain is not well studied. 	Cytochrome P450	25332	25347	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:138	The Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19 gene) is located within a cluster of Cytochrome P450 genes (CYP2C19) on chromosome 10q23.33 with reference sequence number (NM_000769) and ensemble accession number ENST00000371321.8. 	Cytochrome P450	25716	25731	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:138	The Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19 gene) is located within a cluster of Cytochrome P450 genes (CYP2C19) on chromosome 10q23.33 with reference sequence number (NM_000769) and ensemble accession number ENST00000371321.8. 	Cytochrome P450	25716	25731	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:138	The Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19 gene) is located within a cluster of Cytochrome P450 genes (CYP2C19) on chromosome 10q23.33 with reference sequence number (NM_000769) and ensemble accession number ENST00000371321.8. 	Cytochrome P450	25817	25832	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:138	The Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19 gene) is located within a cluster of Cytochrome P450 genes (CYP2C19) on chromosome 10q23.33 with reference sequence number (NM_000769) and ensemble accession number ENST00000371321.8. 	Cytochrome P450	25817	25832	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26697	26712	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26697	26712	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26749	26764	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26749	26764	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26801	26816	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26801	26816	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26860	26875	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26860	26875	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26909	26924	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	Cytochrome P450	26909	26924	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:164	Genetic polymorphisms of Cytochrome P450 enzymes mainly influence drug metabolism, disposition and elimination and lead to alteration of pharmacokinetic parameters resulting in changes in drug response as well as adverse drug reactions. 	Cytochrome P450	31153	31168	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:164	Genetic polymorphisms of Cytochrome P450 enzymes mainly influence drug metabolism, disposition and elimination and lead to alteration of pharmacokinetic parameters resulting in changes in drug response as well as adverse drug reactions. 	Cytochrome P450	31153	31168	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:185	Oxidative processes are mediated primarily by the Cytochrome P450 family of enzymes, whereas conjugation reactions are conducted largely by the enzyme uridine 5-diphospho-glucuronyltransferase. 	Cytochrome P450	35135	35150	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:185	Oxidative processes are mediated primarily by the Cytochrome P450 family of enzymes, whereas conjugation reactions are conducted largely by the enzyme uridine 5-diphospho-glucuronyltransferase. 	Cytochrome P450	35135	35150	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:187	The Cytochrome P450 enzymes activity have four recognizable metabolic categories: (a) poor metabolizers which lack functional enzymes due to deficient allele inheritance; (b) intermediate metabolizers, that are heterozygous with one deficient allele or carrying two reduced activity alleles; (c) extensive metabolizers that have normally functional enzymes due to wild type alleles inheritance, and (d) ultra-rapid metabolizers, which carry more than two copies of active alleles. 	Cytochrome P450	35502	35517	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:187	The Cytochrome P450 enzymes activity have four recognizable metabolic categories: (a) poor metabolizers which lack functional enzymes due to deficient allele inheritance; (b) intermediate metabolizers, that are heterozygous with one deficient allele or carrying two reduced activity alleles; (c) extensive metabolizers that have normally functional enzymes due to wild type alleles inheritance, and (d) ultra-rapid metabolizers, which carry more than two copies of active alleles. 	Cytochrome P450	35502	35517	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:217	For example, the Cytochrome P450 enzymes can play a major role in metabolic drug oxidation and accounts for approximately 75% of the total drug metabolism. 	Cytochrome P450	41607	41622	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:217	For example, the Cytochrome P450 enzymes can play a major role in metabolic drug oxidation and accounts for approximately 75% of the total drug metabolism. 	Cytochrome P450	41607	41622	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:218	Furthermore, Cytochrome P450 enzymes are classified based on gene similarity (cytochromes within families have more than 40% homology in their protein sequence). 	Cytochrome P450	41759	41774	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:218	Furthermore, Cytochrome P450 enzymes are classified based on gene similarity (cytochromes within families have more than 40% homology in their protein sequence). 	Cytochrome P450	41759	41774	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:1	 Cytochrome P450 endoplasmic reticulum-associated degradation: therapeutic and pathophysiological implications. 	Cytochrome P450	1	16	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:1	 Cytochrome P450 endoplasmic reticulum-associated degradation: therapeutic and pathophysiological implications. 	Cytochrome P450	1	16	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:27	Furthermore, reduced futile oxidative cycling upon conditional deletion of the liver Cytochrome P450 Reductase gene elevates the constitutive hepatic CYP3A content in mice, plausibly via protein stabilization. 	Cytochrome P450	5857	5872	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:27	Furthermore, reduced futile oxidative cycling upon conditional deletion of the liver Cytochrome P450 Reductase gene elevates the constitutive hepatic CYP3A content in mice, plausibly via protein stabilization. 	Cytochrome P450	5857	5872	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:100	Functional inactivation of its catalytic partner Cytochrome P450 Reductase abolishes all redox-flux, thus minimizing oxidative damage and stabilizing CYP2E1 by prolonging its t_1/2,. 	Cytochrome P450	23271	23286	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:100	Functional inactivation of its catalytic partner Cytochrome P450 Reductase abolishes all redox-flux, thus minimizing oxidative damage and stabilizing CYP2E1 by prolonging its t_1/2,. 	Cytochrome P450	23271	23286	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:101	Notably, this dual CYP2E1 proteolytic mode is conserved upon its heterologous expression in yeast, even though P450 redox flux and consequent ROS-generating potential are greatly minimized by the poor yeast Cytochrome P450 Reductase content. 	Cytochrome P450	23612	23627	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:101	Notably, this dual CYP2E1 proteolytic mode is conserved upon its heterologous expression in yeast, even though P450 redox flux and consequent ROS-generating potential are greatly minimized by the poor yeast Cytochrome P450 Reductase content. 	Cytochrome P450	23612	23627	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:2	Cytochrome P450 1A (CYP1A), one of the major Cytochrome P450 subfamily in humans, not only metabolizes xenobiotics including clinical drugs and pollutants in the environment, but also mediates the biotransformation of important endogenous substances. 	Cytochrome P450	106	121	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:2	Cytochrome P450 1A (CYP1A), one of the major Cytochrome P450 subfamily in humans, not only metabolizes xenobiotics including clinical drugs and pollutants in the environment, but also mediates the biotransformation of important endogenous substances. 	Cytochrome P450	106	121	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:2	Cytochrome P450 1A (CYP1A), one of the major Cytochrome P450 subfamily in humans, not only metabolizes xenobiotics including clinical drugs and pollutants in the environment, but also mediates the biotransformation of important endogenous substances. 	Cytochrome P450	151	166	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:2	Cytochrome P450 1A (CYP1A), one of the major Cytochrome P450 subfamily in humans, not only metabolizes xenobiotics including clinical drugs and pollutants in the environment, but also mediates the biotransformation of important endogenous substances. 	Cytochrome P450	151	166	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:10	From prokaryotes to eukaryotes, from plants to animals, from non-human primates to humans, thousands of Cytochrome P450 genes have been identified and named. 	Cytochrome P450	1398	1413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:10	From prokaryotes to eukaryotes, from plants to animals, from non-human primates to humans, thousands of Cytochrome P450 genes have been identified and named. 	Cytochrome P450	1398	1413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:12	For the decomposition of clinical drugs, human Cytochrome P450 enzymes belong to the Phase I drug metabolizing enzymes. 	Cytochrome P450	1718	1733	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:12	For the decomposition of clinical drugs, human Cytochrome P450 enzymes belong to the Phase I drug metabolizing enzymes. 	Cytochrome P450	1718	1733	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:13	Among the human Cytochrome P450 isoforms, CYP1A is an important subfamily involved in the metabolism of drugs, environmental pollutants and physiological substances,. 	Cytochrome P450	1807	1822	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:13	Among the human Cytochrome P450 isoforms, CYP1A is an important subfamily involved in the metabolism of drugs, environmental pollutants and physiological substances,. 	Cytochrome P450	1807	1822	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:47	Although progesterone is mainly converted to pregnanediol, direct hydroxylation of progesterone mediated by Cytochrome P450 is also involved^,^,. 	Cytochrome P450	7027	7042	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:47	Although progesterone is mainly converted to pregnanediol, direct hydroxylation of progesterone mediated by Cytochrome P450 is also involved^,^,. 	Cytochrome P450	7027	7042	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:57	Sulfotransferases and glucuronidases conjugate estrone into estrogen conjugates, and some Cytochrome P450 isoforms also hydroxylate it into catechol estrogens or estriol. 	Cytochrome P450	8080	8095	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:57	Sulfotransferases and glucuronidases conjugate estrone into estrogen conjugates, and some Cytochrome P450 isoforms also hydroxylate it into catechol estrogens or estriol. 	Cytochrome P450	8080	8095	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:64	Estradiol is converted into the less potent estrogens to be inactivated and hydroxylated into catechol estrogens through Cytochrome P450 enzymes. 	Cytochrome P450	8799	8814	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:64	Estradiol is converted into the less potent estrogens to be inactivated and hydroxylated into catechol estrogens through Cytochrome P450 enzymes. 	Cytochrome P450	8799	8814	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:79	In addition to the conjugation pathway and 17-ketosteroid pathway, hydroxylation and oxidation of hepatic Cytochrome P450 enzymes are additional pathways for testosterone metabolism. 	Cytochrome P450	10617	10632	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:79	In addition to the conjugation pathway and 17-ketosteroid pathway, hydroxylation and oxidation of hepatic Cytochrome P450 enzymes are additional pathways for testosterone metabolism. 	Cytochrome P450	10617	10632	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	Cytochrome P450	11985	12000	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	Cytochrome P450	11985	12000	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	Cytochrome P450	12172	12187	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	Cytochrome P450	12172	12187	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	Cytochrome P450	12221	12236	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:91	Compared with other Cytochrome P450 isoforms, CYP1A1 and CYP1A2 exhibited retinol dehydrogenase activity with a relative low K_m (8 mol/L for CYP1A1 and 9 mol/L for CYP1A2) and high V_max (507 pmol/min/nmol Cytochrome P450 for CYP1A1 and 491 pmol/min/nmol Cytochrome P450 for CYP1A2) (B). 	Cytochrome P450	12221	12236	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:93	These studies indicate that CYP1A1 and CYP1A2 are two major enzymes for human t-ROH to form t-RA, compared with other Cytochrome P450 isoforms. 	Cytochrome P450	12504	12519	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:93	These studies indicate that CYP1A1 and CYP1A2 are two major enzymes for human t-ROH to form t-RA, compared with other Cytochrome P450 isoforms. 	Cytochrome P450	12504	12519	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:96	Linoleic acid is metabolized by a variety of enzymes, including Cytochrome P450, lipoxygenase, and cyclooxygenase. 	Cytochrome P450	12928	12943	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:96	Linoleic acid is metabolized by a variety of enzymes, including Cytochrome P450, lipoxygenase, and cyclooxygenase. 	Cytochrome P450	12928	12943	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7014017_OgerInput.txtOger_out.csv:1	 Comprehensive Analyses of Cytochrome P450 Monooxygenases and Secondary Metabolite Biosynthetic Gene Clusters in Cyanobacteria. 	Cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7014017_OgerInput.txtOger_out.csv:1	 Comprehensive Analyses of Cytochrome P450 Monooxygenases and Secondary Metabolite Biosynthetic Gene Clusters in Cyanobacteria. 	Cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7014017_OgerInput.txtOger_out.csv:4	Cytochrome P450 monooxygenases (CYPs/P450s) contribute to the production and diversity of various secondary metabolites. 	Cytochrome P450	439	454	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7014017_OgerInput.txtOger_out.csv:4	Cytochrome P450 monooxygenases (CYPs/P450s) contribute to the production and diversity of various secondary metabolites. 	Cytochrome P450	439	454	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7047130_OgerInput.txtOger_out.csv:114	Of the genes that were upregulated and have more than 10 protein to protein interactions are: Cytochrome P450 1a1, IL6, UGT1A6, EGFR, and CYP1B1 (see. 	Cytochrome P450	18796	18811	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7047130_OgerInput.txtOger_out.csv:114	Of the genes that were upregulated and have more than 10 protein to protein interactions are: Cytochrome P450 1a1, IL6, UGT1A6, EGFR, and CYP1B1 (see. 	Cytochrome P450	18796	18811	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7047130_OgerInput.txtOger_out.csv:115	Cytochrome P450 1A1 was upregulated by more than 300-fold and CYP1B1 by 10-fold in the Bioprinted cells. 	Cytochrome P450	18853	18868	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7047130_OgerInput.txtOger_out.csv:115	Cytochrome P450 1A1 was upregulated by more than 300-fold and CYP1B1 by 10-fold in the Bioprinted cells. 	Cytochrome P450	18853	18868	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:1	 Amino acid levels determine metabolism and Cytochrome P450 function of hepatocytes and hepatoma cell lines. 	Cytochrome P450	44	59	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:1	 Amino acid levels determine metabolism and Cytochrome P450 function of hepatocytes and hepatoma cell lines. 	Cytochrome P450	44	59	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:11	As these Cytochrome P450 enzymes differ significantly between species, drug biotransformation and hepatotoxicity can only be evaluated in freshly isolated primary human hepatocytes^. 	Cytochrome P450	1809	1824	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:11	As these Cytochrome P450 enzymes differ significantly between species, drug biotransformation and hepatotoxicity can only be evaluated in freshly isolated primary human hepatocytes^. 	Cytochrome P450	1809	1824	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:16	Nevertheless, as these models still do not reach drug biotransformation capacities of fresh Primary Human Hepatocytes, the major goal of toxicologists remains the generation of expandable models with stable Cytochrome P450 activity levels close to those of fresh PHH^,. 	Cytochrome P450	2646	2661	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:16	Nevertheless, as these models still do not reach drug biotransformation capacities of fresh Primary Human Hepatocytes, the major goal of toxicologists remains the generation of expandable models with stable Cytochrome P450 activity levels close to those of fresh PHH^,. 	Cytochrome P450	2646	2661	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:22	Hepatocyte-Like Cells differ from Primary Human Hepatocytes at the transcriptional, proteomic, and epigenetical level, and specifically express low levels of hepatic transcription factors and Cytochrome P450 enzymes^,,,. 	Cytochrome P450	3421	3436	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:22	Hepatocyte-Like Cells differ from Primary Human Hepatocytes at the transcriptional, proteomic, and epigenetical level, and specifically express low levels of hepatic transcription factors and Cytochrome P450 enzymes^,,,. 	Cytochrome P450	3421	3436	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:29	We also show that extracellular amino acids represent a tool to drive both metabolic maturation and the expression of Cytochrome P450 enzymes, and this in both Hepatocyte-Like Cells and HepG2 hepatoma cells. 	Cytochrome P450	4476	4491	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:29	We also show that extracellular amino acids represent a tool to drive both metabolic maturation and the expression of Cytochrome P450 enzymes, and this in both Hepatocyte-Like Cells and HepG2 hepatoma cells. 	Cytochrome P450	4476	4491	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:36	Surprisingly, Cytochrome P450 genes were found to be co-regulated with metabolic rather than developmental genes, we found a strong correlation between modules containing Cytochrome P450 genes and genes involved in gluconeogenesis, mitochondrial metabolism, AA metabolism, and BETA-oxidation. 	Cytochrome P450	5908	5923	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:36	Surprisingly, Cytochrome P450 genes were found to be co-regulated with metabolic rather than developmental genes, we found a strong correlation between modules containing Cytochrome P450 genes and genes involved in gluconeogenesis, mitochondrial metabolism, AA metabolism, and BETA-oxidation. 	Cytochrome P450	5908	5923	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:36	Surprisingly, Cytochrome P450 genes were found to be co-regulated with metabolic rather than developmental genes, we found a strong correlation between modules containing Cytochrome P450 genes and genes involved in gluconeogenesis, mitochondrial metabolism, AA metabolism, and BETA-oxidation. 	Cytochrome P450	6065	6080	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:36	Surprisingly, Cytochrome P450 genes were found to be co-regulated with metabolic rather than developmental genes, we found a strong correlation between modules containing Cytochrome P450 genes and genes involved in gluconeogenesis, mitochondrial metabolism, AA metabolism, and BETA-oxidation. 	Cytochrome P450	6065	6080	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:37	As a lower correlation was found with modules linked to development, polarity, and cytoskeleton, we hypothesized that an immature metabolism is the prime reason for low Cytochrome P450 expression. 	Cytochrome P450	6356	6371	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:37	As a lower correlation was found with modules linked to development, polarity, and cytoskeleton, we hypothesized that an immature metabolism is the prime reason for low Cytochrome P450 expression. 	Cytochrome P450	6356	6371	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:43	As overexpression of hepatic Transcription Factors has been shown to enhance Cytochrome P450 activity to some extent^,, we next assessed whether these might also rewire hepatic metabolism. 	Cytochrome P450	7895	7910	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:43	As overexpression of hepatic Transcription Factors has been shown to enhance Cytochrome P450 activity to some extent^,, we next assessed whether these might also rewire hepatic metabolism. 	Cytochrome P450	7895	7910	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:53	Hence, although overexpression of hepatic Transcription Factors could induce a metabolic switch from a glucose to a pyruvate-fueled metabolism, they could not induce a gluconeogenic and oxidative phenotype, and Cytochrome P450 function was only modestly increased. 	Cytochrome P450	9914	9929	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:53	Hence, although overexpression of hepatic Transcription Factors could induce a metabolic switch from a glucose to a pyruvate-fueled metabolism, they could not induce a gluconeogenic and oxidative phenotype, and Cytochrome P450 function was only modestly increased. 	Cytochrome P450	9914	9929	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:63	Surprisingly, despite the clear correlation between metabolism, AA catabolism, and Cytochrome P450 expression observed in the WGCNA, AA3 only marginally induced the expression of CYP3A4 when exceeding the nutritional need (Supplementary Fig, C). 	Cytochrome P450	11873	11888	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:63	Surprisingly, despite the clear correlation between metabolism, AA catabolism, and Cytochrome P450 expression observed in the WGCNA, AA3 only marginally induced the expression of CYP3A4 when exceeding the nutritional need (Supplementary Fig, C). 	Cytochrome P450	11873	11888	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:66	As aside from CYP3A4, also other Cytochrome P450 isoforms were induced in Aa3 Medium Supplemented With 2% Glycine medium (Supplementary Fig ), Amino Acids represent a valuable tool to induce Cytochrome P450 enzymes. 	Cytochrome P450	12604	12619	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:66	As aside from CYP3A4, also other Cytochrome P450 isoforms were induced in Aa3 Medium Supplemented With 2% Glycine medium (Supplementary Fig ), Amino Acids represent a valuable tool to induce Cytochrome P450 enzymes. 	Cytochrome P450	12604	12619	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:66	As aside from CYP3A4, also other Cytochrome P450 isoforms were induced in Aa3 Medium Supplemented With 2% Glycine medium (Supplementary Fig ), Amino Acids represent a valuable tool to induce Cytochrome P450 enzymes. 	Cytochrome P450	12762	12777	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:66	As aside from CYP3A4, also other Cytochrome P450 isoforms were induced in Aa3 Medium Supplemented With 2% Glycine medium (Supplementary Fig ), Amino Acids represent a valuable tool to induce Cytochrome P450 enzymes. 	Cytochrome P450	12762	12777	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:69	The top deregulated pathways when comparing HLC Liver Differentiation Medium D20 with Primary Human Hepatocytes contained several genes involved in AA catabolism, glucose metabolism, metabolic pathways, and metabolism of xenobiotics by Cytochrome P450 enzymes and AMP-activated protein kinase), we next stratified these into four quadrants. 	Cytochrome P450	13566	13581	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:69	The top deregulated pathways when comparing HLC Liver Differentiation Medium D20 with Primary Human Hepatocytes contained several genes involved in AA catabolism, glucose metabolism, metabolic pathways, and metabolism of xenobiotics by Cytochrome P450 enzymes and AMP-activated protein kinase), we next stratified these into four quadrants. 	Cytochrome P450	13566	13581	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:75	We found Aa3 Medium Supplemented With 2% Glycine to induce several Cytochrome P450 isoforms in the HepG2 and HUH7.5 hepatic cell lines (Supplementary Fig ), whereas again glycine could be replaced by serine, alanine, or leucine (Supplementary Fig. 	Cytochrome P450	14743	14758	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:75	We found Aa3 Medium Supplemented With 2% Glycine to induce several Cytochrome P450 isoforms in the HepG2 and HUH7.5 hepatic cell lines (Supplementary Fig ), whereas again glycine could be replaced by serine, alanine, or leucine (Supplementary Fig. 	Cytochrome P450	14743	14758	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:77	As both isoforms are expressed in kidney cells^, this may suggest that Amino Acids might also regulate Cytochrome P450 isoforms in other cell types. 	Cytochrome P450	15156	15171	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:77	As both isoforms are expressed in kidney cells^, this may suggest that Amino Acids might also regulate Cytochrome P450 isoforms in other cell types. 	Cytochrome P450	15156	15171	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:164	Genetic polymorphisms of Cytochrome P450 enzymes mainly influence drug metabolism, disposition and elimination and lead to alteration of pharmacokinetic parameters resulting in changes in drug response as well as adverse drug reactions. 	Cytochrome P450 enzymes	31153	31176	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:187	The Cytochrome P450 enzymes activity have four recognizable metabolic categories: (a) poor metabolizers which lack functional enzymes due to deficient allele inheritance; (b) intermediate metabolizers, that are heterozygous with one deficient allele or carrying two reduced activity alleles; (c) extensive metabolizers that have normally functional enzymes due to wild type alleles inheritance, and (d) ultra-rapid metabolizers, which carry more than two copies of active alleles. 	Cytochrome P450 enzymes	35502	35525	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:217	For example, the Cytochrome P450 enzymes can play a major role in metabolic drug oxidation and accounts for approximately 75% of the total drug metabolism. 	Cytochrome P450 enzymes	41607	41630	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:218	Furthermore, Cytochrome P450 enzymes are classified based on gene similarity (cytochromes within families have more than 40% homology in their protein sequence). 	Cytochrome P450 enzymes	41759	41782	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:12	For the decomposition of clinical drugs, human Cytochrome P450 enzymes belong to the Phase I drug metabolizing enzymes. 	Cytochrome P450 enzymes	1718	1741	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:64	Estradiol is converted into the less potent estrogens to be inactivated and hydroxylated into catechol estrogens through Cytochrome P450 enzymes. 	Cytochrome P450 enzymes	8799	8822	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp2e1	8613	8619	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:181	The expression of additional CYPs (Cyp1a1, Cyp1b1, Cyp2e1) was observed in the skin of C57BL/6J mice by Flowers et al.. In the mouse skin the expression of several Cyp genes was demonstrated on the RNA level. 	Cyp2e1	29820	29826	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:187	Cyp1a1, Cyp1b1 and Cyp3a11, but not Ahr expression in the skin also were enhanced by 7,12-Dimethylbenz[A]Anthracene. 	Cyp1a1	31335	31341	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:188	48 h after application of 7,12-Dimethylbenz[A]Anthracene, skin expression of Pxr and Cyp1a1 mRNAs were markedly increased, Cyp1b1 and Cyp3a11 only moderately and Ahr not at all. 	Cyp1a1	31537	31543	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:188	48 h after application of 7,12-Dimethylbenz[A]Anthracene, skin expression of Pxr and Cyp1a1 mRNAs were markedly increased, Cyp1b1 and Cyp3a11 only moderately and Ahr not at all. 	Cyp1a1	31537	31543	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:184	Despite a lower constitutive expression of Cyp4a10 in the female hearts, acute DOX-induced cardiotoxicity caused a marked induction of Cyp4a10 in the hearts of both male and female mice, suggesting that this enzyme may not play an important role in the sexual dimorphism of DOX-induced cardiotoxicity. 	Cyp4a	32656	32661	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:185	In agreement with previous studies, the mRNA levels of Cyp4a12 and Cyp4a14 were below the levels of detection in the hearts of both male and female mice in the current study (data not shown). 	Cyp4a	32878	32883	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:131	Thus, although previous studies identified Amino Acids as important for hepatocyte survival, proliferation, and protein synthesis^,, we here demonstrate that increasing Amino Acids to levels 30-fold above that of typical hepatocyte media, actively induces a metabolic switch, as well as Cytochrome P450 enzyme expression and function (Supplementary Table. 	P450 enzyme	27136	27147	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:131	Thus, although previous studies identified Amino Acids as important for hepatocyte survival, proliferation, and protein synthesis^,, we here demonstrate that increasing Amino Acids to levels 30-fold above that of typical hepatocyte media, actively induces a metabolic switch, as well as Cytochrome P450 enzyme expression and function (Supplementary Table. 	P450 enzyme	27136	27147	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:24	Apart from this QC also reported as an inhibitor of cytochrome P450 enzyme which is the main enzyme of Mycophenolic Acid metabolism (;. 	P450 enzyme	3235	3246	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:24	Apart from this QC also reported as an inhibitor of cytochrome P450 enzyme which is the main enzyme of Mycophenolic Acid metabolism (;. 	P450 enzyme	3235	3246	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:203	In addition, the blood circulation time of Mycophenolic Acid also increased by QC through inhibition of Mycophenolic Acid metabolism mediated by cytochrome P450 enzyme as discussed blow in pharmacokinetic analysis. 	P450 enzyme	31522	31533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:203	In addition, the blood circulation time of Mycophenolic Acid also increased by QC through inhibition of Mycophenolic Acid metabolism mediated by cytochrome P450 enzyme as discussed blow in pharmacokinetic analysis. 	P450 enzyme	31522	31533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:207	Higher AUC_(_0_-__) and T_1_/_2 might be due sustained release of drugs from liposomes and long blood circulation time due Mycophenolic Acid breakdown inhibition through cytochrome P450 enzyme by QC. 	P450 enzyme	32389	32400	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:207	Higher AUC_(_0_-__) and T_1_/_2 might be due sustained release of drugs from liposomes and long blood circulation time due Mycophenolic Acid breakdown inhibition through cytochrome P450 enzyme by QC. 	P450 enzyme	32389	32400	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:217	Meanwhile QC further improved the therapeutic efficacy by increasing the bioavailability of Mycophenolic Acid through inhibiting Cytochrome P450 enzyme. 	P450 enzyme	34438	34449	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:95	Using ^1H-^13C HSQC nuclear magnetic resonance NMR titrations of bacterial P450cam (CYP101), it has been shown that, in the presence of excess camphor, a second camphor molecule binds at the surface of the protein, besides the one bound within the buried active site. 	P450cam	16368	16375	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:104	In total agreement with the results of NMR titrations that were performed on P450cam, a two-step recognition process was also described in ^1H-NMR measurements on bacterial P450 BM3. 	P450cam	17953	17960	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:4	Influence of mentioned extracts and their key constituents on warfarin pharmacodynamic and kinetic actions and Cytochrome P450 Enzymes activity were evaluated. 	Cytochrome P450 Enzymes	794	817	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:6	Furthermore, potential involvement in Cytochrome P450 Enzymes inhibition was also investigated in vitro on isolated primary rat hepatocytes. 	Cytochrome P450 Enzymes	1146	1169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	Cytochrome P450 Enzymes	2129	2152	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:34	In addition, the potential inhibition of selected Cytochrome P450 Enzymes enzymes that are responsible for warfarin metabolism is investigated with the herbal drugs in vitro on rat isolated primary hepatocytes. 	Cytochrome P450 Enzymes	6154	6177	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:100	After 16 h of incubation, each well of cultured rat hepatocytes were treated with 25 l of warfarin, guava leaves extract, quercetin, pomegranate peel extract, ellagic acid, a combination of warfarin with each test compound in addition to the control Cytochrome P450 Enzymes inhibitors namely; ketoconazole, sulfamethoxazole or trimethoprim. 	Cytochrome P450 Enzymes	15835	15858	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450 Enzymes	21875	21898	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450 Enzymes	22027	22050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:4	Influence of mentioned extracts and their key constituents on warfarin pharmacodynamic and kinetic actions and Cytochrome P450 Enzymes activity were evaluated. 	P450 Enzymes	805	817	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:6	Furthermore, potential involvement in Cytochrome P450 Enzymes inhibition was also investigated in vitro on isolated primary rat hepatocytes. 	P450 Enzymes	1157	1169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:6	Furthermore, potential involvement in Cytochrome P450 Enzymes inhibition was also investigated in vitro on isolated primary rat hepatocytes. 	P450 Enzymes	1157	1169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	P450 Enzymes	2140	2152	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	P450 Enzymes	2140	2152	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:34	In addition, the potential inhibition of selected Cytochrome P450 Enzymes enzymes that are responsible for warfarin metabolism is investigated with the herbal drugs in vitro on rat isolated primary hepatocytes. 	P450 Enzymes	6165	6177	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:34	In addition, the potential inhibition of selected Cytochrome P450 Enzymes enzymes that are responsible for warfarin metabolism is investigated with the herbal drugs in vitro on rat isolated primary hepatocytes. 	P450 Enzymes	6165	6177	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:100	After 16 h of incubation, each well of cultured rat hepatocytes were treated with 25 l of warfarin, guava leaves extract, quercetin, pomegranate peel extract, ellagic acid, a combination of warfarin with each test compound in addition to the control Cytochrome P450 Enzymes inhibitors namely; ketoconazole, sulfamethoxazole or trimethoprim. 	P450 Enzymes	15846	15858	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:100	After 16 h of incubation, each well of cultured rat hepatocytes were treated with 25 l of warfarin, guava leaves extract, quercetin, pomegranate peel extract, ellagic acid, a combination of warfarin with each test compound in addition to the control Cytochrome P450 Enzymes inhibitors namely; ketoconazole, sulfamethoxazole or trimethoprim. 	P450 Enzymes	15846	15858	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	P450 Enzymes	21886	21898	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	P450 Enzymes	21886	21898	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	P450 Enzymes	22038	22050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	P450 Enzymes	22038	22050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:154	A comparison with the Raman spectra underlying the relRI trends (c,d) revealed that this was due to overall more cells, with more ferrous cytochrome c, being present in previously stressed samples compared to unstressed samples. 	cytochrome c	25810	25822	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:154	A comparison with the Raman spectra underlying the relRI trends (c,d) revealed that this was due to overall more cells, with more ferrous cytochrome c, being present in previously stressed samples compared to unstressed samples. 	cytochrome c	25810	25822	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:157	Moreover, Nitrosospira also showed significantly more ferrous cytochrome c content in its oxygen-deprived cultures. 	cytochrome c	26327	26339	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:157	Moreover, Nitrosospira also showed significantly more ferrous cytochrome c content in its oxygen-deprived cultures. 	cytochrome c	26327	26339	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:158	However, other than in N. eutropha, cells with more ferric cytochrome c content did occur in oxygen-deprived Nitrosospira, resulting in a relRI curve widely parallel to that of the unstressed samples. 	cytochrome c	26440	26452	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:158	However, other than in N. eutropha, cells with more ferric cytochrome c content did occur in oxygen-deprived Nitrosospira, resulting in a relRI curve widely parallel to that of the unstressed samples. 	cytochrome c	26440	26452	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:159	The occurrence of cells with extremely ferrous overall cytochrome c content in previously stressed samples may have been caused by electron storage within the ammonia-oxidization pathway that increased the amount of ferrous heme c among the total cytochrome c content of a given cell. 	cytochrome c	26637	26649	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:159	The occurrence of cells with extremely ferrous overall cytochrome c content in previously stressed samples may have been caused by electron storage within the ammonia-oxidization pathway that increased the amount of ferrous heme c among the total cytochrome c content of a given cell. 	cytochrome c	26637	26649	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:159	The occurrence of cells with extremely ferrous overall cytochrome c content in previously stressed samples may have been caused by electron storage within the ammonia-oxidization pathway that increased the amount of ferrous heme c among the total cytochrome c content of a given cell. 	cytochrome c	26829	26841	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:159	The occurrence of cells with extremely ferrous overall cytochrome c content in previously stressed samples may have been caused by electron storage within the ammonia-oxidization pathway that increased the amount of ferrous heme c among the total cytochrome c content of a given cell. 	cytochrome c	26829	26841	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:162	It can be assumed that the summarized redox state of a given cell changes considerably faster than its total cytochrome c content, which requires protein expression to occur. 	cytochrome c	27212	27224	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:162	It can be assumed that the summarized redox state of a given cell changes considerably faster than its total cytochrome c content, which requires protein expression to occur. 	cytochrome c	27212	27224	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:164	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used successfully to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo, based on no more than 1000 individual cells per sampling. 	cytochrome c	27772	27784	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:164	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used successfully to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo, based on no more than 1000 individual cells per sampling. 	cytochrome c	27772	27784	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:164	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used successfully to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo, based on no more than 1000 individual cells per sampling. 	cytochrome c	27822	27834	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:164	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used successfully to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo, based on no more than 1000 individual cells per sampling. 	cytochrome c	27822	27834	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:168	In addition, the marker allowed the distinction between cells with more ferric or more ferrous cytochrome c content, giving insight in the ongoing cytochrome c electron transport activity at the time of measurement. 	cytochrome c	28646	28658	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:168	In addition, the marker allowed the distinction between cells with more ferric or more ferrous cytochrome c content, giving insight in the ongoing cytochrome c electron transport activity at the time of measurement. 	cytochrome c	28646	28658	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:168	In addition, the marker allowed the distinction between cells with more ferric or more ferrous cytochrome c content, giving insight in the ongoing cytochrome c electron transport activity at the time of measurement. 	cytochrome c	28698	28710	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:168	In addition, the marker allowed the distinction between cells with more ferric or more ferrous cytochrome c content, giving insight in the ongoing cytochrome c electron transport activity at the time of measurement. 	cytochrome c	28698	28710	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:169	Notably, cells with predominantly ferrous cytochrome c content were found in deprived N. eutropha and Nitrosospira samples, which may be indicative of ongoing electron storage at the time of measurement. 	cytochrome c	28809	28821	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:169	Notably, cells with predominantly ferrous cytochrome c content were found in deprived N. eutropha and Nitrosospira samples, which may be indicative of ongoing electron storage at the time of measurement. 	cytochrome c	28809	28821	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:171	A further study comparing the results obtained with resonant Raman microscopy and quantified results obtained by proteomics or transcriptomics of the same cultures sampled at the same time might allow a quantification of the cytochrome c content elevation reported by Raman microscopy.	cytochrome c	29356	29368	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:171	A further study comparing the results obtained with resonant Raman microscopy and quantified results obtained by proteomics or transcriptomics of the same cultures sampled at the same time might allow a quantification of the cytochrome c content elevation reported by Raman microscopy.	cytochrome c	29356	29368	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7316774_OgerInput.txtOger_out.csv:121	As mentioned earlier, hypoxia leads to change in mitochondria, including decreased oxidative phosphorylation level, cytochrome c oxidase activity and increased ROS production. 	cytochrome c	18399	18411	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7316774_OgerInput.txtOger_out.csv:121	As mentioned earlier, hypoxia leads to change in mitochondria, including decreased oxidative phosphorylation level, cytochrome c oxidase activity and increased ROS production. 	cytochrome c	18399	18411	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7356697_OgerInput.txtOger_out.csv:243	However, the presence of cytochrome c nitrite reductase genes (nrfAH, ) in the genomes of strains F1^T and F21^T suggests that the dissimilatory reduction of nitrite could occur at lower non-toxic concentrations of nitrite. 	cytochrome c	34904	34916	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7356697_OgerInput.txtOger_out.csv:243	However, the presence of cytochrome c nitrite reductase genes (nrfAH, ) in the genomes of strains F1^T and F21^T suggests that the dissimilatory reduction of nitrite could occur at lower non-toxic concentrations of nitrite. 	cytochrome c	34904	34916	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7511789_OgerInput.txtOger_out.csv:47	The napEDABC gene cluster of B. diazoefficiens encodes NapE, a membrane protein of 6.6 kDa with unknown function; NapD (11.8 kDa), a chaperone involved in the maturation of NapA; NapA (94.5 kDa), the catalytic subunit that contains a Mobis-MGD active site and [4Fe4S] cluster; and NapB (16.9 kDa), the electron transfer subunit, which is a diheme cytochrome c_552. 	cytochrome c	7685	7697	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7511789_OgerInput.txtOger_out.csv:47	The napEDABC gene cluster of B. diazoefficiens encodes NapE, a membrane protein of 6.6 kDa with unknown function; NapD (11.8 kDa), a chaperone involved in the maturation of NapA; NapA (94.5 kDa), the catalytic subunit that contains a Mobis-MGD active site and [4Fe4S] cluster; and NapB (16.9 kDa), the electron transfer subunit, which is a diheme cytochrome c_552. 	cytochrome c	7685	7697	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7511789_OgerInput.txtOger_out.csv:53	In Bj-USDA 6 NapB, both the cytochrome c-binding sites and motif for translocation via the general secretory pathway were conserved. 	cytochrome c	8452	8464	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7511789_OgerInput.txtOger_out.csv:53	In Bj-USDA 6 NapB, both the cytochrome c-binding sites and motif for translocation via the general secretory pathway were conserved. 	cytochrome c	8452	8464	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7540168_OgerInput.txtOger_out.csv:122	This is supported by the need for an infinitesimal PO_2 gradient for O_2 to diffuse from the sarcoplasm to cytochrome c oxidase and the estimate that a mitochondrial PO_2 of ~1 mmHg may be sufficient to support maximal mitochondrial respiration.,  The remaining O_2 may also represent muscle metabolismperfusion mismatch,  and an inevitable lower O_2 extraction from the blood perfusing the skin, connective tissue, fat and bone marrow of the leg causing venous admixture. 	cytochrome c	27441	27453	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7540168_OgerInput.txtOger_out.csv:122	This is supported by the need for an infinitesimal PO_2 gradient for O_2 to diffuse from the sarcoplasm to cytochrome c oxidase and the estimate that a mitochondrial PO_2 of ~1 mmHg may be sufficient to support maximal mitochondrial respiration.,  The remaining O_2 may also represent muscle metabolismperfusion mismatch,  and an inevitable lower O_2 extraction from the blood perfusing the skin, connective tissue, fat and bone marrow of the leg causing venous admixture. 	cytochrome c	27441	27453	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7540168_OgerInput.txtOger_out.csv:156	For instance, after 2 weeks of highintensity interval training that elevated the cytochrome c oxidase activity by 20% but caused no change in Qmax, VO2max was increased by 8% and was entirely attributed to the improved systemic (calculated a-vO2 difference) and leg (increased deoxyhaemoglobin and decreased tissue oxygenation index in Vastus Lateralis, assessed using NIRS) O_2 extraction. 	cytochrome c	36400	36412	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7540168_OgerInput.txtOger_out.csv:156	For instance, after 2 weeks of highintensity interval training that elevated the cytochrome c oxidase activity by 20% but caused no change in Qmax, VO2max was increased by 8% and was entirely attributed to the improved systemic (calculated a-vO2 difference) and leg (increased deoxyhaemoglobin and decreased tissue oxygenation index in Vastus Lateralis, assessed using NIRS) O_2 extraction. 	cytochrome c	36400	36412	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7545470_OgerInput.txtOger_out.csv:343	Due to the easily accessible C-terminal catalytic center, TrxRs can reduce a broad range of substrates including hydrogen peroxide, selenite, lipoic acid, ascorbate, and ubiquinone, and TrxR-2 was demonstrated to act on cytochrome c, but the main substrates remain Thioredoxins. 	cytochrome c	56252	56264	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7545470_OgerInput.txtOger_out.csv:343	Due to the easily accessible C-terminal catalytic center, TrxRs can reduce a broad range of substrates including hydrogen peroxide, selenite, lipoic acid, ascorbate, and ubiquinone, and TrxR-2 was demonstrated to act on cytochrome c, but the main substrates remain Thioredoxins. 	cytochrome c	56252	56264	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7555760_OgerInput.txtOger_out.csv:149	Early work with rat liver mitochondria shows that Chloroquine alters mitochondrial lipid composition, decreases the activities of NADH dehydrogenase, succinate dehydrogenase, and cytochrome c, and inhibits both mitochondrial respiration and ATP synthesis. 	cytochrome c	21698	21710	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7555760_OgerInput.txtOger_out.csv:149	Early work with rat liver mitochondria shows that Chloroquine alters mitochondrial lipid composition, decreases the activities of NADH dehydrogenase, succinate dehydrogenase, and cytochrome c, and inhibits both mitochondrial respiration and ATP synthesis. 	cytochrome c	21698	21710	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7561548_OgerInput.txtOger_out.csv:194	However, while genes indeed include a cytochrome b_6, there is no homology to a cytochrome f, but there is to a cytochrome c_1. 	cytochrome c	26183	26195	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7561548_OgerInput.txtOger_out.csv:194	However, while genes indeed include a cytochrome b_6, there is no homology to a cytochrome f, but there is to a cytochrome c_1. 	cytochrome c	26183	26195	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7707949_OgerInput.txtOger_out.csv:187	It also evoked the production of caspase 9 and cytochrome c. The cytotoxic effects of resminostat were reinforced by inhibitors of the mammalian target of rapamycin, which has been characterized as a resistance factor of resminostat. 	cytochrome c	27970	27982	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7707949_OgerInput.txtOger_out.csv:187	It also evoked the production of caspase 9 and cytochrome c. The cytotoxic effects of resminostat were reinforced by inhibitors of the mammalian target of rapamycin, which has been characterized as a resistance factor of resminostat. 	cytochrome c	27970	27982	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7762604_OgerInput.txtOger_out.csv:421	On the other hand, it is known that if the levels of Reactive Oxygen Species exceed the antioxidant capacity of the cell, homeostasis is disrupted, and cell survival is compromised by oxidization of proteins and the release of the mitochondrial protein cytochrome c into the cytoplasm, an event that occurs during the activation of apoptotic machinery with the activation of the caspase cascade. 	cytochrome c	72601	72613	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7762604_OgerInput.txtOger_out.csv:421	On the other hand, it is known that if the levels of Reactive Oxygen Species exceed the antioxidant capacity of the cell, homeostasis is disrupted, and cell survival is compromised by oxidization of proteins and the release of the mitochondrial protein cytochrome c into the cytoplasm, an event that occurs during the activation of apoptotic machinery with the activation of the caspase cascade. 	cytochrome c	72601	72613	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7911101_OgerInput.txtOger_out.csv:34	The resulting plasmid was transformed in E. coli JM109(DE3) strain, previously transformed with the vector pEC86 that encodes the cytochrome c maturation system (Ccm). 	cytochrome c	7274	7286	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7911101_OgerInput.txtOger_out.csv:34	The resulting plasmid was transformed in E. coli JM109(DE3) strain, previously transformed with the vector pEC86 that encodes the cytochrome c maturation system (Ccm). 	cytochrome c	7274	7286	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:9	We visualized localization of cytochromes by Raman imaging in the breast and brain tissues and analyzed cytochrome c vibrations at 750, 1126, 1337 and 1584 cm1 as a function of malignancy grade. 	cytochrome c	1453	1465	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:9	We visualized localization of cytochromes by Raman imaging in the breast and brain tissues and analyzed cytochrome c vibrations at 750, 1126, 1337 and 1584 cm1 as a function of malignancy grade. 	cytochrome c	1453	1465	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:10	We found that the concentration of reduced cytochrome c becomes abnormally high in human brain tumors and breast cancers and correlates with the grade of cancer. 	cytochrome c	1587	1599	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:10	We found that the concentration of reduced cytochrome c becomes abnormally high in human brain tumors and breast cancers and correlates with the grade of cancer. 	cytochrome c	1587	1599	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:24	Early studies on glioma cell rat xenografts identified lower cytochrome c oxidase (COX, Complex IV) and SDH (Complex II) enzyme expression in more hypoxic areas of the tumor. 	cytochrome c	4135	4147	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:24	Early studies on glioma cell rat xenografts identified lower cytochrome c oxidase (COX, Complex IV) and SDH (Complex II) enzyme expression in more hypoxic areas of the tumor. 	cytochrome c	4135	4147	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:30	Cytochromes are classified based on their lowest electronic energy absorption band in their reduced state: cytochrome P450 (450 nm), cytochrome c (550 nm), cytochromes b (565 nm), cytochromes a (605 nm). 	cytochrome c	5229	5241	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:30	Cytochromes are classified based on their lowest electronic energy absorption band in their reduced state: cytochrome P450 (450 nm), cytochrome c (550 nm), cytochromes b (565 nm), cytochromes a (605 nm). 	cytochrome c	5229	5241	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:31	The family of cytochromes are localized in the third complex in the electron transport chain, also known as complex III or Coenzyme Q - Cyt c reductase, sometimes called the cytochrome bc_1 complex (cytochrome b, cytochrome c_1), as well as in cytochrome c loosely associated with the inner membrane of the mitochondrion. 	cytochrome c	5513	5525	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:31	The family of cytochromes are localized in the third complex in the electron transport chain, also known as complex III or Coenzyme Q - Cyt c reductase, sometimes called the cytochrome bc_1 complex (cytochrome b, cytochrome c_1), as well as in cytochrome c loosely associated with the inner membrane of the mitochondrion. 	cytochrome c	5513	5525	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:31	The family of cytochromes are localized in the third complex in the electron transport chain, also known as complex III or Coenzyme Q - Cyt c reductase, sometimes called the cytochrome bc_1 complex (cytochrome b, cytochrome c_1), as well as in cytochrome c loosely associated with the inner membrane of the mitochondrion. 	cytochrome c	5544	5556	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:31	The family of cytochromes are localized in the third complex in the electron transport chain, also known as complex III or Coenzyme Q - Cyt c reductase, sometimes called the cytochrome bc_1 complex (cytochrome b, cytochrome c_1), as well as in cytochrome c loosely associated with the inner membrane of the mitochondrion. 	cytochrome c	5544	5556	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:36	Cytochrome c, which is reduced to cyt c Fe^2+ (ferrous) by the electron from the complex III, passes an electron to the copper binuclear center, being oxidized back to cytochrome c (cyt c Fe^3+ (ferric)). 	cytochrome c	6460	6472	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:36	Cytochrome c, which is reduced to cyt c Fe^2+ (ferrous) by the electron from the complex III, passes an electron to the copper binuclear center, being oxidized back to cytochrome c (cyt c Fe^3+ (ferric)). 	cytochrome c	6460	6472	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:37	Using different excitations being in resonance with the absorption bands of the cytochromes one can spectrally enhance various cytochrome chromophores in the complex III, cytochrome c and complex IV by Resonance Raman enhancement scattering. 	cytochrome c	6668	6680	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:37	Using different excitations being in resonance with the absorption bands of the cytochromes one can spectrally enhance various cytochrome chromophores in the complex III, cytochrome c and complex IV by Resonance Raman enhancement scattering. 	cytochrome c	6668	6680	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:38	Using different excitations, we are able to monitor contribution of cytochrome family in the electron transfer chain in the mitochondrial respiration originating from cytochrome b, c_1 in complex III, cytochrome c, and a, a_3 cytochromes in complex IV. 	cytochrome c	6940	6952	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:38	Using different excitations, we are able to monitor contribution of cytochrome family in the electron transfer chain in the mitochondrial respiration originating from cytochrome b, c_1 in complex III, cytochrome c, and a, a_3 cytochromes in complex IV. 	cytochrome c	6940	6952	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:40	The spectral features of cytochrome c can be monitored at 532 nm due to absorbance band (Q band) centered at 530 nm. 	cytochrome c	7249	7261	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:40	The spectral features of cytochrome c can be monitored at 532 nm due to absorbance band (Q band) centered at 530 nm. 	cytochrome c	7249	7261	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:50	It is well known that cytochrome c is undoubtedly one of the most prominent molecules in the electron transport chain required to fuel life via ATP, but its role in molecular mechanisms associated with an aggressive phenotype of cancer remain largely unclear. 	cytochrome c	9288	9300	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:50	It is well known that cytochrome c is undoubtedly one of the most prominent molecules in the electron transport chain required to fuel life via ATP, but its role in molecular mechanisms associated with an aggressive phenotype of cancer remain largely unclear. 	cytochrome c	9288	9300	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:52	In this paper we explore a hypothesis involving the role of reduction-oxidation pathways related to cytochrome c in cancer state. 	cytochrome c	9894	9906	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:52	In this paper we explore a hypothesis involving the role of reduction-oxidation pathways related to cytochrome c in cancer state. 	cytochrome c	9894	9906	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:91	To show the perfect match between Raman spectra of human tissue samples and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99951 at the confidence level 0.95 with the p-value of 0.00001). 	cytochrome c	16290	16302	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:91	To show the perfect match between Raman spectra of human tissue samples and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99951 at the confidence level 0.95 with the p-value of 0.00001). 	cytochrome c	16290	16302	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:105	shows the average Raman spectra of the ex vivo human breast cancer tissue surgically resected specimens, ductal cancer, grade of malignancy WHO G3 at different excitations 532 nm, 633 nm, 785 nm, (number of patients n = 5), and Raman spectrum of the pure cytochrome c at 532 nm excitation. 	cytochrome c	19005	19017	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:105	shows the average Raman spectra of the ex vivo human breast cancer tissue surgically resected specimens, ductal cancer, grade of malignancy WHO G3 at different excitations 532 nm, 633 nm, 785 nm, (number of patients n = 5), and Raman spectrum of the pure cytochrome c at 532 nm excitation. 	cytochrome c	19005	19017	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:110	B shows the spectrum of isolated cytochrome c. Using 532 nm laser excitation one can monitor spectral features of complex III and cytochrome c due to Q bands at 500-550 nm related to intra-porphyrin transitions of the heme group in cytochrome c. Excitation at 633 nm provides information about cytochromes a and a_3 (1744 cm^1 and 1396 cm^1, both in cyt oxidized and reduced cytochrome oxidase; 1584 cm^1, heme a + a_3 oxidized form). 	cytochrome c	19684	19696	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:110	B shows the spectrum of isolated cytochrome c. Using 532 nm laser excitation one can monitor spectral features of complex III and cytochrome c due to Q bands at 500-550 nm related to intra-porphyrin transitions of the heme group in cytochrome c. Excitation at 633 nm provides information about cytochromes a and a_3 (1744 cm^1 and 1396 cm^1, both in cyt oxidized and reduced cytochrome oxidase; 1584 cm^1, heme a + a_3 oxidized form). 	cytochrome c	19684	19696	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:110	B shows the spectrum of isolated cytochrome c. Using 532 nm laser excitation one can monitor spectral features of complex III and cytochrome c due to Q bands at 500-550 nm related to intra-porphyrin transitions of the heme group in cytochrome c. Excitation at 633 nm provides information about cytochromes a and a_3 (1744 cm^1 and 1396 cm^1, both in cyt oxidized and reduced cytochrome oxidase; 1584 cm^1, heme a + a_3 oxidized form). 	cytochrome c	19781	19793	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:110	B shows the spectrum of isolated cytochrome c. Using 532 nm laser excitation one can monitor spectral features of complex III and cytochrome c due to Q bands at 500-550 nm related to intra-porphyrin transitions of the heme group in cytochrome c. Excitation at 633 nm provides information about cytochromes a and a_3 (1744 cm^1 and 1396 cm^1, both in cyt oxidized and reduced cytochrome oxidase; 1584 cm^1, heme a + a_3 oxidized form). 	cytochrome c	19781	19793	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:110	B shows the spectrum of isolated cytochrome c. Using 532 nm laser excitation one can monitor spectral features of complex III and cytochrome c due to Q bands at 500-550 nm related to intra-porphyrin transitions of the heme group in cytochrome c. Excitation at 633 nm provides information about cytochromes a and a_3 (1744 cm^1 and 1396 cm^1, both in cyt oxidized and reduced cytochrome oxidase; 1584 cm^1, heme a + a_3 oxidized form). 	cytochrome c	19883	19895	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:110	B shows the spectrum of isolated cytochrome c. Using 532 nm laser excitation one can monitor spectral features of complex III and cytochrome c due to Q bands at 500-550 nm related to intra-porphyrin transitions of the heme group in cytochrome c. Excitation at 633 nm provides information about cytochromes a and a_3 (1744 cm^1 and 1396 cm^1, both in cyt oxidized and reduced cytochrome oxidase; 1584 cm^1, heme a + a_3 oxidized form). 	cytochrome c	19883	19895	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:112	First, let us concentrate on the contribution of cytochrome c using 532 nm excitation.  	cytochrome c	20278	20290	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:112	First, let us concentrate on the contribution of cytochrome c using 532 nm excitation.  	cytochrome c	20278	20290	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:115	Comparison of the Raman spectra of the brain tissue in  and the Raman spectra of the breast tissue in A with purified cytochrome c in B shows that the Raman enhancement upon 532 nm excitation corresponds perfectly to vibrations of cytochrome c. To show the perfect match between Raman spectra of human tissue samples and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99951 at the confidence level 0.95 with the p-value of 0.00001). 	cytochrome c	20846	20858	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:115	Comparison of the Raman spectra of the brain tissue in  and the Raman spectra of the breast tissue in A with purified cytochrome c in B shows that the Raman enhancement upon 532 nm excitation corresponds perfectly to vibrations of cytochrome c. To show the perfect match between Raman spectra of human tissue samples and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99951 at the confidence level 0.95 with the p-value of 0.00001). 	cytochrome c	20846	20858	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:115	Comparison of the Raman spectra of the brain tissue in  and the Raman spectra of the breast tissue in A with purified cytochrome c in B shows that the Raman enhancement upon 532 nm excitation corresponds perfectly to vibrations of cytochrome c. To show the perfect match between Raman spectra of human tissue samples and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99951 at the confidence level 0.95 with the p-value of 0.00001). 	cytochrome c	20959	20971	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:115	Comparison of the Raman spectra of the brain tissue in  and the Raman spectra of the breast tissue in A with purified cytochrome c in B shows that the Raman enhancement upon 532 nm excitation corresponds perfectly to vibrations of cytochrome c. To show the perfect match between Raman spectra of human tissue samples and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99951 at the confidence level 0.95 with the p-value of 0.00001). 	cytochrome c	20959	20971	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:115	Comparison of the Raman spectra of the brain tissue in  and the Raman spectra of the breast tissue in A with purified cytochrome c in B shows that the Raman enhancement upon 532 nm excitation corresponds perfectly to vibrations of cytochrome c. To show the perfect match between Raman spectra of human tissue samples and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99951 at the confidence level 0.95 with the p-value of 0.00001). 	cytochrome c	21067	21079	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:115	Comparison of the Raman spectra of the brain tissue in  and the Raman spectra of the breast tissue in A with purified cytochrome c in B shows that the Raman enhancement upon 532 nm excitation corresponds perfectly to vibrations of cytochrome c. To show the perfect match between Raman spectra of human tissue samples and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99951 at the confidence level 0.95 with the p-value of 0.00001). 	cytochrome c	21067	21079	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:116	It indicates that cytochrome c can be used for pathology assessment for ex vivo tissues. 	cytochrome c	21247	21259	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:116	It indicates that cytochrome c can be used for pathology assessment for ex vivo tissues. 	cytochrome c	21247	21259	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:117	To check if vibrations of cytochrome c can be used also for pathology assessment in living cells we analysed Raman spectra of brain and breast cancer cells lines at in vitro incubation.  	cytochrome c	21344	21356	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:117	To check if vibrations of cytochrome c can be used also for pathology assessment in living cells we analysed Raman spectra of brain and breast cancer cells lines at in vitro incubation.  	cytochrome c	21344	21356	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:119	We compared Raman spectra of single cells at in vitro incubation and Raman spectrum of cytochrome c. To show the perfect match between Raman spectra of human cells and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99941 at the confidence level 0.95 with the p-value of 0.00002). 	cytochrome c	22084	22096	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:119	We compared Raman spectra of single cells at in vitro incubation and Raman spectrum of cytochrome c. To show the perfect match between Raman spectra of human cells and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99941 at the confidence level 0.95 with the p-value of 0.00002). 	cytochrome c	22084	22096	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:119	We compared Raman spectra of single cells at in vitro incubation and Raman spectrum of cytochrome c. To show the perfect match between Raman spectra of human cells and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99941 at the confidence level 0.95 with the p-value of 0.00002). 	cytochrome c	22183	22195	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:119	We compared Raman spectra of single cells at in vitro incubation and Raman spectrum of cytochrome c. To show the perfect match between Raman spectra of human cells and Raman spectrum of cytochrome c the correlation analysis was performed (Pearson correlation coefficient was equal 0.99941 at the confidence level 0.95 with the p-value of 0.00002). 	cytochrome c	22183	22195	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:104	Examples of cytochrome-c-resonant Raman spectra as recorded from native cultures of Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) under well aerated (+O_2) and oxygen-deprived (O_2) growth conditions are shown in. 	cytochrome-c	15711	15723	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:104	Examples of cytochrome-c-resonant Raman spectra as recorded from native cultures of Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) under well aerated (+O_2) and oxygen-deprived (O_2) growth conditions are shown in. 	cytochrome-c	15711	15723	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:107	^ While MCF-7 cells used to develop the ER-Luc cells express metabolic enzymes from the cytochrome P450 superfamily (and thus possess the ability for endogenous biotransformation of chemicals), formation of MBP was dependent on the presence of S9 enzymes. 	cytochrome P450 superfamily	23273	23300	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_353', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:179	and the highest andrographolide was detected in leaf as compared to other panchang (Pandey and Mandal ; Sharma et al.. Therefore, some other isomers of cytochrome p450 (cytochrome p450 98, cytochrome p450 706, etc.) 	cytochrome p450	27150	27165	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:179	and the highest andrographolide was detected in leaf as compared to other panchang (Pandey and Mandal ; Sharma et al.. Therefore, some other isomers of cytochrome p450 (cytochrome p450 98, cytochrome p450 706, etc.) 	cytochrome p450	27150	27165	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:18	The metabolic activation of PCBs is initiated by cytochrome p450 (CYP) family members and includes the oxidation of PCBs to OH-PCBs. 	cytochrome p450	2329	2344	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6134581_OgerInput.txtOger_out.csv:35	Subsequent genetic studies based on mitochondrial DNA (cytochrome b and data from restriction profiles across the entire mitochondrial genome), supported some, but not all, of these designations [,. 	cytochrome b	6312	6324	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:9	Progestin receptor membrane component 1 is a single transmembrane heme-binding protein containing a cytochrome b_5 motif, which has been proposed as a progesterone binding protein in vertebrates (,. 	cytochrome b	1572	1584	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:127	For example, Progestin Receptor Membrane Component 1 is a heme-binding protein with a cytochrome b_5 motif, which binds and activates P450 proteins and is involved in steroidogenesis and drug metabolism. 	cytochrome b	22001	22013	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:156	Pgrmc1 has a role in the regulation of cholesterol and steroid synthesis because of its cytochrome b_5 motif and its ability to bind and activate P450 proteins (,. 	cytochrome b	27423	27435	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:124	The recombinant baculosomes with hyperexpressed CYP3A4 and coexpressed NADPH cytochrome P450 reductase and cytochrome b_5, was used as source of enzyme. 	cytochrome b	18458	18470	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6266551_OgerInput.txtOger_out.csv:176	All major protein complexes involved in photosynthesis were impacted: the light-harvesting complexes were affected with the down regulation of 32 chlorophyll a/b-binding proteins as well as 4 proteins involved in chlorophyll synthesis, 38 proteins associated with photosystems I and II were downregulated, 2 proteins involved in the NDH complex as well as 7 subunits of the chloroplastic ATP synthase, and a subunit of the cytochrome b6-f complex, were also downregulated. 	cytochrome b	37621	37633	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6292600_OgerInput.txtOger_out.csv:4	Results of two different approaches, experimental surface gillnets capture and environmental DNA metabarcoding assays based on 12S ribosomal RNA and cytochrome b, were compared during 3 years (2014-2016). 	cytochrome b	676	688	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6292600_OgerInput.txtOger_out.csv:51	This fragment is proved to be reliable on degraded DNA, is informative to discriminate vertebrates species and is adapted to survey fish diversity (eg); (ii) a longer cytochrome b fragment (235bp) to potentially improve the taxonomic resolution. 	cytochrome b	7572	7584	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6292600_OgerInput.txtOger_out.csv:119	For this study, a PCR approach targeting short fragments of two mitochondrial markers (12S RNA and cytochrome b, hereafter 12S and cytb respectively, ) was designed. 	cytochrome b	18042	18054	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6345922_OgerInput.txtOger_out.csv:10	Progesterone receptor membrane component 1 is a multifunctional protein with a C-terminal cytochrome b_5 domain^. 	cytochrome b	1992	2004	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6345922_OgerInput.txtOger_out.csv:16	Progesterone Receptor Membrane Component1 regulates cell proliferation and apoptosis in granulosa and luteal cells via interaction between its cytoplasmic cytochrome b_5 binding domain (amino acids 70-130) and plasminogen activator inhibitor RNA-binding protein-1 (PAIR-BP1)^,. 	cytochrome b	3247	3259	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6356338_OgerInput.txtOger_out.csv:11	A molecular clock model estimated the divergence time between sturgeon and paddlefish at 204.1 Mya, approximately 10% later than previous estimates based on cytochrome b data (184.4 Mya). 	cytochrome b	1541	1553	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6356338_OgerInput.txtOger_out.csv:38	(2000) to be sister species based the mitochondrial genes NADH dehydrogenase subunit 4L (ND4L) and NADH dehydrogenase subunit 4 (ND4), but cytochrome b (cytb), 16S ribosomal DNA (rDNA), and 12S rDNA did not confirm this. 	cytochrome b	5362	5374	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:19	CYP2B6 variants, reference allele P450 oxidoreductase (POR), and reference allele cytochrome b _5 vectors were previously generated, and recombinant proteins previously expressed in insect cells, as described.,  Haplotype selection was based on the known clinical significance and frequency of the polymorphism, and a desire to inform the mechanistic basis for the influence of these polymorphisms on metabolism. 	cytochrome b	3406	3418	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6479175_OgerInput.txtOger_out.csv:146	According to our analysis, first, Ech, and cytochrome b0 were not present among the ruminal microorganisms. 	cytochrome b	27446	27458	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:3	A genus-specific conventional cytochrome b Polymerase Chain Reaction has shown high sensitivity in field studies, detecting 70% submicroscopic malaria. 	cytochrome b	280	292	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6611585_OgerInput.txtOger_out.csv:27	Examples of these multi-targets are chromosomal small subunit ribosomal RNA 18S locus, cytochrome b gene on the mitochondrial genome, the chromosomal subtelomeric targets telomere-associated repetitive element 2 (TARE-2) and var gene acidic terminal sequence. 	cytochrome b	4454	4466	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6637849_OgerInput.txtOger_out.csv:204	Indeed, transcriptomic and proteomic analysis in other diatom species (Thalassiosira pseudonada, T. oceanica, and Pseudo-nitzschia granii) showed downregulation of the heme b-containing cytochrome b_6f and conservation of the PSII proteins expression (;. 	cytochrome b	33446	33458	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6823466_OgerInput.txtOger_out.csv:51	Two mitochondrial genes and one nuclear gene were used for phylogenetic analyses, cytochrome oxidase I (coxI), cytochrome b (cytb) and recombination activating gene 2 (RAG2), respectively (see Table  in Supplementary Data for a complete list of sequences and other details). 	cytochrome b	8443	8455	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:76	It should be noted that the 17,20-lyase activity of CYP17A1 is dependent on augmentation by cytochrome b_5 (CYB5A) in addition to electron transfer from P450 Oxidoreductase. 	cytochrome b	12858	12870	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:9	In the mammalian liver, the endoplasmic reticulum (ER)-anchored P450s function together with their redox partners cytochrome P450 reductase and cytochrome b_5 in the oxidative metabolism and elimination of numerous endobiotics (arachidonic acid, retinoic acid, steroids, vitamin D) as well as xenobiotics (pharmacological and recreational drugs, carcinogens, toxins and other foreign substances of dietary or environmental origin),. 	cytochrome b	2383	2395	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:34	In addition, plants express redox co-factors dedicated to secondary metabolism, such as specialized cytochrome b5 proteins, and many CYPs depend on such co-factors for optimal activity. 	cytochrome b	5629	5641	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	cytochrome b5	9006	9019	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	cytochrome b5	9006	9019	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6052406_OgerInput.txtOger_out.csv:84	The electron leakage in the electron transport chain during respiration is generally considered as the main source of mitochondrial Reactive Oxygen Species but other mitochondrial enzymatic systems, such as monoamine oxidase and cytochrome b5 reductase in the outer membranes, cytochromes P450 enzymes in the inner membranes, or several matrix enzymes such as aconitase, can also produce Reactive Oxygen Species (Andreyev, Kushnareva, Murphy, & Starkov, ; Andreyev, Kushnareva, & Starkov,. 	cytochrome b5	15689	15702	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6052406_OgerInput.txtOger_out.csv:84	The electron leakage in the electron transport chain during respiration is generally considered as the main source of mitochondrial Reactive Oxygen Species but other mitochondrial enzymatic systems, such as monoamine oxidase and cytochrome b5 reductase in the outer membranes, cytochromes P450 enzymes in the inner membranes, or several matrix enzymes such as aconitase, can also produce Reactive Oxygen Species (Andreyev, Kushnareva, Murphy, & Starkov, ; Andreyev, Kushnareva, & Starkov,. 	cytochrome b5	15689	15702	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:196	(presence of CYP and cytochrome b5). 	cytochrome b5	32182	32195	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:100	This finding was consistent with that of a mouse study that showed that liver microsomal EROD activity was unaffected by berberine when CYP1A2 mRNA was elevated. 	EROD	13724	13728	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:151	Interestingly, the presence of highly conserved LxxxL motif between L121 and L125 was observed in the amino acid sequences of cytochrome b_5 from various eukaryotes, as shown in Fig. 	cytochrome b_5	34181	34195	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome b_5	34715	34729	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome b_5	34715	34729	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome b_5	34853	34867	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:154	Based on these leucine residues present in the transmembrane ALPHA-helices of cytochrome b_5 and cytochrome P450, a leucine zipper-like structure can be found in the transmembrane interactions of the cytochrome P450-cytochrome b_5 complex^, -,. 	cytochrome b_5	34853	34867	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:155	The experimental results indicate that the topology of cytochrome b_5 in the DMPC lipid bilayers suggest that amino acid residues, L121 and L125 are located near the upper chain/glycerol region, which has an unique environment for membrane-associated proteins. 	cytochrome b_5	34937	34951	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:155	The experimental results indicate that the topology of cytochrome b_5 in the DMPC lipid bilayers suggest that amino acid residues, L121 and L125 are located near the upper chain/glycerol region, which has an unique environment for membrane-associated proteins. 	cytochrome b_5	34937	34951	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:160	Herein, possible driving forces for the transmembrane complex formation in cytochrome P450-cytochrome b_5 would be a combination of: (i) van der Waals-London interactions^, (ii) electrostatic attraction, estimated by 1-3 kcal, between oppositely charged electric dipolar moments in the association of C- and N-terminal ALPHA-helices^, and (iii) hydrophobic interactions of ALPHA-helices near the surface of the lipid bilayer based on the leucine zipper-like motifs ^, -,. 	cytochrome b_5	35884	35898	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:160	Herein, possible driving forces for the transmembrane complex formation in cytochrome P450-cytochrome b_5 would be a combination of: (i) van der Waals-London interactions^, (ii) electrostatic attraction, estimated by 1-3 kcal, between oppositely charged electric dipolar moments in the association of C- and N-terminal ALPHA-helices^, and (iii) hydrophobic interactions of ALPHA-helices near the surface of the lipid bilayer based on the leucine zipper-like motifs ^, -,. 	cytochrome b_5	35884	35898	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:161	These types of specific transmembrane dimerization motifs can be found in the amino acid sequences of both cytochrome b_5 and cytochrome P450; however, the transmembrane region of cytochrome P450 reductase does not possess such type of dimerization motifs^. 	cytochrome b_5	36372	36386	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:161	These types of specific transmembrane dimerization motifs can be found in the amino acid sequences of both cytochrome b_5 and cytochrome P450; however, the transmembrane region of cytochrome P450 reductase does not possess such type of dimerization motifs^. 	cytochrome b_5	36372	36386	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:164	This study represents the first experimental report revealing the topology and structure of the transmembrane domains of membrane-bound cytochrome P450-cytochrome b_5 complex in the functional full-length form. 	cytochrome b_5	36950	36964	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:164	This study represents the first experimental report revealing the topology and structure of the transmembrane domains of membrane-bound cytochrome P450-cytochrome b_5 complex in the functional full-length form. 	cytochrome b_5	36950	36964	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:171	In particular, the remarkable sensitivity enhancement of NMR signals achieved by DNP at cryogenic temperatures can potentially provide structural information of in-vivo membrane protein complexes at-work, as we have recently demonstrated for cytochrome b_5 in in-cell conditions^,. 	cytochrome b_5	38669	38683	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:171	In particular, the remarkable sensitivity enhancement of NMR signals achieved by DNP at cryogenic temperatures can potentially provide structural information of in-vivo membrane protein complexes at-work, as we have recently demonstrated for cytochrome b_5 in in-cell conditions^,. 	cytochrome b_5	38669	38683	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:9	Progestin receptor membrane component 1 is a single transmembrane heme-binding protein containing a cytochrome b_5 motif, which has been proposed as a progesterone binding protein in vertebrates (,. 	cytochrome b_5	1572	1586	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:117	Further studies of chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin inhibition of CYP3A4 are needed to determine inactivation kinetics and steps of the catalytic cycle of cytochrome P450 3A4 that are affected by the inhibitor or potential reactive intermediate products/metabolites. 	cytochrome P450 3A	17338	17356	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:117	Further studies of chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin inhibition of CYP3A4 are needed to determine inactivation kinetics and steps of the catalytic cycle of cytochrome P450 3A4 that are affected by the inhibitor or potential reactive intermediate products/metabolites. 	cytochrome P450 3A4	17338	17357	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6358801_OgerInput.txtOger_out.csv:74	Similarly, the blue light induced the expression of putative LDA enzymes including aryl-alcohol dehydrogenase (XLOC_008717), pyranose 2-oxidase (XLOC_009983), and monooxygenase (XLOC_003435) and the red light influenced the expression of cytochrome P-450 (XLOC_007791, XLOC_00671, XLOC_006683, XLOC_001969, and XLOC_007717). 	cytochrome P-450	15561	15577	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:3	Cytochrome c showed a significant response to Bombyx Mori Nucleopolyhedrovirus infection in our previous transcriptome study. 	Cytochrome c	207	219	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:7	Cytochrome c content was found to be elevated in oxygen-deprived and previously oxygen-deprived samples. 	Cytochrome c	1134	1146	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:7	Cytochrome c content was found to be elevated in oxygen-deprived and previously oxygen-deprived samples. 	Cytochrome c	1134	1146	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:167	Cytochrome c content was found to be elevated in oxygen-deprived and previously oxygen-deprived samples. 	Cytochrome c	28446	28458	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:167	Cytochrome c content was found to be elevated in oxygen-deprived and previously oxygen-deprived samples. 	Cytochrome c	28446	28458	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:207	Higher AUC_(_0_-__) and T_1_/_2 might be due sustained release of drugs from liposomes and long blood circulation time due Mycophenolic Acid breakdown inhibition through cytochrome P450 enzyme by QC. 	cytochrome P450 enzyme	32378	32400	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:89	CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo.,  However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity.,  CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 	CYP2B6	17085	17091	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:89	CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo.,  However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity.,  CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 	CYP2B6	17099	17105	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:89	CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo.,  However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity.,  CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 	CYP2B6	17099	17105	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:90	We previously demonstrated that common CYP2B6 haplotypes, including missense variants and noncoding variants that affect gene splicing, are associated with differences in in vivo nicotine metabolism. 	CYP2B6	17230	17236	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:90	We previously demonstrated that common CYP2B6 haplotypes, including missense variants and noncoding variants that affect gene splicing, are associated with differences in in vivo nicotine metabolism. 	CYP2B6	17230	17236	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:91	However, the small contribution of CYP2B6 to hepatic nicotine metabolism is unlikely to influence smoking behaviors. 	CYP2B6	17426	17432	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:91	However, the small contribution of CYP2B6 to hepatic nicotine metabolism is unlikely to influence smoking behaviors. 	CYP2B6	17426	17432	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:92	CYP2B6 mRNA expression has been reported in human brain, although direct evidence of CYP2B6 activity in brain tissue was not previously demonstrated. 	CYP2B6	17508	17514	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:92	CYP2B6 mRNA expression has been reported in human brain, although direct evidence of CYP2B6 activity in brain tissue was not previously demonstrated. 	CYP2B6	17508	17514	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:92	CYP2B6 mRNA expression has been reported in human brain, although direct evidence of CYP2B6 activity in brain tissue was not previously demonstrated. 	CYP2B6	17593	17599	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:92	CYP2B6 mRNA expression has been reported in human brain, although direct evidence of CYP2B6 activity in brain tissue was not previously demonstrated. 	CYP2B6	17593	17599	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:93	It has therefore been suggested that genetically determined variation in CYP2B6 activity in extrahepatic tissues might influence smoking behavior by altering local nicotine levels in the brain. 	CYP2B6	17731	17737	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:93	It has therefore been suggested that genetically determined variation in CYP2B6 activity in extrahepatic tissues might influence smoking behavior by altering local nicotine levels in the brain. 	CYP2B6	17731	17737	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:104	Given the high K _m of CYP2B6 for nicotine, we further probed human brain microsomes with two common CYP2B6 substrates, ketamine and methadone, and found no evidence of metabolism of either. 	CYP2B6	19342	19348	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:104	Given the high K _m of CYP2B6 for nicotine, we further probed human brain microsomes with two common CYP2B6 substrates, ketamine and methadone, and found no evidence of metabolism of either. 	CYP2B6	19342	19348	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:104	Given the high K _m of CYP2B6 for nicotine, we further probed human brain microsomes with two common CYP2B6 substrates, ketamine and methadone, and found no evidence of metabolism of either. 	CYP2B6	19420	19426	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:104	Given the high K _m of CYP2B6 for nicotine, we further probed human brain microsomes with two common CYP2B6 substrates, ketamine and methadone, and found no evidence of metabolism of either. 	CYP2B6	19420	19426	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:109	Unlike CYP2A6, CYP2B6 mRNA expression has been reported in human brain tissue, but aside from its role in bupropion metabolism, genetic variation in CYP2B6 has not been associated with smoking phenotypes. 	CYP2B6	20683	20689	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:109	Unlike CYP2A6, CYP2B6 mRNA expression has been reported in human brain tissue, but aside from its role in bupropion metabolism, genetic variation in CYP2B6 has not been associated with smoking phenotypes. 	CYP2B6	20683	20689	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:109	Unlike CYP2A6, CYP2B6 mRNA expression has been reported in human brain tissue, but aside from its role in bupropion metabolism, genetic variation in CYP2B6 has not been associated with smoking phenotypes. 	CYP2B6	20817	20823	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:109	Unlike CYP2A6, CYP2B6 mRNA expression has been reported in human brain tissue, but aside from its role in bupropion metabolism, genetic variation in CYP2B6 has not been associated with smoking phenotypes. 	CYP2B6	20817	20823	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:110	However, given the welldocumented substrate specificity of functional variation in CYP2B6, it was also necessary to determine which variants affect nicotine metabolism, a question not previously addressed in vitro. 	CYP2B6	20956	20962	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:110	However, given the welldocumented substrate specificity of functional variation in CYP2B6, it was also necessary to determine which variants affect nicotine metabolism, a question not previously addressed in vitro. 	CYP2B6	20956	20962	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:112	Nevertheless, if undetected CYP2B6 activity does occur in the human brain, with the potential to influence smoking behavior in a similar manner to FMO3, associations between CYP2B6 genotype and nicotine dependence should be detectable in human genetic studies based on our in vitro activity results together with previously published findings regarding variation in CYP2B6 expression. 	CYP2B6	21213	21219	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:112	Nevertheless, if undetected CYP2B6 activity does occur in the human brain, with the potential to influence smoking behavior in a similar manner to FMO3, associations between CYP2B6 genotype and nicotine dependence should be detectable in human genetic studies based on our in vitro activity results together with previously published findings regarding variation in CYP2B6 expression. 	CYP2B6	21213	21219	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:112	Nevertheless, if undetected CYP2B6 activity does occur in the human brain, with the potential to influence smoking behavior in a similar manner to FMO3, associations between CYP2B6 genotype and nicotine dependence should be detectable in human genetic studies based on our in vitro activity results together with previously published findings regarding variation in CYP2B6 expression. 	CYP2B6	21359	21365	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:112	Nevertheless, if undetected CYP2B6 activity does occur in the human brain, with the potential to influence smoking behavior in a similar manner to FMO3, associations between CYP2B6 genotype and nicotine dependence should be detectable in human genetic studies based on our in vitro activity results together with previously published findings regarding variation in CYP2B6 expression. 	CYP2B6	21359	21365	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:112	Nevertheless, if undetected CYP2B6 activity does occur in the human brain, with the potential to influence smoking behavior in a similar manner to FMO3, associations between CYP2B6 genotype and nicotine dependence should be detectable in human genetic studies based on our in vitro activity results together with previously published findings regarding variation in CYP2B6 expression. 	CYP2B6	21551	21557	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:112	Nevertheless, if undetected CYP2B6 activity does occur in the human brain, with the potential to influence smoking behavior in a similar manner to FMO3, associations between CYP2B6 genotype and nicotine dependence should be detectable in human genetic studies based on our in vitro activity results together with previously published findings regarding variation in CYP2B6 expression. 	CYP2B6	21551	21557	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:131	Thus, although previous studies identified Amino Acids as important for hepatocyte survival, proliferation, and protein synthesis^,, we here demonstrate that increasing Amino Acids to levels 30-fold above that of typical hepatocyte media, actively induces a metabolic switch, as well as Cytochrome P450 enzyme expression and function (Supplementary Table. 	Cytochrome P450 enzyme	27125	27147	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC6214003_OgerInput.txtOger_out.csv:134	The genes that are overexpressed in Theca cells (cluster 4) are particularly involved in cholesterol import (SCARB1, STARD5), bile acid metabolism (CH25H), HDL-mediated lipid transport (APOA1, PLTP, SCARB1), lipid degradation (LPL, PLIN5), and steroidogenesis (CYP27A, CYP7B1, TM7SF2). 	CYP7	25478	25482	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_712', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:29	Cell viability, apoptosis rate and expressions of cytochrome C and cleaved caspase3 were determined prior to the experiment for assessing endothelial function at 12 hours following bubble contact. 	cytochrome C	4222	4234	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:78	3738; 1:1000 dilution), cytochrome C (Cat. 	cytochrome C	9338	9350	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6850936_OgerInput.txtOger_out.csv:78	3738; 1:1000 dilution), cytochrome C (Cat. 	cytochrome C	9338	9350	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:100	Bubble contact for 10, 20 or 30 minutes induced a significant decrease in cell viability and remarkable increases in apoptosis rate, cytochrome C and cleaved caspase3. 	cytochrome C	11520	11532	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6850936_OgerInput.txtOger_out.csv:100	Bubble contact for 10, 20 or 30 minutes induced a significant decrease in cell viability and remarkable increases in apoptosis rate, cytochrome C and cleaved caspase3. 	cytochrome C	11520	11532	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:191	The liver metabolism of regorafenib, even if less well-characterized, is comparable with that of sorafenib and occurs through an oxidative process mediated by Cytochrome P450 3a4 and glucuronidation mediated by Udp Glucuronosyltransferase 1a9. 	Cytochrome P450 3a	39064	39082	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	Cytochrome P450 3a	39811	39829	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:191	The liver metabolism of regorafenib, even if less well-characterized, is comparable with that of sorafenib and occurs through an oxidative process mediated by Cytochrome P450 3a4 and glucuronidation mediated by Udp Glucuronosyltransferase 1a9. 	Cytochrome P450 3a4	39064	39083	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	Cytochrome P450 3a4	39811	39830	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b 5	2180	2194	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b 5	2180	2194	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14661	14676	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14661	14676	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	cytochrome b _5	14814	14829	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	cytochrome b _5	14814	14829	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	cytochrome b _5	14840	14855	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	cytochrome b _5	14840	14855	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:77	The results of our present study as well as those reported previously indicated that cytochrome b _5 can play a dual role in the CYP3A4-mediated oxidation of ellipticine. 	cytochrome b _5	15979	15994	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:77	The results of our present study as well as those reported previously indicated that cytochrome b _5 can play a dual role in the CYP3A4-mediated oxidation of ellipticine. 	cytochrome b _5	15979	15994	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	cytochrome b _5	16256	16271	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	cytochrome b _5	16256	16271	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	cytochrome b _5	16297	16312	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	cytochrome b _5	16297	16312	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:85	However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane (ie NADH:cytochrome b _5 reductase and cytochrome b _5) are also expressed at basal levels in these Supersomes (Gentest Corp., Woburn, MI, USA). 	cytochrome b _5	17248	17263	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:85	However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane (ie NADH:cytochrome b _5 reductase and cytochrome b _5) are also expressed at basal levels in these Supersomes (Gentest Corp., Woburn, MI, USA). 	cytochrome b _5	17248	17263	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:211	Cyp1a2 Knockout mice liver cDNA microarray analysis showed that Cyp1a2 deficiency affected insulin function, lipogenesis, fatty acid biosynthesis and cholesterol biosynthesis. 	Cyp1a2	28108	28114	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:211	Cyp1a2 Knockout mice liver cDNA microarray analysis showed that Cyp1a2 deficiency affected insulin function, lipogenesis, fatty acid biosynthesis and cholesterol biosynthesis. 	Cyp1a2	28108	28114	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:89	In line with these data, we observed a significant increase in the expression of Cyp3a11 in female SPF mice compared to the male group. 	Cyp3a	12540	12545	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:167	Sort=Bait and CYP11B2. 	CYP11B2	23713	23720	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:167	Sort=Bait and CYP11B2. 	CYP11B2	23713	23720	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:177	Sort=Bait  CYP11B2 interaction used as a control. 	CYP11B2	24813	24820	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:177	Sort=Bait  CYP11B2 interaction used as a control. 	CYP11B2	24813	24820	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:177	Sort=Bait  CYP11B2 interaction used as a control. 	CYP11B2	24813	24820	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:177	Sort=Bait  CYP11B2 interaction used as a control. 	CYP11B2	24813	24820	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	CYP11B2	25456	25463	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:120	A major difference between CYP11A1 and CYP90B1 is the stereo specificity. 	CYP11A1	17210	17217	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:120	A major difference between CYP11A1 and CYP90B1 is the stereo specificity. 	CYP11A1	17210	17217	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:121	The latter inserts the hydroxyl group in the S position, whereas CYP11A1 is in the R position. 	CYP11A1	17322	17329	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:121	The latter inserts the hydroxyl group in the S position, whereas CYP11A1 is in the R position. 	CYP11A1	17322	17329	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:121	The latter inserts the hydroxyl group in the S position, whereas CYP11A1 is in the R position. 	CYP11A1	17322	17329	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:121	The latter inserts the hydroxyl group in the S position, whereas CYP11A1 is in the R position. 	CYP11A1	17322	17329	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:123	In CYP90B1, the active site is characterized by the conformations side-chain in and steroid-core out, similar to CYP11A1, and for CYP90B1 the 3-hydroxy group hydrogen is bonded with H385 and the carbonyl oxygen of V216 via a water molecule. 	CYP11A1	17567	17574	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:111	Within the adrenal, A4 can serve as a substrate for CYP11B1, yielding the 11-oxygenated androgen precursor, 11OHA4, with conversion of testosterone to 11BETA-hydroxytestosterone (11OHT), also occurring. 	CYP11B1	18922	18929	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_448', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:111	Within the adrenal, A4 can serve as a substrate for CYP11B1, yielding the 11-oxygenated androgen precursor, 11OHA4, with conversion of testosterone to 11BETA-hydroxytestosterone (11OHT), also occurring. 	CYP11B1	18922	18929	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_781', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:162	Treatment of resveratrol (p-value < 0.0001, n =3), ellipticine (p-value < 0.0001, n =3), or tryptamine (p-value < 0.0001, n =3) significantly reduced the viral load in CCS-EVs exposed U1 cells, suggesting the role of CYP 1A1 and 2A6, and oxidative stress on viral load increase in U1 cells (A,B). 	CYP 1A1	28317	28324	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:115	In our study, genetic variation of mitochondrial cytochrome B was found in the two Chinese woodchuck populations with different outcomes of experimental WHV infection. 	cytochrome B	17712	17724	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:116	Though all of the animals belong to the same subspecies M. himalayana, robusta, cytochrome B Allele A was predominant in animals with high replicative pattern of WHV infection, while Allele H (nucleotide substitution at nt 695 from T to C) in those with low replicative pattern. 	cytochrome B	17911	17923	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:118	Furthermore, cytochrome B Alleles A and H will be of benefit for the selection of high WHV susceptible Chinese woodchucks, which could be used as an animal model to evaluate antiviral drugs or therapeutic vaccines [,. 	cytochrome B	18296	18308	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:21	Moreover, inhibitors of CYP19 aromatase are frequently used for endocrine therapy of breast cancer patients, while the role of genetic variability of the target gene in the treatment efficacy or adverse effects is yet unexploited for therapeutic decisions. 	CYP19	3339	3344	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:21	Moreover, inhibitors of CYP19 aromatase are frequently used for endocrine therapy of breast cancer patients, while the role of genetic variability of the target gene in the treatment efficacy or adverse effects is yet unexploited for therapeutic decisions. 	CYP19	3339	3344	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:21	Moreover, inhibitors of CYP19 aromatase are frequently used for endocrine therapy of breast cancer patients, while the role of genetic variability of the target gene in the treatment efficacy or adverse effects is yet unexploited for therapeutic decisions. 	CYP19	3339	3344	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:21	Moreover, inhibitors of CYP19 aromatase are frequently used for endocrine therapy of breast cancer patients, while the role of genetic variability of the target gene in the treatment efficacy or adverse effects is yet unexploited for therapeutic decisions. 	CYP19	3339	3344	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP2B1	21099	21105	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_500', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP2B1	21099	21105	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP2B1	21099	21105	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP2B1	21099	21105	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:102	CYP1A1 protein level was significantly induced by berberine in MCF-7 cells after the transfection of a miR-21-3p hairpin inhibitor, demonstrating that miR-21-3p suppressed CYP1A1 protein induction. 	CYP1A1 protein	13968	13982	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:102	CYP1A1 protein level was significantly induced by berberine in MCF-7 cells after the transfection of a miR-21-3p hairpin inhibitor, demonstrating that miR-21-3p suppressed CYP1A1 protein induction. 	CYP1A1 protein	14140	14154	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:506	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD or BROD activities (LOD 1, 4 and 1 pmol/min/mg protein, respectively). 	PROD	78333	78337	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:612	report that in human skin and in the reconstructed human skin model EpiDerm^ they did not detect PROD activity (LOD < 0.2 pmol/min/mg protein). 	PROD	93402	93406	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:612	report that in human skin and in the reconstructed human skin model EpiDerm^ they did not detect PROD activity (LOD < 0.2 pmol/min/mg protein). 	PROD	93402	93406	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:613	Likewise Guth did not detect PROD activity in StrataTest^ (LOD 4 pmol/min/mg protein). 	PROD	93478	93482	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:679	reported that native human skin had a low level of CYP3A4 protein, moderately induced after 24 h by 2 mM phenobarbital, which, however, was not accompanied by an increase in CYP3A4-dependent BROD activity by phenobarbital (0.5-2 mM for 24, 48 and 72 h) nor by rifampicin (50 and 100 M for 24 h) nor by dexamethasone (10 and 50 M for 24, 48 and 72 h). 	BROD	103807	103811	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_387', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:69	It is unclear why our patient did not exhibit any side or adverse effects; however, it could be that the Carbamazepine he received played a role, although studies have shown that there is little or no in vivo effects of CYP 2D6 on Paliperidone. 	CYP 2D6	10685	10692	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:69	It is unclear why our patient did not exhibit any side or adverse effects; however, it could be that the Carbamazepine he received played a role, although studies have shown that there is little or no in vivo effects of CYP 2D6 on Paliperidone. 	CYP 2D6	10685	10692	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:193	Another intriguing association we found, though not FDR-validated, is an association of rs62150087 (CYP26B1) with shorter Disease-Free Survival. 	CYP26B1	27007	27014	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:443	However, it seems that the comparison of standard middle point potentials is more correct, as D1/D2/Cytochrome B559 is bound within a protein matrix, and a considerable difference in the local concentrations of O_2 and O_2^ is questionable. 	Cytochrome B	65703	65715	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:444	A possible alternative solution is that D1/D2/Cytochrome B559 mediates the formation of semiquinones at Q_D and Q_C sites. 	Cytochrome B	65890	65902	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:445	Experimental evidence of the reduction in O_2 by a loosely bound plastosemiquinone anion radical (PQ^) at the Q_C site was provided by Yadav et al.. The authors showed that PQ^ can be formed by a one electron reduction in PQ at the Q_B site and one electron oxidation of PQH_2 by D1/D2/Cytochrome B559 at the Q_C site. 	Cytochrome B	66253	66265	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:446	Because a PQ molecule has been crystallographically detected in the Q_C site, PQ might be tightly bound within the Q_C pocket and act as an electron carrier from D1/D2/Cytochrome B559 to P680. 	Cytochrome B	66454	66466	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:448	In this case, the PQ pool can serve as an electron donor for D1/D2/Cytochrome B559. 	Cytochrome B	66656	66668	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:449	It might be proposed that the formation of O_2^ in a cyt b559-dependent pathway couples D1/D2/Cytochrome B559 and quinones and depends on the redox state of the PQ pool (A). 	Cytochrome B	66767	66779	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7316774_OgerInput.txtOger_out.csv:71	In addition, the Bax, cleaved-caspase3 and Cytochrome C protein expression levels were further increased using HIF-1ALPHA knockdown while Bcl2 expression levels were significantly augmented showed that si-RNA reduced the HIF-1ALPHA aggregation in mitochondria in hypoxia-stimulated chondrocytes (Fig. 	Cytochrome C	9581	9593	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7316774_OgerInput.txtOger_out.csv:71	In addition, the Bax, cleaved-caspase3 and Cytochrome C protein expression levels were further increased using HIF-1ALPHA knockdown while Bcl2 expression levels were significantly augmented showed that si-RNA reduced the HIF-1ALPHA aggregation in mitochondria in hypoxia-stimulated chondrocytes (Fig. 	Cytochrome C	9581	9593	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7762604_OgerInput.txtOger_out.csv:423	In addition, they isolated mitochondrial and cytosol fractions and observed a time-dependent release of Cytochrome C to cytosol. 	Cytochrome C	73097	73109	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7084598_OgerInput.txtOger_out.csv:208	The molecular docking study suggested that 12n could be used as an inhibitor of CYP17A1 (6CIZ). 	CYP17	34780	34785	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:208	The molecular docking study suggested that 12n could be used as an inhibitor of CYP17A1 (6CIZ). 	CYP17	34780	34785	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:29	Then, the 17ALPHA-hydroxylase activity of CYP17A1 converts pregnenolone to 17OH-pregnenolone. 	CYP17	3495	3500	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:29	Then, the 17ALPHA-hydroxylase activity of CYP17A1 converts pregnenolone to 17OH-pregnenolone. 	CYP17	3495	3500	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	17,20-lyase	33691	33702	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_464', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:126	Similarly, by generating Cyp27a1^/Cyp46a1^/Apoe^/ mice, we expected an additive genotype effect due to simultaneous blockage of the two major pathways of retinal cholesterol output - cholesterol removal via metabolism (CYP27A1 and CYP46A1) and Lipoprotein Particles containing Apolipoprotein E which accepts cholesterol effluxed from cells. 	CYP46A1	21877	21884	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:133	Rather, retinal proteomics pointed to enhanced vesicle formation in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina as an expression of 7 proteins from the endosomal, secretory, and protrusion formation pathways (CHGA, HDAC6, PAFAH1B, SEPT6, SRP19, TAGLN2, and TAGLN3, ) was increased in the former. 	Cyp46	23293	23298	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:134	Hence, retinal vesicle formation was investigated by TEM and found to be most prominent in the Cyp27a1^/Cyp46a1^/Soat1^/ retina followed by Cyp27a1^/Cyp46a1^/Apoe^/ and then Wild Type retina (;. 	Cyp46	23622	23627	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:134	Hence, retinal vesicle formation was investigated by TEM and found to be most prominent in the Cyp27a1^/Cyp46a1^/Soat1^/ retina followed by Cyp27a1^/Cyp46a1^/Apoe^/ and then Wild Type retina (;. 	Cyp46	23667	23672	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:135	Notably, in the Cyp27a1^/Cyp46a1^/Soat1^/ retina, vesicles were detected at both apical and basal Retinal Pigment Epithelium sides, possibly a reflection of the bi-directional traffic to the intraretinal and choroidal vascular networks. 	Cyp46	23738	23743	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:136	Traffic to the intraretinal vasculature was further supported by abundant vesicles in the intraretinal space of the outer nuclear layer and neurovascular units of the ganglion cell layer, which were upregulated in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina and participate in glucose production and utilization as well as fatty acid BETA-oxidation. 	Cyp46	24177	24182	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:137	If energy homeostasis is indeed affected in the Cyp27a1^/Cyp46a1^/Soat1^/ retina, there should be an increased production of ATP due to glycolysis and increased acetyl CoA availability as the latter is necessary for the tricarboxylic acid cycle, which provides NADPH for ATP production during mitochondrial or extra mitochondrial oxidative phosphorylation. 	Cyp46	24367	24372	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:138	Also, extracellular vesicles contain proteins, therefore enhanced vesicle formation will lead to retinal protein loss, if this loss is not compensated for, a possible reason for an increase in abundance of the overwhelming majority of proteins in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina. 	Cyp46	24927	24932	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:139	The expression of LAMTOR3, PSAT, BPHL, and SLC14A1, which are involved in protein homeostasis, was increased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina and could be the consequence of the enhanced extracellular vesicle formation. 	Cyp46	25094	25099	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:140	Thus not only the formation of extracellular vesicles seemed to be enhanced in the Cyp27a1^/Cyp46a1^/Soat1^/ retina but also the processes which are required (ie, ATP production) and affected (ie, protein homeostasis and ubiquitination) by vesicle formation. 	Cyp46	25288	25293	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:133	Rather, retinal proteomics pointed to enhanced vesicle formation in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina as an expression of 7 proteins from the endosomal, secretory, and protrusion formation pathways (CHGA, HDAC6, PAFAH1B, SEPT6, SRP19, TAGLN2, and TAGLN3, ) was increased in the former. 	Cyp46a1	23293	23300	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:134	Hence, retinal vesicle formation was investigated by TEM and found to be most prominent in the Cyp27a1^/Cyp46a1^/Soat1^/ retina followed by Cyp27a1^/Cyp46a1^/Apoe^/ and then Wild Type retina (;. 	Cyp46a1	23622	23629	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:134	Hence, retinal vesicle formation was investigated by TEM and found to be most prominent in the Cyp27a1^/Cyp46a1^/Soat1^/ retina followed by Cyp27a1^/Cyp46a1^/Apoe^/ and then Wild Type retina (;. 	Cyp46a1	23622	23629	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:134	Hence, retinal vesicle formation was investigated by TEM and found to be most prominent in the Cyp27a1^/Cyp46a1^/Soat1^/ retina followed by Cyp27a1^/Cyp46a1^/Apoe^/ and then Wild Type retina (;. 	Cyp46a1	23667	23674	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:134	Hence, retinal vesicle formation was investigated by TEM and found to be most prominent in the Cyp27a1^/Cyp46a1^/Soat1^/ retina followed by Cyp27a1^/Cyp46a1^/Apoe^/ and then Wild Type retina (;. 	Cyp46a1	23667	23674	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:135	Notably, in the Cyp27a1^/Cyp46a1^/Soat1^/ retina, vesicles were detected at both apical and basal Retinal Pigment Epithelium sides, possibly a reflection of the bi-directional traffic to the intraretinal and choroidal vascular networks. 	Cyp46a1	23738	23745	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:135	Notably, in the Cyp27a1^/Cyp46a1^/Soat1^/ retina, vesicles were detected at both apical and basal Retinal Pigment Epithelium sides, possibly a reflection of the bi-directional traffic to the intraretinal and choroidal vascular networks. 	Cyp46a1	23738	23745	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:136	Traffic to the intraretinal vasculature was further supported by abundant vesicles in the intraretinal space of the outer nuclear layer and neurovascular units of the ganglion cell layer, which were upregulated in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina and participate in glucose production and utilization as well as fatty acid BETA-oxidation. 	Cyp46a1	24177	24184	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:136	Traffic to the intraretinal vasculature was further supported by abundant vesicles in the intraretinal space of the outer nuclear layer and neurovascular units of the ganglion cell layer, which were upregulated in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina and participate in glucose production and utilization as well as fatty acid BETA-oxidation. 	Cyp46a1	24177	24184	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:137	If energy homeostasis is indeed affected in the Cyp27a1^/Cyp46a1^/Soat1^/ retina, there should be an increased production of ATP due to glycolysis and increased acetyl CoA availability as the latter is necessary for the tricarboxylic acid cycle, which provides NADPH for ATP production during mitochondrial or extra mitochondrial oxidative phosphorylation. 	Cyp46a1	24367	24374	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:137	If energy homeostasis is indeed affected in the Cyp27a1^/Cyp46a1^/Soat1^/ retina, there should be an increased production of ATP due to glycolysis and increased acetyl CoA availability as the latter is necessary for the tricarboxylic acid cycle, which provides NADPH for ATP production during mitochondrial or extra mitochondrial oxidative phosphorylation. 	Cyp46a1	24367	24374	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:138	Also, extracellular vesicles contain proteins, therefore enhanced vesicle formation will lead to retinal protein loss, if this loss is not compensated for, a possible reason for an increase in abundance of the overwhelming majority of proteins in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina. 	Cyp46a1	24927	24934	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:138	Also, extracellular vesicles contain proteins, therefore enhanced vesicle formation will lead to retinal protein loss, if this loss is not compensated for, a possible reason for an increase in abundance of the overwhelming majority of proteins in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina. 	Cyp46a1	24927	24934	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:139	The expression of LAMTOR3, PSAT, BPHL, and SLC14A1, which are involved in protein homeostasis, was increased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina and could be the consequence of the enhanced extracellular vesicle formation. 	Cyp46a1	25094	25101	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:139	The expression of LAMTOR3, PSAT, BPHL, and SLC14A1, which are involved in protein homeostasis, was increased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina and could be the consequence of the enhanced extracellular vesicle formation. 	Cyp46a1	25094	25101	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:140	Thus not only the formation of extracellular vesicles seemed to be enhanced in the Cyp27a1^/Cyp46a1^/Soat1^/ retina but also the processes which are required (ie, ATP production) and affected (ie, protein homeostasis and ubiquitination) by vesicle formation. 	Cyp46a1	25288	25295	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:140	Thus not only the formation of extracellular vesicles seemed to be enhanced in the Cyp27a1^/Cyp46a1^/Soat1^/ retina but also the processes which are required (ie, ATP production) and affected (ie, protein homeostasis and ubiquitination) by vesicle formation. 	Cyp46a1	25288	25295	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:155	By contrast, the Cyp27b1-KO rats for analysis were continuously fed the CE-2 diet because most male Cyp27b1-Knockout rats were not able to survive more than 10 weeks when fed the F-2 diet (data not shown). 	Cyp27b1	25226	25233	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:155	By contrast, the Cyp27b1-KO rats for analysis were continuously fed the CE-2 diet because most male Cyp27b1-Knockout rats were not able to survive more than 10 weeks when fed the F-2 diet (data not shown). 	Cyp27b1	25226	25233	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:156	Homozygotes of all Genetically Modified strains (Cyp27b1-KO, Vdr (R270L),and Vdr-KO) were maintained by mating of heterozygotes. 	Cyp27b1	25381	25388	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:156	Homozygotes of all Genetically Modified strains (Cyp27b1-KO, Vdr (R270L),and Vdr-KO) were maintained by mating of heterozygotes. 	Cyp27b1	25381	25388	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:157	Genotypes of each strain were determined by electrophoresis of PCR products of the target site for Cyp27b1-KO or direct sequencing for Vdr (R270L) and Vdr-KO (see Supplementary Figs.  	Cyp27b1	25560	25567	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:157	Genotypes of each strain were determined by electrophoresis of PCR products of the target site for Cyp27b1-KO or direct sequencing for Vdr (R270L) and Vdr-KO (see Supplementary Figs.  	Cyp27b1	25560	25567	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:162	The target site for Cyp27b1-KO was selected to delete the cysteine at position 462 in exon 8, which is the 5th ligand of heme iron and an active center of Cyp27b1 (see Supplementary Fig. 	Cyp27b1	26084	26091	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:162	The target site for Cyp27b1-KO was selected to delete the cysteine at position 462 in exon 8, which is the 5th ligand of heme iron and an active center of Cyp27b1 (see Supplementary Fig. 	Cyp27b1	26084	26091	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:162	The target site for Cyp27b1-KO was selected to delete the cysteine at position 462 in exon 8, which is the 5th ligand of heme iron and an active center of Cyp27b1 (see Supplementary Fig. 	Cyp27b1	26219	26226	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:162	The target site for Cyp27b1-KO was selected to delete the cysteine at position 462 in exon 8, which is the 5th ligand of heme iron and an active center of Cyp27b1 (see Supplementary Fig. 	Cyp27b1	26219	26226	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:164	Potential off target sites of Cyp27b1 and Vdr in rat genomes were searched by the CRISPR Direct tool (http://crispr.dbcls.jp/) to validate the off-target events. 	Cyp27b1	26440	26447	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:164	Potential off target sites of Cyp27b1 and Vdr in rat genomes were searched by the CRISPR Direct tool (http://crispr.dbcls.jp/) to validate the off-target events. 	Cyp27b1	26440	26447	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:168	Cyp27b1-KO rats and Vdr (R270L) rats were fed 25(OH)D_3 for comparison of its effects on rickets symptoms. 	Cyp27b1	26846	26853	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
